Nrf2 Activating Compounds
Compounds represented by general formula (I) serve as Nrf2 activators, addressing the need for effective treatments by enhancing oxidative stress defense gene expression for diseases like multiple sclerosis, psoriasis, diabetic retinopathy, and glaucoma.
Patent Information
- Application Number
- JP2021529207
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-03
- Filing Date
- 2020-07-03
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2040-07-03
AI Technical Summary
Current treatments for diseases such as multiple sclerosis, psoriasis, diabetic nephropathy, diabetic retinopathy, and glaucoma lack effective Nrf2 activators that can enhance oxidative stress defense gene expression.
Development of compounds represented by general formula (I) and their salts or solvates, which act as Nrf2 activators, promoting the translocation of Nrf2 into the nucleus and activating oxidative stress defense genes.
The compounds effectively activate Nrf2, providing therapeutic benefits for various diseases by enhancing oxidative stress defense gene expression, thereby preventing or treating conditions like multiple sclerosis, psoriasis, diabetic retinopathy, and glaucoma.
Smart Images

Figure 0007583718000001 
Figure 0007583718000002 
Figure 0007583718000003
Abstract
Description
[Technical Field]
[0001] The present invention relates to an Nrf2-activating compound and the like. [Background technology]
[0002] Nrf2 (NF-E2-related factor 2) is a transcription factor that promotes the expression of oxidative stress defense genes. Nrf2 is ubiquitinated and degraded by the proteasome through its interaction with Keap1 (Kelch-like ECH-associated protein 1). Therefore, inhibiting the interaction between Nrf2 and Keap1 promotes the translocation of Nrf2 into the nucleus, activating the expression of oxidative stress defense genes. For example, Nrf2 activators are expected to be therapeutic agents for a variety of systemic diseases, including multiple sclerosis, psoriasis, and diabetic nephropathy, as well as ophthalmological diseases, such as dry eye, diabetic retinopathy, retinitis pigmentosa, and glaucoma.
[0003] Patent Document 1 discloses an Nrf2 activator primarily intended for the treatment of COPD (chronic obstructive pulmonary disease). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] International Publication No. 2015 / 092713 Summary of the Invention [Problem to be solved by the invention]
[0005] An objective of the present invention is to provide a compound that has Nrf2 activation activity. [Means for solving the problem]
[0006] In view of the above problems, the present inventors have conducted extensive research and found that the compounds represented by the general formula (I) described below, their salts, and solvates thereof have Nrf2 activation activity. Based on this finding, further research has led to the completion of the present invention.
[0007] That is, the present invention includes the following aspects.
[0008] Section 1. General formula (I):
[0009] [ka]
[0010] [In the formula: R 1a and R 1b are the same or different and represent a hydrogen atom, an alkyl group, or a halogen atom. 2 R represents a group derived from an optionally substituted heterocycle, and the heterocycle represents thiophene, furan, pyrrole, or thiazole, or a fused ring containing any of these heterocycles. 4 and R 5 are the same or different and represent a hydrogen atom or an optionally substituted alkyl group, or R 4 and R 5 R combines with each other to form -NH-CH=N-. 6 represents an alkyl group which may be substituted. 1 , A 2 , A 3 and A 4 are the same or different and represent CH or N (provided that there is one or less N). Z represents a hydrogen atom or a halogen atom. A compound represented by the formula (I), a salt thereof, or a solvate thereof.
[0011] Section 2. Said R 2 Item 2. The compound according to item 1, a salt thereof, or a solvate thereof, wherein is an optionally substituted thienyl group.
[0012] Item 3. The compound, salt thereof, or solvate thereof according to Item 2, wherein the substituent that the thienyl group may have includes an electron-withdrawing group.
[0013] Item 4. The compound, salt thereof, or solvate thereof according to Item 2 or 3, wherein the substituent that the thienyl group may have includes an acetyl group, an aminosulfonyl group, a cyano group, or a cycloalkylcarbonyl group.
[0014] Section 5. Said R 2 is of the general formula (R2A):
[0015] [ka]
[0016] [In the formula: R 3 represents an acetyl group, an aminosulfonyl group, a cyano group, or a cycloalkylcarbonyl group; and Y represents a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group. 5. The compound according to any one of items 1 to 4, a salt thereof, or a solvate thereof, wherein R is a group represented by the following formula:
[0017] Section 6. Said R 2 is of the general formula (R2Aa) or (R2Ab):
[0018] [ka]
[0019] [In the formula: R 3 represents an acetyl group, an aminosulfonyl group, a cyano group, or a cycloalkylcarbonyl group; and Y represents a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group. 6. The compound according to any one of items 1 to 5, a salt thereof, or a solvate thereof, wherein R is a group represented by the following formula:
[0020] Section 7. Said R 3 Item 7. The compound, salt thereof, or solvate thereof according to Item 5 or 6, wherein is an acetyl group.
[0021] Section 8. Said R 4 and the above R 5 and are the same or different and represent a hydrogen atom or an alkyl group, or a salt thereof, or a solvate thereof according to any one of items 5 to 7.
[0022] Section 9. Said R 1a and the R 1b and are the same or different and represent a hydrogen atom or an alkyl group, or a salt thereof, or a solvate thereof according to any one of items 5 to 8.
[0023] Section 10. Said R 1a and the R 1b are the same or different and are a hydrogen atom or an alkyl group, R 3 is an acetyl group, R 4 and the above R 5 are the same or different and are a hydrogen atom or an alkyl group, R 6 is an optionally substituted ethyl group, The above A 1 , the above-mentioned A 2 , and the A 4 are all CH, and the A 3 is CH or N, Y is a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group, and wherein Z is a hydrogen atom. Item 10. The compound, salt thereof, or solvate thereof according to any one of items 5 to 9.
[0024] Section 11.R 1a and R 1b one of which is an alkyl group and the other is a hydrogen atom, or R 1a and R 1b and both are alkyl groups, and preferably the alkyl groups have 1 to 3 carbon atoms, R 2 is of the general formula (R2Aa):
[0025] [ka]
[0026] [In the formula: R 3 represents an acetyl group. Y represents a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group. Preferably, the alkyl group has 1 to 3 carbon atoms, the halogen atom is a fluorine atom, and the alkoxy group has 1 to 3 carbon atoms.] and R 4 is a hydrogen atom, R 5 is an alkyl group, preferably having 1 to 3 carbon atoms; R 6 is an optionally substituted ethyl group, and the substituent that the ethyl group may have is preferably an arylalkoxy group, and particularly preferably a benzyloxy group; The above A 1 , the above-mentioned A 2 , and the A 4 are all CH, and the A 3 is CH or N, and wherein Z is a hydrogen atom. Item 11. The compound, salt thereof, or solvate thereof according to any one of items 5 to 10.
[0027] Item 12. Any of the following compounds, salts thereof, or solvates thereof: 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (Compound 1), 3-(5-acetyl-4-methylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 2), 3-(4-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 3), 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (Compound 4) 3-(5-acetylthiophen-2-yl)-3-[3-({4-[2-(benzyloxy)ethyl]-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl}methyl)-4-methylphenyl]-2-methylpropanoic acid (compound 13), 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 16), 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 48), 3-(5-acetyl-4-fluorothiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 49), 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 50), 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 51).
[0028] Item 13. A medicine containing at least one selected from the group consisting of the compound according to any one of items 1 to 12, a salt thereof, and a solvate thereof.
[0029] Item 14. The pharmaceutical agent according to Item 13, which is an Nrf2 (NF-E2-related factor 2) activator.
[0030] Item 15. The pharmaceutical agent according to Item 13 or 14, which is a topical formulation.
[0031] Item 16. The pharmaceutical composition according to any one of Items 13 to 15, which is an ophthalmic preparation, an otolaryngological preparation, a respiratory preparation, or a dermatological preparation.
[0032] Item 17. The pharmaceutical composition according to Item 13 or 14, which is an oral administration formulation.
[0033] Item 18. The pharmaceutical composition according to Item 13 or 14, which is a parenteral administration formulation.
[0034] Item 19. The pharmaceutical agent according to Item 13, 14, or 18, which is an intravenous administration formulation, an intranasal administration formulation, or a transdermal administration formulation.
[0035] Item 20. The pharmaceutical composition according to any one of Items 11 to 19, which is a pharmaceutical composition for preventing or treating a brain disease, a lung disease, a skin disease, an otolaryngological disease, a kidney disease, or an ophthalmological disease.
[0036] Item 21. A method for preventing or treating a disease or symptom associated with the regulation of Nrf2 (NF-E2-related factor 2) activity in a subject suffering from a disease associated with the regulation of Nrf2 (NF-E2-related factor 2) activity, the method comprising administering to the subject at least one compound selected from the group consisting of the compound according to any one of Items 1 to 13, a salt thereof, and a solvate thereof.
[0037] Item 22. A method for preventing or treating a brain disease, lung disease, skin disease, otolaryngological disease, kidney disease, or ophthalmological disease in a subject suffering from such a disease, the method comprising administering to the subject at least one compound selected from the group consisting of the compound according to any one of Items 1 to 13, a salt thereof, and a solvate thereof.
[0038] Item 23. At least one compound selected from the group consisting of the compound according to any one of Items 1 to 13, a salt thereof, and a solvate thereof for use as a pharmaceutical.
[0039] Item 24. At least one compound selected from the group consisting of the compound according to any one of Items 1 to 13, a salt thereof, and a solvate thereof, for use in the prevention or treatment of a disease or symptom associated with the regulation of Nrf2 (NF-E2-related factor 2) activity.
[0040] Item 25. At least one compound selected from the group consisting of the compound according to any one of Items 1 to 13, a salt thereof, and a solvate thereof for use in the prevention or treatment of a brain disease, a lung disease, a skin disease, an otolaryngological disease, a kidney disease, or an ophthalmological disease.
[0041] Item 26. Use of at least one compound selected from the group consisting of the compound according to any one of Items 1 to 13, a salt thereof, and a solvate thereof for the manufacture of a medicament. [Effects of the Invention]
[0042] The present invention can provide compounds having Nrf2 activation activity, salts thereof, and solvates thereof. Furthermore, the present invention can provide pharmaceuticals containing at least one of these compounds, more specifically, Nrf2 activators, topical preparations, and pharmaceuticals for the prevention or treatment of brain diseases, lung diseases, skin diseases, otolaryngological diseases, kidney diseases, or ophthalmological diseases. DETAILED DESCRIPTION OF THE INVENTION
[0043] In this specification, the expressions "contain" and "comprise" include the concepts of "contain," "comprise," "consist essentially of," and "consist only of."
[0044] 1.Compound In one aspect, the present invention provides a compound of general formula (I):
[0045] [ka]
[0046] The present invention relates to a compound represented by the formula (I), a salt thereof, or a solvate thereof (also referred to as "compound (I) of the present invention" in this specification). This will be explained below.
[0047] <1-1.R 1a , R 1b > R 1a and R 1b are the same or different and represent a hydrogen atom, an alkyl group or a halogen atom.
[0048] R 1a or R 1bThe alkyl group represented by the formula (I) includes both linear and branched (preferably linear) groups. The number of carbon atoms in the alkyl group is not particularly limited, but is, for example, 1 to 4, preferably 1 to 3, more preferably 1 to 2, and even more preferably 1. Specific examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, and a sec-butyl group.
[0049] R 1a or R 1b Examples of the halogen atom represented by the formula (I) include a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, etc., preferably a fluorine atom, a chlorine atom, etc., more preferably a fluorine atom.
[0050] In a preferred embodiment of the present invention, preferably R 1a and R 1b are the same or different and each is a hydrogen atom or an alkyl group. In particular, from the viewpoint of Nrf2 activation activity, R 1a and R 1b one of which is an alkyl group and the other is a hydrogen atom or an alkyl group, and more preferably R 1a and R 1b One of the groups is an alkyl group and the other is a hydrogen atom.
[0051] <1-2.R 2 > R 2 represents a group derived from an optionally substituted heterocycle, and the heterocycle represents thiophene, furan, pyrrole, or thiazole, or a fused ring containing any of these heterocycles.
[0052] Examples of the fused ring include a fused ring (bicyclic) formed between thiophene, furan, pyrrole, or thiazole and a 5- to 7-membered ring. Examples of the 5- to 7-membered ring forming the fused ring include a ring having, for example, 0 to 3 heteroatoms (e.g., sulfur atoms, oxygen atoms, nitrogen atoms, etc.) and with or without an oxo group. More specific examples of the fused ring include indole, hydroindole, oxohydroindole, thienopyrrole, hydrothienopyrrole, oxohydrothienopyrrole, etc., and preferred examples include oxohydroindole (more specifically, 4-oxo-1,5,6,7-tetrahydro-1H-indole), oxohydrothienopyrrole (more specifically, 6-oxo-4,5-dihydro-6H-thieno[2,3-c]pyrrole), etc.
[0053] Examples of groups derived from heterocycles include thienyl groups (e.g., 2-thienyl groups, 3-thienyl groups, etc., preferably 2-thienyl groups), furyl groups (e.g., 2-furyl groups, 3-furyl groups, etc., preferably 2-furyl groups), pyrrolyl groups (e.g., 1-pyrrolyl groups, 2-pyrrolyl groups, 3-pyrrolyl groups), thiazolyl groups (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), and groups derived from the above-mentioned fused rings.
[0054] R 2 Examples of the substituent that the heterocyclic group represented by the formula (I) may have include an acetyl group, an acyl group such as a cycloalkylcarbonyl group, an aminosulfonyl group, a cyano group, -R 21 -NR 22 R 23 (R 21 represents a single bond, a carbonyl group, or an alkylene group. 22 and R 23 are the same or different and each represent a hydrogen atom, an optionally substituted alkyl group, or R 22 and R 23are bonded to each other to form an alkylene group, which then forms a ring together with the adjacent nitrogen atom. Examples of the substituent include an alkoxy group, a halogen atom, and an alkyl group. The position of the substituent is not particularly limited, and may be, for example, any of the ring-constituting atoms on the heterocycle (e.g., carbon atom, sulfur atom, oxygen atom, nitrogen atom, etc.), preferably a carbon atom on the heterocycle. The number of the substituents is not particularly limited, and may be, for example, 0 to 4, preferably 0 to 2, and more preferably 1 to 2.
[0055] The acyl group as a substituent that may be possessed by the heterocyclic group is not particularly limited as long as it is a group obtained by removing a hydroxy group from a carboxylic acid, but is preferably -CO-R 24 (R 24 R represents an alkyl group or a cycloalkyl group (preferably an alkyl group). 24 The alkyl group represented by the formula (I) includes both straight-chain and branched-chain (preferably straight-chain) alkyl groups. The number of carbon atoms in the alkyl group is not particularly limited, but is, for example, 1 to 8, preferably 1 to 6, more preferably 1 to 4, even more preferably 1 to 2, and particularly preferably 1. Specific examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, a sec-butyl group, an n-pentyl group, a neopentyl group, an n-hexyl group, and a 3-methylpentyl group. R 24 The number of carbon atoms in the cycloalkyl group represented by the formula (I) is not particularly limited, but is, for example, 3 to 8, preferably 3 to 6, more preferably 3 to 4, and even more preferably 3. Preferred examples of the acyl group as the substituent include an acetyl group and a cycloalkylcarbonyl group, and from the viewpoint of Nrf2 activation activity in particular, an acetyl group is particularly preferred.
[0056] -R as a substituent that may be possessed by a heterocyclic group 21 -NR 22 R 23 Configure R 21 represents a single bond, a carbonyl group, or an alkylene group (preferably a carbonyl group). 21The alkylene group represented by the formula (I) includes both straight-chain and branched-chain (preferably straight-chain) alkylene groups. The number of carbon atoms in the alkylene group is not particularly limited, but is, for example, 1 to 8, preferably 1 to 6, more preferably 1 to 4, even more preferably 1 to 2, and particularly preferably 1. Specific examples of the alkylene group include a methylene group, an ethylene group, a propylene group, and a butylene group. -R as the above substituent 21 -NR 22 R 23 Configure R 22 and R 23 are the same or different and each represent a hydrogen atom, an optionally substituted alkyl group, or R 22 and R 23 are bonded to each other to form an alkylene group and form a ring together with the adjacent nitrogen atom (preferably R 22 and R 23 are the same or different and each represents a hydrogen atom or an alkyl group, and more preferably R 22 and R 23 one of which is a hydrogen atom and the other is an alkyl group, and more preferably R 22 and R 23 are both hydrogen atoms. 22 or R 23The alkyl group represented by the formula (I) includes both linear and branched (preferably linear) groups. The number of carbon atoms in the alkyl group is not particularly limited, but is, for example, 1 to 8, preferably 1 to 6, more preferably 1 to 4, even more preferably 1 to 2, and particularly preferably 1. Specific examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, a sec-butyl group, an n-pentyl group, a neopentyl group, an n-hexyl group, and a 3-methylpentyl group. An example of a substituent that the alkyl group may have is an alkoxy group. The alkoxy group includes both linear and branched (preferably linear) groups. The number of carbon atoms in the alkoxy group is not particularly limited, but is, for example, 1 to 8, preferably 1 to 6, more preferably 1 to 4, even more preferably 1 to 2, and particularly preferably 1. Specific examples of the alkoxy group include a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a sec-butoxy group, and a tert-butoxy group.
[0057] The alkoxy group as a substituent that the heterocycle-derived group may have includes both linear and branched (preferably linear) ones. The number of carbon atoms in the alkoxy group is not particularly limited, but is, for example, 1 to 8, preferably 1 to 6, more preferably 1 to 4, even more preferably 1 to 2, and particularly preferably 1. Specific examples of the alkoxy group include a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a sec-butoxy group, and a tert-butoxy group.
[0058] Examples of the halogen atom as a substituent that the heterocycle-derived group may have include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom, preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.
[0059] The alkyl group as a substituent that the heterocycle-derived group may have includes both linear and branched (preferably linear) alkyl groups. The number of carbon atoms in the alkyl group is not particularly limited, but is, for example, 1 to 4, preferably 1 to 3, more preferably 1 to 2, and even more preferably 1. Specific examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, and a sec-butyl group.
[0060] In a preferred embodiment of the present invention, preferably R 2 is an optionally substituted thienyl group or an optionally substituted furyl group, and from the viewpoint of the compound being more easily metabolized, R 2 is an optionally substituted thienyl group.
[0061] In a preferred embodiment of the present invention, in particular R 2 When is an optionally substituted thienyl group or an optionally substituted furyl group (preferably an optionally substituted thienyl group), from the viewpoint of particularly increasing the ease of metabolism of the compound, preferably, the substituent that the heterocycle-derived group may have includes an electron-withdrawing group (i.e., when there is one substituent, the substituent is an electron-withdrawing group, and when there are two or more substituents, at least one of the substituents is an electron-withdrawing group). More preferably, the substituent that the heterocycle-derived group may have includes an acyl group, an aminosulfonyl group, or a cyano group (more preferably, an acetyl group, an aminosulfonyl group, a cyano group, or a cycloalkylcarbonyl group; particularly, from the viewpoint of Nrf2 activation activity, an acetyl group is particularly preferred). (i.e., when there is one substituent, the substituent is any of these groups, and when there are two or more substituents, at least one of the substituents is any of these groups.) In these embodiments, preferably, the number of substituents that the heterocycle-derived group has is 0 to 2 (preferably 1 to 2), and when the number of substituents is 2 or more, at least one of the substituents is an alkyl group, a halogen atom, or an alkoxy group.
[0062] In a preferred embodiment of the present invention, preferably R 2 is represented by the general formula (R2X1) or the general formula (R2X2):
[0063] [ka]
[0064] wherein X is S, O or NR 31 Y represents a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group. 3 is an acyl group, a hydrogen atom, an aminosulfonyl group, a cyano group, or -R 21 -NR 22 R 23 Indicates R 31 represents a hydrogen atom or an alkyl group. It is a group represented by the following formula:
[0065] X is preferably S or O, and particularly preferably S.
[0066] R 3 The substituents represented by and Y are the same as those described above in "R 2 The substituents are the same as those that may be possessed by the heterocyclic group represented by the formula "
[0067] R 3 is preferably an acyl group (preferably -CO-R 24 (R 24 represents an alkyl group or a cycloalkyl group), an aminosulfonyl group, a cyano group, etc., more preferably an acetyl group, an aminosulfonyl group, a cyano group, a cycloalkylcarbonyl group, etc., and particularly from the viewpoint of Nrf2 activation activity, an acetyl group is particularly preferred.
[0068] R 31 is preferably an alkyl group. 31The alkyl group represented by the formula (I) includes both linear and branched (preferably linear) groups. The number of carbon atoms in the alkyl group is not particularly limited, but is, for example, 1 to 8, preferably 1 to 6, more preferably 1 to 4, even more preferably 1 to 2, and particularly preferably 1. Specific examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, a sec-butyl group, an n-pentyl group, a neopentyl group, an n-hexyl group, and a 3-methylpentyl group.
[0069] The above R represented by the general formula 2 As the group represented by the general formula (R2X1), a group represented by the general formula (R2A) is preferable, and a group represented by the general formula (R2A) is more preferable.
[0070] [ka]
[0071] [Wherein: Y and R 3 is the same as above.] and more preferably a group represented by the general formula (R2Aa) or (R2Ab):
[0072] [ka]
[0073] [Wherein: Y and R 3 is the same as above.] Examples of the group include a group represented by the following formula:
[0074] <1-3.R 4 , R 5 > R 4 and R 5 are the same or different and represent a hydrogen atom or an optionally substituted alkyl group, or R 4 and R 5 are bonded to each other to form -NH-CH=N-.
[0075] R4 or R 5 The alkyl group represented by the formula (I) includes both linear and branched (preferably linear) groups. The number of carbon atoms in the alkyl group is not particularly limited, but is, for example, 1 to 4, preferably 1 to 3, more preferably 1 to 2, and even more preferably 1. Specific examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, and a sec-butyl group.
[0076] R 4 or R 5 Examples of the substituent that the alkyl group represented by the following formula may have include a halogen atom. Examples of the halogen atom include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom. The number of the substituents is not particularly limited and is, for example, 0 to 3, and preferably 0.
[0077] "R 4 and R 5 are bonded to each other to form -NH-CH=N-" means the following partial structure in general formula (I):
[0078] [ka]
[0079] But the following structure:
[0080] [ka]
[0081] The key is to take
[0082] In a preferred embodiment of the present invention, preferably R 4 and R 5 are the same or different and are a hydrogen atom or an alkyl group, and more preferably R 4 and R 5 one of which is an alkyl group and the other is a hydrogen atom, and more preferably R4 is a hydrogen atom and R 5 is an alkyl group.
[0083] <1-4.R 6 > R 6 represents an optionally substituted alkyl group.
[0084] R 6 The alkyl group represented by the formula (I) includes both straight-chain and branched-chain (preferably straight-chain) ones. The number of carbon atoms in the alkyl group is not particularly limited, but is, for example, 1 to 8, preferably 1 to 6, more preferably 1 to 4, even more preferably 1 to 2, and particularly preferably 2. Specific examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, a sec-butyl group, an n-pentyl group, a neopentyl group, an n-hexyl group, and a 3-methylpentyl group.
[0085] R 6 Examples of the substituent that the alkyl group represented by the formula (I) may have include a hydroxyl group, an alkoxy group, an arylalkoxy group, an aryloxy group, -NR 61 R 62 (R 61 and R 62 are the same or different and represent a hydrogen atom or an alkyl group.) The position of the substituent is not particularly limited, but in one embodiment of the present invention, it is preferably the terminal of the alkyl group. The number of the substituents is not particularly limited and is, for example, 0 to 3, preferably 0 to 1.
[0086] The alkoxy group as the substituent includes both straight-chain and branched-chain (preferably straight-chain) alkoxy groups. The number of carbon atoms in the alkoxy group is not particularly limited, but is, for example, 1 to 8, preferably 1 to 6, more preferably 1 to 4, even more preferably 1 to 2, and particularly preferably 1. Specific examples of the alkoxy group include a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a sec-butoxy group, and a tert-butoxy group.
[0087] The arylalkoxy group as the substituent is not particularly limited as long as it is the alkoxy group substituted with an aryl group. The number of carbon atoms in the aryl group is not particularly limited, but is, for example, 6 to 14, preferably 6 to 8. Specific examples of such aryl groups include phenyl, naphthyl, biphenyl, pentalenyl, indenyl, anthryl, tetracenyl, pentacenyl, pyrenyl, perylenyl, fluorenyl, and phenanthryl groups, with phenyl being particularly preferred. The substitution position of the aryl group in the alkoxy group is not particularly limited, but in one embodiment of the present invention, it is preferably at the terminal of the alkoxy group. Examples of the arylalkoxy group include benzyloxy and phenethyloxy groups.
[0088] The number of carbon atoms in the aryloxy group as the substituent is not particularly limited, but is, for example, 6 to 14, and preferably 6 to 8. Specific examples of the aryl group constituting the aryloxy group include a phenyl group, a naphthyl group, a biphenyl group, a pentalenyl group, an indenyl group, an anthranyl group, a tetracenyl group, a pentacenyl group, a pyrenyl group, a perylenyl group, a fluorenyl group, and a phenanthryl group, with a phenyl group being particularly preferred. The aryloxy group includes, for example, a phenyloxy group.
[0089] -NR as the above substituent 61 R 62 Configure R 61 and R 62 are the same or different and represent a hydrogen atom or an alkyl group. 61 or R 62The alkyl group represented by the formula (I) includes both straight-chain and branched-chain (preferably straight-chain) ones. The number of carbon atoms in the alkyl group is not particularly limited, but is, for example, 1 to 8, preferably 1 to 6, more preferably 1 to 4, even more preferably 1 to 2, and particularly preferably 2. Specific examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, a sec-butyl group, an n-pentyl group, a neopentyl group, an n-hexyl group, and a 3-methylpentyl group.
[0090] In a preferred embodiment of the present invention, preferably R 6 represents an alkyl group which may be substituted with a hydroxyl group, an alkoxy group, or an arylalkoxy group, more preferably an alkyl group which may be substituted with an arylalkoxy group, and even more preferably an alkyl group.
[0091] <1-5.A 1 , A 2 , A 3 , A 4 > A 1 , A 2 , A 3 and A 4 are the same or different and represent CH or N (provided that N is one or less).
[0092] A 1 , A 2 , A 3 and A 4 If any one of is N, then preferably A 1 or A 3 is N, more preferably A 3 is N.
[0093] In a preferred embodiment of the present invention, preferably, A 1 , A 2 and A 4 are all CH and A 3 is CH or N, more preferably A 1 , A 2 , A 3 and A4 are all CH.
[0094] <1-6.Z> Z represents a hydrogen atom or a halogen atom.
[0095] Examples of the halogen atom represented by Z include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom, preferably a fluorine atom and a chlorine atom, and more preferably a fluorine atom.
[0096] When Z is a halogen atom, its bonding position is A 1 , A 2 , A 3 and A 4 Either of these is acceptable, but for example, A 4 is.
[0097] In a preferred embodiment of the present invention, Z is preferably a hydrogen atom.
[0098] <1-7. General formula (I)> In one embodiment of the present invention, among the general formula (I), preferably the general formula (IA):
[0099] [ka]
[0100] [In the formula: R 1a , R 1b , R 3 , R 4 , R 5 , R 6 , A 1 , A 2 , A 3 , A 4 , X, Y and Z are the same as above.] More preferably, the general formula (IAA):
[0101] [ka]
[0102] [In the formula: R 1a , R 1b , R 3 , R 4 , R 5 , R 6 , A 3 , X, Y and Z are the same as above.] More preferably, the compound represented by the general formula (IAAA):
[0103] [ka]
[0104] [In the formula: R 1a , R 1b , R 3 , R 4 , R 5 , R 6 , A 3 , Y and Z are the same as above.] and even more preferably the general formula (IAAAA1):
[0105] [ka]
[0106] [In the formula: R 1a , R 1b , R 3 , R 4 , R 5 , R 6 , A 3 , Y and Z are the same as above.] or general formula (IAAAA2):
[0107] [ka]
[0108] [In the formula: R 1a , R 1b , R 3 , R 4 , R 5 , R 6 , A3 , Y and Z are the same as above.] Examples include:
[0109] In a preferred embodiment of the present invention, R 1a and R 1b are the same or different and are a hydrogen atom or an alkyl group, R 3 is an acetyl group, R 4 and R 5 are the same or different and are a hydrogen atom or an alkyl group, R 6 is an optionally substituted ethyl group, A 1 , A 2 , and A 4 are all CH, and A 3 is CH or N, Y is a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group, and Z is a hydrogen atom; It is preferable.
[0110] In a preferred embodiment of the present invention, R 1a and R 1b one of which is an alkyl group and the other is a hydrogen atom, or R 1a and R 1b and both are alkyl groups, and preferably the alkyl groups have 1 to 3 carbon atoms, R 2 is of the general formula (R2Aa):
[0111] [ka]
[0112] [In the formula: R 3 represents an acetyl group. Y represents a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group. Preferably, the alkyl group has 1 to 3 carbon atoms, the halogen atom is a fluorine atom, and the alkoxy group has 1 to 3 carbon atoms.] and R 4 is a hydrogen atom, R 5 is an alkyl group, preferably having 1 to 3 carbon atoms; R 6 is an optionally substituted ethyl group, and the substituent that the ethyl group may have is preferably an arylalkoxy group, and particularly preferably a benzyloxy group; The above A 1 , the above-mentioned A 2 , and the A 4 are all CH, and the A 3 is CH or N, and wherein Z is a hydrogen atom. It is preferable.
[0113] In one embodiment of the present invention, preferred examples of the compound represented by general formula (I) include the following compounds.
[0114] 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (Compound 1), 3-(5-acetyl-4-methylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 2), 3-(4-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 3), 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (Compound 4) 3-(5-acetylthiophen-2-yl)-3-[3-({4-[2-(benzyloxy)ethyl]-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl}methyl)-4-methylphenyl]-2-methylpropanoic acid (compound 13), 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 16), 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 48), 3-(5-acetyl-4-fluorothiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 49), 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 50), 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 51).
[0115] <1-8.Other> The salt of the compound represented by general formula (I) is not particularly limited as long as it is a pharmaceutically acceptable salt. Both acid salts and basic salts can be used as the salt. Examples of acid salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, nitrate, and phosphate; organic acid salts such as acetate, propionate, tartrate, fumarate, maleate, malate, citrate, methanesulfonate, and paratoluenesulfonate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt; salts with ammonia; salts with organic amines such as morpholine, piperidine, pyrrolidine, monoalkylamine, dialkylamine, trialkylamine, mono(hydroxyalkyl)amine, di(hydroxyalkyl)amine, and tri(hydroxyalkyl)amine.
[0116] The solvate of the compound represented by general formula (I) is not particularly limited. Examples of the solvent that constitutes the solvate include water and pharmaceutically acceptable organic solvents (e.g., ethanol, glycerol, acetic acid, etc.).
[0117] Compound (I) of the present invention can also be produced by modifying it to a compound in which each B is independently C, CH, or N in the following general formula. In the following general formula, a double line consisting of a dotted line and a solid line represents a single bond or a double bond. In one embodiment of the compound represented by the following general formula, the number of N in the 6-membered ring containing B is 1 to 3. R 1a , R 1b , R 2 , R 4 , R 5 , R 6 , A 1 , A 2 , A 3 , A 4 , Z is the same as above.
[0118] [ka]
[0119] 2. Manufacturing method The compound (I) of the present invention can be prepared by various methods.
[0120] Compound (I) of the present invention can be produced, for example, by the method shown in Scheme 1 below or a method analogous thereto.
[0121] [ka]
[0122] In step a, synthetic intermediate 2 and synthetic intermediate 3 are reacted in the presence of a catalyst and a base to produce synthetic intermediate 4. Synthetic intermediate 3 can be used in an amount of, for example, 1 to 5 equivalents, preferably 1.2 to 3 equivalents, relative to synthetic intermediate 2; catalyst can be used in an amount of, for example, 0.05 to 0.5 equivalents, preferably 0.05 to 0.2 equivalents; and base can be used in an amount of, for example, 1.5 to 5 equivalents, preferably 1.5 to 3 equivalents. Examples of catalysts include rhodium complexes, preferably [RhCl(cod)]2. Examples of bases include, for example, N,N-dicyclohexylmethylamine, triethylamine, pyridine, N,N-diisopropylethylamine, etc., with triethylamine being preferred. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include 1,4-dioxane, 1,2-dimethoxyethane, tetrahydrofuran, etc., with 1,4-dioxane being preferred. The reaction time varies depending on the reagents or solvent used, but is usually 1 to 24 hours, preferably 1 to 18 hours. The reaction temperature varies depending on the reagents or solvent used, but is usually 0°C to 150°C, preferably 25°C to 100°C.
[0123] In step b, synthetic intermediate 4 is reacted with iodomethane in the presence of a base to produce synthetic intermediate 5. Lithium diisopropylamide can be used in an amount of, for example, 1 to 2 equivalents, preferably 1 to 1.8 equivalents, relative to synthetic intermediate 4, and iodomethane can be used in an amount of, for example, 1 to 20 equivalents, preferably 1 to 15 equivalents. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include tetrahydrofuran. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 24 hours, preferably 1 to 5 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually -78°C to 40°C, preferably -78°C to 25°C.
[0124] In step c, a deprotection reaction of the acetal of synthetic intermediate 5 is carried out. An excess amount of hydrochloric acid is used relative to synthetic intermediate 5. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples thereof include methanol, dichloromethane, tetrahydrofuran, 1,4-dioxane, etc., with methanol or tetrahydrofuran being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 hour to 24 hours, preferably 1 hour to 18 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 25°C to 150°C, preferably 25°C to 100°C.
[0125] In step d, compound (I) of the present invention is produced by hydrolysis of synthetic intermediate 4 or an ester equivalent thereto. A base can be used in an amount of, for example, 5 to 20 equivalents, preferably 10 to 20 equivalents, relative to synthetic intermediate 4. Examples of the base include lithium hydroxide, sodium hydroxide, and potassium hydroxide, with sodium hydroxide or lithium hydroxide being preferred. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include methanol, dichloromethane, and tetrahydrofuran, with methanol or tetrahydrofuran being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 hour to 24 hours, preferably 1 hour to 18 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 25°C to 150°C, preferably 25°C to 140°C.
[0126] Compound (I) of the present invention can also be produced, for example, by the method shown in Scheme 2 below or a method analogous thereto.
[0127] [ka]
[0128] Step d of Scheme 2 is carried out according to Scheme 1.
[0129] In step e, synthetic intermediate 8 is produced from synthetic intermediate 6 and synthetic intermediate 7. Synthetic intermediate 7 can be used in an amount of, for example, 1 to 1.5 equivalents, preferably 1 to 1.2 equivalents, and n-butyllithium can be used in an amount of, for example, 1 to 2 equivalents, preferably 1 to 1.5 equivalents, relative to synthetic intermediate 6. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples thereof include tetrahydrofuran. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 10 hours, preferably 1 to 4 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually -80°C to 25°C, preferably -78°C to 25°C.
[0130] In step f, synthetic intermediate 9 is produced from synthetic intermediate 8. Relative to synthetic intermediate 8, trichloroacetonitrile can be used in an amount of, for example, 1 to 3 equivalents, preferably 1 to 2 equivalents; 1,8-diazabicyclo[5,4,0]-7-undecene can be used in an amount of, for example, 0.01 to 0.1 equivalents, preferably 0.01 to 0.05 equivalents; dimethylketene methyltrimethylsilyl acetal can be used in an amount of, for example, 1 to 3 equivalents, preferably 1 to 2.5 equivalents; and bis(trifluoromethanesulfonyl)imide can be used in an amount of, for example, 0.01 to 0.1 equivalents, preferably 0.05 to 0.1 equivalents. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include dichloromethane, tetrahydrofuran, acetonitrile, etc., with acetonitrile being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 10 hours, preferably 1 to 5 hours. The reaction temperature varies depending on the reagents or solvent used, but is usually 0°C to 25°C, preferably 10°C to 25°C.
[0131] In step g, synthetic intermediate 10 is produced from synthetic intermediate 9. 2,3-dichloro-5,6-dicyano-p-benzoquinone can be used in an amount of, for example, 1 to 3 equivalents, preferably 1 to 2.5 equivalents, relative to synthetic intermediate 9. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and an example is a mixed solvent of dichloromethane and water. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 5 hours, preferably 1 to 3 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 25°C, preferably 10°C to 25°C.
[0132] In step h, synthetic intermediate 12 is produced from synthetic intermediate 10 and synthetic intermediate 11. Synthetic intermediate 11 can be used in an amount of, for example, 1 to 2 equivalents, preferably 1 to 1.2 equivalents, relative to synthetic intermediate 10. Triphenylphosphine can be used in an amount of, for example, 1 to 2 equivalents, preferably 1 to 1.2 equivalents, and diethyl azodicarboxylate can be used in an amount of, for example, 1 to 1.5 equivalents, preferably 1 to 1.2 equivalents. Bis(2-methoxyethyl)azodicarboxylate, diisopropyl azodicarboxylate, cyanomethylenetributylphosphorane, or the like can also be used instead of diethyl azodicarboxylate. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction. Examples of the solvent include dichloromethane, 1,4-dioxane, tetrahydrofuran, toluene, and N,N-dimethylformamide, with tetrahydrofuran being preferred. The reaction time varies depending on the reagents or solvent used, but is usually 1 to 24 hours, preferably 5 to 8 hours. The reaction temperature varies depending on the reagents or solvent used, but is usually 0 to 40°C, preferably 0 to 25°C.
[0133] Synthetic intermediates 2, 6, and 11 in Schemes 1 and 2 can be produced according to known methods, such as those described in Patent Document 1 (WO2015 / 092713) and WO2016 / 202253, or methods analogous thereto, for example, Scheme 3 below.
[0134] [ka]
[0135] Step h of Scheme 3 is carried out according to Scheme 2.
[0136] In step i, synthetic intermediate 14 is produced by an amination reaction of synthetic intermediate 13. An excess amount of aqueous ammonia is used relative to synthetic intermediate 13. The reaction time varies depending on the reagents or solvent used, but is usually 1 hour to 24 hours, preferably 1 hour to 18 hours. The reaction temperature varies depending on the reagents or solvent used, but is usually 25°C to 150°C, preferably 25°C to 40°C.
[0137] In step j, synthetic intermediate 14 and synthetic intermediate 15 are reacted to produce synthetic intermediate 11 via synthetic intermediate 16.
[0138] In the first step, synthetic intermediate 14 and synthetic intermediate 15 are reacted in the presence of a base. The base can be used in an amount of, for example, 1 to 2 equivalents, preferably 1 to 1.5 equivalents, relative to synthetic intermediate 14, and synthetic intermediate 15 can be used in an amount of, for example, 0.8 to 1.5 equivalents, preferably 0.8 to 1.2 equivalents. Examples of bases include potassium carbonate and sodium carbonate, with potassium carbonate being preferred. The reaction is typically carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include mixed solvents of water with an organic solvent such as tetrahydrofuran or dimethylformamide, with a preferred example being a mixed solvent of tetrahydrofuran and water. The reaction time varies depending on the reagents and solvent used, but is typically 1 to 24 hours, preferably 1 to 3 hours. The reaction temperature varies depending on the reagents and solvent used, but is typically 25°C to 150°C, preferably 25°C to 40°C.
[0139] In the second step, synthetic intermediate 11 is produced from synthetic intermediate 16 in the presence of a base. The base can be used in an amount of, for example, 1 to 5 equivalents, preferably 2 to 3 equivalents, relative to synthetic intermediate 16. Examples of the base include potassium tert-butoxide, potassium carbonate, and potassium hydroxide, with potassium tert-butoxide being preferred. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include dimethyl sulfoxide and dimethylformamide, with dimethyl sulfoxide being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 24 hours, preferably 1 to 3 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 25°C to 150°C, preferably 60°C to 100°C.
[0140] In step k, synthetic intermediate 17 is reduced to produce synthetic intermediate 18. The reducing agent can be used in an amount of, for example, 1 to 2 equivalents, preferably 1 to 1.5 equivalents, relative to synthetic intermediate 17. Examples of the reducing agent include borane-tetrahydrofuran complex and borane-dimethyl sulfide complex. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and an example of the solvent is tetrahydrofuran. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 40 hours, preferably 1 to 24 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 25°C to 150°C, preferably 25°C to 40°C.
[0141] In step 1, synthetic intermediate 19 is reacted with bis-pinacolatodiboron in the presence of a base and a catalyst to produce synthetic intermediate 2. For synthetic intermediate 19, for example, 1 to 3 equivalents, preferably 1 to 2.5 equivalents, of the base can be used; for example, 0.05 to 0.1 equivalents, preferably 0.05 to 0.08 equivalents, of the catalyst can be used; and for example, 1 to 2 equivalents, preferably 1 to 1.5 equivalents, of the bis-pinacolatodiboron can be used. Potassium acetate, for example, can be used as the base. Examples of catalysts include palladium catalysts such as PdCl(dppf)·CHCl and Pd(dba), with PdCl(dppf)·CHCl being preferred. The reaction is typically carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples thereof include 1,4-dioxane, tetrahydrofuran, dimethyl sulfoxide, N,N-dimethylformamide, etc., with 1,4-dioxane being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 hour to 24 hours, preferably 5 hours to 8 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 60°C to 120°C, preferably 60°C to 100°C.
[0142] In step m, synthetic intermediate 20 is produced from synthetic intermediate 18. Sodium hydride can be used in an amount of, for example, 1 to 2 equivalents, preferably 1 to 1.5 equivalents, relative to synthetic intermediate 20, and p-methoxybenzyl chloride can be used in an amount of, for example, 1 to 2 equivalents, preferably 1 to 1.2 equivalents. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include tetrahydrofuran and N,N-dimethylformamide, with N,N-dimethylformamide being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 hour to 24 hours, preferably 5 hours to 15 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 60°C, preferably 0°C to 25°C.
[0143] In step n, synthetic intermediate 6 is produced from synthetic intermediate 20. For example, 1 to 1.5 equivalents, preferably 1 to 1.2 equivalents, of n-butyllithium can be used relative to synthetic intermediate 20, and 1 to 2 equivalents, preferably 1 to 1.5 equivalents, of N,N-dimethylformamide can be used. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include tetrahydrofuran. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 10 hours, preferably 1 to 3 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually -80°C to 25°C, preferably -78°C to 25°C.
[0144] Synthetic intermediate 3 can be obtained, for example, by the methods shown in the following Schemes 4 to 7 or methods analogous thereto.
[0145] [ka]
[0146] In step o, synthetic intermediate 21 is reacted with N,O-dimethylhydroxylamine hydrochloride in the presence of a base, a condensing agent, and an additive to produce synthetic intermediate 22. N,O-dimethylhydroxylamine hydrochloride can be used in an amount of usually 1 to 3 equivalents, preferably 1.5 to 2 equivalents, relative to synthetic intermediate 21. Furthermore, the condensing agent can be used in an amount of usually 1 to 3 equivalents, preferably 1 to 2 equivalents, the additive can be used in an amount of usually 0.1 to 2 equivalents, preferably 1 to 2 equivalents, and the base can be used in an amount of usually 0.5 to 5 equivalents, preferably 2 to 4 equivalents, relative to synthetic intermediate 21. Examples of the condensing agent include N,N'-dicyclohexylcarbodiimide, 1,1'-carbonyldiimidazole, 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride, benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, O-(7-azabenzotriazol-1-yl)-N,N Examples of suitable bases include, but are not limited to, N,N',N'-tetramethyluronium hexafluorophosphate, diethyl cyanophosphate, diphenylphosphoryl azide, pentafluorophenyl trifluoroacetate, and isopropyl chloroformate. Preferred examples include 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate. Examples of suitable additives include 1-hydroxybenzotriazole, 1-hydroxy-7-azabenzotriazole, and N-hydroxysuccinimide. Preferred examples include 1-hydroxybenzotriazole. Examples of suitable bases include triethylamine, pyridine, N,N-diisopropylethylamine, and 4-dimethylaminopyridine. Preferred examples include triethylamine, N,N-diisopropylethylamine, and 4-dimethylaminopyridine. The reaction is usually carried out in a solvent.The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples thereof include dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, diethyl ether, acetonitrile, N,N-dimethylformamide, etc., with dichloromethane or N,N-dimethylformamide being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 hour to 24 hours, preferably 3 hours to 24 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 100°C, preferably 25°C to 40°C.
[0147] In step p, synthetic intermediate 22 or synthetic intermediate 24 is subjected to a bromination reaction to produce synthetic intermediate 23 or synthetic intermediate 25. N-bromosuccinimide can be used in an amount of typically 1 to 5 equivalents, preferably 2 to 3 equivalents, relative to synthetic intermediate 22 or synthetic intermediate 24, and trifluoroacetic acid can be used in an amount of typically 1 to 3 equivalents, preferably 1 to 2 equivalents. Instead of trifluoroacetic acid, concentrated sulfuric acid, concentrated hydrochloric acid, acetic acid, or the like can also be used. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples thereof include dichloromethane, chloroform, carbon tetrachloride, 1,2-dimethoxyethane, N,N-dimethylformamide, and the like, with N,N-dimethylformamide being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 24 hours, preferably 3 to 24 hours. The reaction temperature varies depending on the reagents or solvent used, but is usually 0°C to 100°C, preferably 25°C to 40°C.
[0148] In step q, synthetic intermediate 25 is produced from synthetic intermediate 23. Methylmagnesium bromide can be used in an amount of, for example, 1 to 3 equivalents, preferably 1 to 1.5 equivalents, relative to synthetic intermediate 23. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, diethyl ether, etc., with tetrahydrofuran being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 hour to 24 hours, preferably 3 hours to 24 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 100°C, preferably 0°C to 40°C.
[0149] In step r, synthetic intermediate 25 is reacted with ethylene glycol in the presence of an acid catalyst to produce synthetic intermediate 26. The acid catalyst can be used in an amount of, for example, 0.1 to 5 equivalents, preferably 0.1 to 0.5 equivalents, relative to synthetic intermediate 25, and ethylene glycol can be used in an amount of, for example, 5 to 20 equivalents, preferably 10 to 15 equivalents. Examples of acid catalysts include p-toluenesulfonic acid monohydrate, hydrochloric acid, and trifluoroacetic acid, with p-toluenesulfonic acid monohydrate being preferred. The reaction is typically carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include toluene and benzene, with toluene being preferred. The reaction time varies depending on the reagents and solvent used, but is typically 1 to 24 hours, preferably 3 to 24 hours. The reaction temperature varies depending on the reagents and solvent used, but is typically 40°C to 150°C, preferably 100°C to 130°C.
[0150] In step s, synthetic intermediate 25 or synthetic intermediate 26 is reacted with methyl acrylate in the presence of a catalyst, a base, and an additive to produce synthetic intermediate 27. Relative to synthetic intermediate 25 or synthetic intermediate 26, the catalyst can be used in an amount of, for example, 0.05 to 0.2 equivalents, preferably 0.05 to 0.1 equivalents; the base can be used in an amount of, for example, 1.5 to 5 equivalents, preferably 1.5 to 3 equivalents; the additive can be used in an amount of, for example, 0.05 to 0.2 equivalents, preferably 0.05 to 0.1 equivalents; and the methyl acrylate can be used in an amount of, for example, 1.5 to 3 equivalents, preferably 1.5 to 2 equivalents. Examples of catalysts include palladium catalysts such as PdCl(dppf)·CHCl, Pd(OAc), PdCl(PPh), and Pd(PPh), with PdCl(dppf)·CHCl being preferred. Examples of bases include N,N-dicyclohexylmethylamine, triethylamine, pyridine, and N,N-diisopropylethylamine, with N,N-dicyclohexylmethylamine being preferred. Examples of additives include tetrabutylammonium chloride and tetrabutylammonium iodide, with tetrabutylammonium chloride being preferred. The reaction is typically carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include dimethylformamide and dimethylacetamide, with dimethylacetamide being preferred. The reaction time varies depending on the reagents and solvent used, but is typically 1 hour to 24 hours, preferably 1 hour to 8 hours. The reaction temperature varies depending on the reagents and solvent used, but is typically 40°C to 150°C, preferably 100°C to 140°C, using microwaves.
[0151] [ka]
[0152] Scheme 5 is carried out in accordance with steps o and s of Scheme 4, except that in step o, the corresponding amine is used in place of N,O-dimethylhydroxylamine hydrochloride.
[0153] [ka]
[0154] Step s of Scheme 6 is carried out according to Scheme 4.
[0155] In step t, synthetic intermediate 29 is produced from synthetic intermediate 28. Methylmagnesium bromide can be used in an amount of, for example, 1 to 3 equivalents, preferably 1 to 1.5 equivalents, relative to synthetic intermediate 28. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, diethyl ether, etc., with tetrahydrofuran being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 hour to 24 hours, preferably 3 hours to 24 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 100°C, preferably 0°C to 40°C.
[0156] In step u, synthetic intermediate 29 is oxidized with a sulfur trioxide-pyridine complex in the presence of a base to produce synthetic intermediate 30. The base can be used in an amount of, for example, 1 to 5 equivalents, preferably 1 to 3 equivalents, relative to synthetic intermediate 29, and the sulfur trioxide-pyridine complex can be used in an amount of, for example, 1 to 3 equivalents, preferably 1 to 2.5 equivalents. Examples of bases include triethylamine, pyridine, N,N-diisopropylethylamine, and 4-dimethylaminopyridine, with triethylamine being preferred. The reaction is typically carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and dimethyl sulfoxide is preferred. The reaction time varies depending on the reagents and solvent used, but is typically 1 to 24 hours, preferably 3 to 24 hours. The reaction temperature varies depending on the reagents and solvent used, but is typically 0°C to 100°C, preferably 0°C to 40°C.
[0157] Furthermore, synthetic intermediate 3 can be produced according to a known method, for example, the method described in JP2008 / 273924, or a method analogous thereto, for example, Scheme 7 below.
[0158] [ka]
[0159] Steps p and s in Scheme 7 are carried out according to Scheme 4.
[0160] In step v, synthetic intermediate 31 is reacted with tert-butylamine and acetic acid to produce synthetic intermediate 32. For example, 1 to 3 equivalents, preferably 1 to 1.5 equivalents, of tert-butylamine can be used relative to synthetic intermediate 31, and 1 to 20 equivalents, preferably 2.5 to 5 equivalents, of acetic acid can be used. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, toluene, etc., with dichloromethane being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 5 hours, preferably 2 to 4 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 40°C, preferably 10 to 30°C.
[0161] In step w, synthetic intermediate 34 is produced by a deprotection reaction of synthetic intermediate 33 with tert-butylamine. A mixed solvent of trifluoroacetic acid and water can be preferably used for synthetic intermediate 33. The mixed solvent ratio is trifluoroacetic acid / water = 10-20 / 1-5, preferably trifluoroacetic acid / water = 10-12 / 1-2. The reaction time varies depending on the reagents and solvent used, but is usually 1-5 hours, preferably 2-4 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 150°C, preferably 90°C to 110°C.
[0162] Compound (I) of the present invention can also be produced by using synthetic intermediate 38 in place of synthetic intermediate 10 in Scheme 2. Synthetic intermediate 38 can also be produced, for example, by the method shown in Scheme 8 below or a method analogous thereto.
[0163] [ka]
[0164] Each step in Scheme 8 is carried out in accordance with Schemes 1 to 3.
[0165] Compound (I) of the present invention can also be produced by using synthetic intermediate 47 in place of synthetic intermediate 2 in Scheme 1. Synthetic intermediate 47 can also be produced, for example, by the method shown in Scheme 9 below or a method analogous thereto.
[0166] [ka]
[0167] Step 1 of Scheme 9 is carried out according to Scheme 3.
[0168] In step x, synthetic intermediate 40 is produced from synthetic intermediate 39. Bromine can be used in an amount of, for example, 1 to 2 equivalents, preferably 1 to 1.2 equivalents, relative to synthetic intermediate 39. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include acetic acid and trifluoroacetic acid, with acetic acid being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 0.5 to 3 hours, preferably 1 to 2 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 40°C, preferably 0°C to 25°C.
[0169] In step y, synthetic intermediate 41 is produced from synthetic intermediate 40. Tin(II) chloride can be used in an amount of, for example, 1 to 10 equivalents, preferably 2 to 5 equivalents, relative to synthetic intermediate 40. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include methanol, ethanol, propanol, isopropanol, etc., with methanol being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 6 hours, preferably 1.5 to 4 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 100°C, preferably 60°C to 80°C.
[0170] In step z, synthetic intermediate 42 is produced from synthetic intermediate 41. An excess amount of formic acid is used relative to synthetic intermediate 41. The reaction time is usually 0.5 to 5 hours, preferably 1 to 2 hours. The reaction temperature is usually 25°C to 150°C, preferably 90°C to 110°C. In step a-1, synthetic intermediate 43 is produced from synthetic intermediate 42. Trityl chloride can be used in an amount of, for example, 1 to 3 equivalents, preferably 1.1 to 1.3 equivalents, relative to synthetic intermediate 42. A base can be used in an amount of, for example, 1 to 3 equivalents, preferably 1.1 to 1.7 equivalents. Examples of the base include triethylamine, N,N-diisopropylethylamine, pyridine, 4-dimethylaminopyridine, and N-methylmorpholine, with N-methylmorpholine or triethylamine being preferred. The reaction is typically carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, diethyl ether, acetonitrile, and N,N-dimethylformamide, with dichloromethane being preferred. The reaction time varies depending on the reagents and solvent used, but is typically 1 to 12 hours, preferably 1 to 2 hours. The reaction temperature varies depending on the reagents or solvent used, but is usually 0 to 100°C, preferably 40 to 60°C.
[0171] In step a-2, synthetic intermediate 44 is produced from synthetic intermediate 43. The reducing agent can be used in an amount of, for example, 1 to 5 equivalents, preferably 1.5 to 3 equivalents, relative to synthetic intermediate 43. Examples of reducing agents include lithium borohydride, lithium aluminum hydride, lithium borohydride, and borane-tetrahydrofuran complex, with lithium borohydride being preferred. The reaction is typically carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include tetrahydrofuran, diethyl ether, and 1,2-dimethoxyethane, with tetrahydrofuran being preferred. The reaction time varies depending on the reagents and solvent used, but is typically 0.2 to 3 hours, preferably 0.5 to 1.5 hours. The reaction temperature varies depending on the reagents and solvent used, but is typically 0°C to 60°C, preferably 0°C to 30°C.
[0172] In step a-3, synthetic intermediate 44 is reacted with methanesulfonyl chloride and lithium chloride in the presence of a base to produce synthetic intermediate 45. For example, 1 to 5 equivalents, preferably 1.5 to 2.5 equivalents, of methanesulfonyl chloride can be used relative to synthetic intermediate 44. For example, 1 to 10 equivalents, preferably 3 to 5 equivalents, of lithium chloride can be used. For example, 1 to 10 equivalents, preferably 3 to 8 equivalents, of base can be used. Examples of bases include triethylamine, N,N-diisopropylethylamine, pyridine, 4-dimethylaminopyridine, and N-methylmorpholine, with N,N-diisopropylethylamine being preferred. The reaction is usually carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction. Examples include dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, and N,N-dimethylformamide, with dichloromethane being preferred. The reaction time varies depending on the reagents or solvent used, but is usually 1 to 24 hours, preferably 1 to 12 hours. The reaction temperature varies depending on the reagents or solvent used, but is usually 0°C to 40°C, preferably 0°C to 25°C.
[0173] In step a-4, synthetic intermediate 45 is reacted with synthetic intermediate 11 and tetrabutylammonium iodide in the presence of a base to produce synthetic intermediate 46. Synthetic intermediate 11 can be used in an amount of, for example, 1 to 3 equivalents, preferably 1 to 1.2 equivalents, relative to synthetic intermediate 45; tetrabutylammonium iodide can be used in an amount of, for example, 0.1 to 1 equivalent, preferably 0.1 to 0.2 equivalents; and a base can be used in an amount of, for example, 1 to 5 equivalents, preferably 1 to 3 equivalents. Examples of bases include potassium carbonate, sodium carbonate, and sodium bicarbonate, with potassium carbonate being preferred. The reaction is typically carried out in a solvent. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include dichloromethane, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, with N,N-dimethylformamide being preferred. The reaction time varies depending on the reagents and solvent used, but is typically 1 to 24 hours, preferably 1 to 18 hours. The reaction temperature varies depending on the reagents or solvent used, but is usually 0°C to 60°C, preferably 25°C to 40°C.
[0174] Compound (I) of the present invention can also be produced, for example, by the method shown in Scheme 10 below or a method analogous thereto.
[0175] [ka]
[0176] Steps a-3 and a-4 in Scheme 10 are carried out according to Scheme 9, and step d is carried out according to Scheme 1.
[0177] Compound (I) of the present invention can also be produced, for example, by the method shown in Scheme 11 below or a method analogous thereto.
[0178] [ka]
[0179] Steps c and d in Scheme 11 are carried out in accordance with Scheme 1, step g in accordance with Scheme 2, and steps a-3 and a-4 in accordance with Scheme 9.
[0180] <Process a-5> In step a-5, compound 49 is produced from compound 9. Tetrabutylammonium fluoride is used in an amount of 2 to 5 equivalents, preferably 2 to 3 equivalents, relative to compound 9. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include tetrahydrofuran and N,N-dimethylformamide, with tetrahydrofuran being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 24 hours, preferably 1 to 3 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 100°C, preferably 25°C to 40°C.
[0181] <Process a-6> In step a-6, compound 50 is produced from compound 49. Manganese dioxide is used in an amount of 10 to 50 equivalents, preferably 25 to 50 equivalents, relative to compound 49. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include dichloromethane, acetone, benzene, toluene, tetrahydrofuran, 1,4-dioxane, etc., with dichloromethane being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 24 hours, preferably 2 to 24 hours. The reaction temperature varies depending on the reagents and solvent used, but is usually 0°C to 100°C, preferably 25°C to 40°C.
[0182] <Process a-7> In step a-7, compound 52 is produced from compound 51. TMS ethanol is used in an amount of 1 to 5 equivalents, preferably 3 to 5 equivalents, relative to compound 51. A condensing agent is usually used in an amount of 1 to 3 equivalents, preferably 1.5 to 2 equivalents, and a base is usually used in an amount of 1 to 5 equivalents, preferably 2 to 5 equivalents. Examples of the condensing agent include N,N'-dicyclohexylcarbodiimide, 1,1'-carbonyldiimidazole, 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride, benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, diethyl cyanophosphate, diphenylphosphoryl azide, pentafluorophenyl trifluoroacetate, and isopropyl chloroformate, and preferably O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium Examples of suitable bases include hexafluorophosphate and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate. Examples of suitable bases include triethylamine, pyridine, N,N-diisopropylethylamine, 4-dimethylaminopyridine, and the like, with triethylamine, N,N-diisopropylethylamine, and 4-dimethylaminopyridine being preferred. The solvent is not particularly limited as long as it does not adversely affect the reaction, and examples include dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, diethyl ether, acetonitrile, and N,N-dimethylformamide, with dichloromethane or N,N-dimethylformamide being preferred. The reaction time varies depending on the reagents and solvent used, but is usually 1 to 24 hours, preferably 3 to 24 hours. The reaction temperature varies depending on the reagents or solvent used, but is usually 0°C to 100°C, preferably 25°C to 40°C.
[0183] The compound (I) of the present invention thus produced can be isolated or purified as a free form or as a salt thereof after a conventional salt formation treatment. The isolation or purification method is not particularly limited, and commonly used methods such as crystallization, recrystallization, distillation, liquid separation, and chromatography can be appropriately selected and combined. When multiple isomers are present, a single isomer or a mixture of multiple isomers can be obtained by purification. When multiple single isomers or a mixture of multiple isomers are obtained by purification, each of them can be used as is or mixed together as compound (I) of the present invention. A solvate of the compound represented by general formula (I) can be obtained by a method known per se. The structure of the product can also be determined by elemental analysis, MS (ESI-MS) analysis, IR analysis, or the like. 1 H-NMR, 13 It can be identified by C-NMR or the like.
[0184] 3.Applications Compound (I) of the present invention has an Nrf2 activating effect. Therefore, at least one compound selected from the group consisting of compounds represented by general formula (I), salts thereof, and solvates thereof (sometimes referred to herein as the "active ingredient of the present invention") can be used, for example, as a medicine, a reagent, etc. From this perspective, in one aspect, the present invention relates to a medicine (sometimes referred to herein as the "medicine of the present invention") containing the active ingredient of the present invention.
[0185] The pharmaceutical of the present invention can be used as an Nrf2 activator, an activator of oxidative stress defense gene expression, etc., based on the action of the active ingredient of the present invention.
[0186] The medicament of the present invention can be used for the prevention or treatment of various diseases. The target diseases are not particularly limited, as long as they can be prevented or treated based on the above-mentioned effects of the active ingredient of the present invention. The medicament of the present invention can be used for the prevention or treatment of diseases or symptoms associated with the modulation of Nrf2 activity. "Treatment" refers to preventing the deterioration of a disorder or disease upon its onset, slowing its progression, and maintaining, alleviating, or eliminating the condition. "Prevention" refers to preventing the onset of a disorder or disease before it occurs. Examples of target diseases include, for example, ophthalmic diseases such as dry eye, diabetic retinopathy, retinitis pigmentosa, glaucoma, cataract, age-related macular degeneration, proliferative vitreoretinopathy, retinal artery occlusion, retinal vein occlusion, uveitis, Leber's disease, retinopathy of prematurity, retinal detachment, retinal pigment epithelial detachment, optic neuropathy caused by these diseases, optic neuropathy caused by glaucoma, ischemic optic neuropathy, postoperative inflammation suppression, and pain suppression. In addition, examples of skin diseases include ultraviolet-responsive skin damage, epidermolysis bullosa, psoriasis, atopic dermatitis, and scleroderma; otorhinolaryngological diseases include noise-induced hearing loss and sensorineural hearing loss; brain diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, Batten disease, dementia, and epilepsy; pulmonary diseases include asthma, bronchitis, and chronic obstructive pulmonary disease; renal diseases include diabetic nephropathy, Alport syndrome, autosomal dominant polycystic kidney disease, focal segmental glomerulosclerosis, and IgA nephropathy; and other systemic diseases include arteriosclerosis, hypertension, cancer, cardiac arrest, Friedreich's ataxia, amyotrophic lateral sclerosis, hepatitis, rheumatoid arthritis, pancreatitis, vasculitis, esophagitis, ulcerative colitis, neutropenia, cellular immunity, diabetes, mitochondrial myopathy, sickle cell anemia, and multiple sclerosis. Of these, preferred are ophthalmological diseases such as multiple sclerosis, psoriasis, Alzheimer's disease, retinitis pigmentosa, glaucoma, and cataracts.
[0187] The subjects to which the pharmaceutical agent of the present invention is administered are not particularly limited, and examples thereof include mammals (eg, humans, mice, rats, hamsters, rabbits, cats, dogs, cows, sheep, monkeys, etc.).
[0188] The administration route of the medicament of the present invention is not particularly limited. For example, enteral administration such as oral administration, tube feeding, and enema administration; parenteral administration such as intravenous administration, intraarterial administration, intramuscular administration, intracardiac administration, subcutaneous administration, intradermal administration, and intraperitoneal administration; and local administration such as local ocular administration (e.g., ophthalmic administration, intravitreal administration, subconjunctival administration, sub-Tenon administration, etc.), epicutaneous administration, inhalation administration, enema administration, ear drops, nasal administration, and intravaginal administration can be employed. Among these, topical administration and parenteral administration are preferred. In particular, when a compound that is more easily metabolized is used as Compound (I) of the present invention, it can be suitably used for topical administration and parenteral administration from the viewpoint of being metabolized more rapidly after acting locally. Furthermore, the medicament of the present invention is preferably in a formulation suitable for these preferred administration routes, and from this viewpoint, a topical administration formulation or a parenteral administration formulation is preferred. In one embodiment, the medicament of the present invention can be an oral administration formulation, etc. In one embodiment, the medicament of the present invention can be an ophthalmic formulation, an otorhinologic formulation, a respiratory formulation, a dermatological formulation, etc. In this specification, the term "preparation for a particular department" refers to a preparation that is applied to a disease or the like that is treated in that department. In one aspect, the medicament of the present invention can be an intravenous administration preparation, an intranasal administration preparation, a transdermal administration preparation, or the like.
[0189] The pharmaceutical of the present invention can be in a dosage form suitable for the route of administration. Examples include eye drops, eye ointments, eye washes, injections, patches, lotions, creams, powders, granules, tablets, capsules, syrups, liquids, ointments, gels, liniments, suppositories, aerosols, inhalants, sprays, and nasal drops. These can be prepared using conventional techniques commonly used in the field. In addition to these formulations, the active ingredient of the present invention can also be formulated into intraocular implant formulations or DDS (drug delivery systems) such as microspheres.
[0190] The medicament of the present invention may consist solely of the active ingredient of the present invention, or may be a composition containing, if necessary, a pharmaceutically acceptable additive (sometimes simply referred to as "additive" in this specification). The medicament of the present invention can be produced by mixing the active ingredient of the present invention together with, typically, at least one additive, according to a method known per se in the technical field of pharmaceutical formulation. The additive can be appropriately selected depending on the formulation form preferred for administration. The content of the active ingredient of the present invention in the medicament varies depending on the dosage form, dosage, etc., and can be appropriately selected. For example, it can usually be 0.01 to 99.9% by mass, preferably 0.1 to 80% by mass, of the total medicament.
[0191] Examples of additives include bases, carriers, solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, thickeners, moisturizers, colorants, flavorings, and chelating agents, etc. These can be selected appropriately depending on the route of administration, dosage form, etc.
[0192] For example, when preparing an otolaryngological preparation containing the active ingredient of the present invention, water (purified or sterile water, distilled water for injection, etc.), physiological saline, glucose solution, water-soluble organic solvents (lower aliphatic alcohols such as ethanol and isopropanol, and polyalkylene glycols such as ethylene glycol, diethylene glycol, and polyethylene glycol), animal and vegetable oils (vegetable oils such as jojoba oil, olive oil, coconut oil, and cottonseed oil; animal oils such as squalane), mineral oils (liquid paraffin, silicone oil, etc.), waxes (beeswax, carnauba wax, lanolin, paraffin, petrolatum, etc.), long-chain fatty acid esters (saturated or unsaturated fatty acid alkyl esters, esters of fatty acids and polyhydric alcohols (poly C2-4 alkylene glycol, glycerin, polyglycerin, etc.)), hydrogenated oils, higher alcohols (saturated aliphatic alcohols such as stearyl alcohol, unsaturated aliphatic alcohols such as oleyl alcohol), higher fatty acids (stearic acid, oleic acid, etc.), etc. may be added. Furthermore, antiseptics or preservatives (e.g., parabens such as methylparaben and butylparaben), odorants or fragrances (e.g., fragrances such as menthol), freshening agents, soothing agents (e.g., local anesthetics such as lidocaine), as well as active ingredients for treating infections and inflammation (e.g., antibacterial agents, antibiotics, anti-inflammatory agents, etc.) may also be blended in. The amount of these additives to be added varies depending on the type and application of the additive, but it is sufficient to add them at a concentration that can achieve the purpose of the additive.
[0193] For example, when preparing a dermatological preparation containing the active ingredient of the present invention, examples of solvents include purified water, ethanol, isopropanol, dipropylene glycol, etc., and one or more of these can be selected and used. Examples of bases include animal and vegetable fats and oils such as olive oil, soybean oil, camellia oil, sesame oil, peanut oil, cocoa butter, beef tallow, and lard; waxes such as carnauba wax and beeswax; aliphatic alcohols such as octyldodecanol, cetanol, and stearyl alcohol; fatty acids such as oleic acid, palmitic acid, and stearic acid; oleaginous bases such as squalane, white petrolatum, liquid paraffin, ceresin, and microcrystalline wax; and hydrophilic bases such as gelatin and macrogol, and one or more of these can be selected and used. Other additives include excipients such as light anhydrous silicic acid, crystalline cellulose, and dextrin; solubilizers such as diisopropyl adipate, capric acid, crotamiton, and propylene carbonate; suspending agents such as propylene glycol alginate, sodium dioctyl sulfosuccinate, soybean lecithin, and povidone; surfactants or emulsifiers such as polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, glycerin monostearate, and sucrose fatty acid esters; carboxyvinyl polymer, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, and polyvinyl alcohol (partially ketone). plasticizers such as triacetin and isopropyl myristate; moisturizers such as glycerin, 1,3-butylene glycol, sodium DL-pyrrolidonecarboxylate and sodium hyaluronate; stabilizers such as sodium edetate, sorbitol, thymol and polyoxyethylene polyoxypropylene glycol; antioxidants such as ascorbic acid, sodium erythorbate, tocopherol acetate and dibutylhydroxytoluene; preservatives such as sorbic acid, sodium dehydroacetate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate and butyl parahydroxybenzoate; pH adjusters such as hydrochloric acid, citric acid, sodium citrate, acetic acid, sodium acetate, sodium hydroxide and sodium hydrogen phosphate may also be added.The amount of these additives to be added varies depending on the type of additive to be added, the purpose of use, etc., but it is sufficient to add the additives at a concentration that can achieve the purpose of the additives. For example, when preparing an ophthalmic preparation (ophthalmic topical preparation: eye drops, eye ointment, eyewash, etc.) containing the active ingredient of the present invention, stabilizers (e.g., sodium bisulfite, sodium thiosulfate, sodium edetate, sodium citrate, ascorbic acid, dibutylhydroxytoluene, etc.), solubilizers (e.g., glycerin, propylene glycol, macrogol, polyoxyethylene hydrogenated castor oil, etc.), suspending agents (e.g., polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydroxymethylcellulose, sodium carboxymethylcellulose, etc.), emulsifiers (e.g., polyvinylpyrrolidone, soybean lecithin, egg yolk lecithin, polyoxyethylene hydrogenated castor oil, polysorbate 80, etc.), buffers (e.g., phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, Tris buffer, glutamic acid, epsilon aminocaproic acid, etc.), thickeners (e.g., methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, sodium carboxymethylcellulose, etc.), etc., may be added. Additives that can be added include water-soluble cellulose derivatives such as cellulose, carboxymethylcellulose, sodium chondroitin sulfate, sodium hyaluronate, carboxyvinyl polymers, polyvinyl alcohol, polyvinylpyrrolidone, macrogol, etc., preservatives (e.g., benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, parahydroxybenzoates, sodium edetate, boric acid, etc.), isotonicity agents (e.g., sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, glucose, propylene glycol, etc.), pH adjusters (e.g., hydrochloric acid, sodium hydroxide, phosphoric acid, acetic acid, boric acid, citric acid, etc.), refreshing agents (e.g., l-menthol, d-camphor, d-borneol, peppermint oil, etc.), ointment bases (white petrolatum, purified lanolin, liquid paraffin, vegetable oils (olive oil, camellia oil, peanut oil, etc.), etc.). The amount of these additives to be added varies depending on the type of additive to be added, the purpose of use, etc., but it is sufficient to add the additives at a concentration that can achieve the purpose of the additives.
[0194] When the pharmaceutical of the present invention is made into an otolaryngological composition such as ear drops or nasal liquid, it may be produced according to a method commonly used in the field of formulations, for example, the method described in the 17th Edition of the Japanese Pharmacopoeia, General Provisions for Preparations, Section "Preparations to be Administered to the Ear" or Section "Preparations to be Applied to the Nose."
[0195] When the pharmaceutical of the present invention is used as a dermatological composition such as a topical skin preparation, it may be produced according to a method commonly used in the pharmaceutical field, for example, the method described in the Japanese Pharmacopoeia, 17th Edition, General Rules for Preparations, section "Preparations for Application to Skin, etc." When the pharmaceutical of the present invention is used as an ophthalmic composition such as eye drops or eye ointment, it may be produced according to a method commonly used in the pharmaceutical field, for example, the method described in the Japanese Pharmacopoeia, 17th Edition, General Rules for Preparations, section "Drugs to be Administered to the Eye" (e.g., the section on eye drops and the section on eye ointments).
[0196] The dosage of the pharmaceutical of the present invention varies depending on the target disease and cannot be generalized, but can be set so that the concentration of the active ingredient of the present invention in the target tissue to exert its effect is, for example, 0.001 nM to 100 μM, preferably 0.01 nM to 100 μM.
[0197] When the medicament of the present invention is used topically on the eyes of an adult, it is appropriate to apply a medicament containing, for example, 0.01 nM to 1000 μM, preferably 0.1 nM to 1000 μM of the active ingredient of the present invention 1 to 8 times per day, preferably 1 to 5 times per day. The application amount can be appropriately determined depending on the concentration and dosage form of the active ingredient of the present invention.
[0198] Furthermore, the pharmaceutical of the present invention may contain one or more other optional medicinal ingredients as long as the effects of the present invention are not impaired. [Example]
[0199] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.
[0200] The present invention will be explained in more detail below with reference to the following Reference Examples, Examples, Formulation Examples and Test Examples, but the present invention is not limited to these examples in any way.
[0201] In the Reference Examples, Examples, and Experimental Examples, all temperatures are specified in degrees Celsius (°C) unless otherwise specified. All amounts and percentages are by weight unless otherwise specified. Reagents were purchased from reagent suppliers such as Sigma-Aldrich Corporation, Tokyo Chemical Industry Co., Ltd., Fujifilm Wako Pure Chemical Industries, Ltd., or Nacalai Tesque Inc., and were used without purification unless otherwise specified.
[0202] In the Reference Examples and Examples, operations were generally carried out in anhydrous solvents under an argon atmosphere. Reactions were analyzed by TLC (Thin Layer Chromatography) and terminated based on the consumption of the starting material. TLC was performed using silica gel 60F254 (Merck), developed with an appropriate solvent, and displayed at an appropriate position. A UV detector was used for detection. Unless otherwise specified, elution in column chromatography in the Reference Examples and Examples was performed under TLC observation. The silica gel used for column chromatography was SI silica gel (particle size 30-50 μm) or NH silica gel (particle size 60 μm) manufactured by Fuji Silysia Chemical Ltd., or silica gel (particle size 40 μm) or amino silica gel (particle size 40 μm) manufactured by Yamazen Corporation. Room temperature generally refers to a temperature of approximately 10°C to 35°C.
[0203] The following abbreviations are used in the following examples: mCPBA: trichloroperbenzoic acid M: Molar concentration N: Normality CDCl3: deuterated chloroform CD3OD: deuterated methanol DMSO-d6: deuterated dimethyl sulfoxide 1 H NMR: proton nuclear magnetic resonance DBU: 1,8-diazabicyclo[5.4.0]-7-undecene DDQ: 2,3-dichloro-5,6-dicyano-p-benzoquinone DEAD: Diethyl azodicarboxylate DIPEA: N,N-diisopropylethylamine DMF: N,N-dimethylformamide DMA: N,N-dimethylacetamide DMSO: dimethyl sulfoxide EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride HOBt: 1-hydroxybenzotriazole LDA: lithium diisopropylamide PdCl2(dppf)2-CH2Cl2: [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct TEA: Triethylamine TFA: trifluoroacetic acid THF: tetrahydrofuran p-TsOH-H2O: p-toluenesulfonic acid monohydrate [RhCl(cod)]2: Chloro(1,5-cyclooctadiene)rhodium(I) (dimer) HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HBTU: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.
[0204] 1H NMR spectra were recorded on a Bruker instrument operating at 400 MHz. NMR spectra were acquired as CDCl3 solutions, using chloroform as the reference standard (7.26 ppm) or internal tetramethylsilane (0.00 ppm) as appropriate. Other NMR solvents were also used as needed. When reporting peak multiplicities, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), septd (septet), m (multiplet), br (broad), dd (doublet of doublet), dt (doublet of triplet), and td (triplet of doublet). Coupling constants (J values), when given, are reported in Hertz (Hz).
[0205] Reference example 1 Preparation of (R)-4-ethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide
[0206] [ka]
[0207] To a stirred solution of aqueous ammonia (approximately 28%) (84 mL), (R)-(+)-butylene oxide (5.0 mL, 58.2 mmol) was added dropwise over 10 minutes, and the mixture was stirred at room temperature for 22 hours. The solvent was evaporated under reduced pressure, and the resulting oil was dissolved in THF / HO (72 mL / 18 mL). Potassium carbonate (4.55 g, 32.9 mmol) and 2-fluorobenzenesulfonyl chloride (4.3 mL, 32.9 mmol) were added to the solution, and the mixture was stirred at room temperature for 2 hours. The resulting solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was dissolved in DMSO (130 mL), potassium tert-butoxide (11 g, 98 mmol) was added, and the mixture was stirred at 80 °C for 1 hour. The pH of the resulting solution was adjusted to ~5 with 2N hydrochloric acid, and then extracted with ethyl acetate. The organic layer was washed with water, then dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Dichloromethane at 0 °C was added to the resulting residue, and the mixture was filtered. The residue was dried under reduced pressure to give the title compound (3.36 g, 45%) as a white solid. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 3 / 2 → 1 / 1) to give the title compound (2.93 g, 39%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.83 (1H, dd, J = 7.6, 1.6 Hz), 7.47 (1H, td, J = 7.6, 1.6 Hz), 7.19 (1H, td, J = 7.6, 1.2 Hz), 7.17 (1H, dd, J = 7.6, 1.2 Hz), 4.66 (1H, br s), 3.89-3.82 (1H, m), 3.70-3.62 (1H, m), 3.39 (1H, ddd, J =14.8, 5.2, 2.0 Hz), 1.83-1.71 (1H, m), 1.67-1.56 (1H, m), 1.13 (3H, t, J = 7.2 Hz).
[0208] Reference example 2 Preparation of (R)-4-methyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide
[0209] [ka]
[0210] Using (R)-(-)-1-amino-2-propanol (2.89 g, 38.3 mmol), THF / water (125 mL / 31.3 mL), potassium carbonate (5.29 g, 38.3 mmol), 2-fluorobenzenesulfonyl chloride (5.0 mL, 38.3 mmol), DMSO (120 mL), and potassium tert-butoxide (10.0 g, 89.1 mmol) as starting materials, and operating in the same manner as in Step j of Reference Example 1, the title compound (6.42 g, 79%) was obtained as a pale yellow solid. 1 H NMR(400 MHz, CDCl3)δ 7.81 (1H, dd, J = 8.0, 1.6 Hz), 7.46 (1H, td, J = 8.0, 1.6 Hz), 7.19 (1H, td, J = 8.0, 1.2 Hz), 7.15 (1H, dd, J = 8.0, 1.2 Hz), 4.75 (1H, br s), 4.19-4.12 (1H, m), 3.67-3.59 (1H, m), 3.41 (1H, ddd, J = 14.8, 5.2, 2.0 Hz), 1.40 (3H, d, J = 6.4 Hz).
[0211] Reference example 3 Preparation of (R)-4-ethyl-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepine 1,1-dioxide
[0212] [ka]
[0213] Aqueous ammonia (approximately 28%) (2.9 mL), (R)-(+)-butylene oxide (172 μL, 2 mmol), THF / water (2.4 mL / 0.6 mL), potassium carbonate (163.1 mg, 1.18 mmol), 2-chloro-pyridine-3-sulfonyl chloride (250 mg, 1.18 mmol), DMSO (4.7 mL), and potassium tert-butoxide (397 mg, 3.54 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 1 to obtain the title compound (210.4 mg, 78%) as a brown oil. 1 H NMR(400 MHz, CDCl3)δ 8.40 (1H, dd, J = 4.8, 2.0 Hz), 8.15 (1H, dd, J = 7.6, 2.0 Hz), 7.19 (1H, dd, J = 7.6, 4.8 Hz), 6.34 (1H, br s), 4.26-4.21 (1H, m), 3.66-3.58 (1H, m), 3.50-3.44 (1H, m), 1.84-1.75 (1H, m), 1.71-1.65 (1H, m), 1.12 (3H, t, J = 7.6 Hz).
[0214] Reference example 4 Preparation of (R)-4-ethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepine 1,1-dioxide
[0215] [ka]
[0216] Aqueous ammonia (approximately 28%) (4.35 mL), (R)-(+)-butylene oxide (258 μL, 3 mmol), THF / water (2.5 mL / 1.0 mL), potassium carbonate (180 mg, 1.3 mmol), 4-chloro-pyridine-3-sulfonyl chloride (250 mg, 1.18 mmol), DMSO (8.0 mL), and potassium tert-butoxide (397 mg, 3.54 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 1 to obtain the title compound (140.8 mg, 52%) as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ 8.82 (1H, s), 8.53 (1H, d, J = 5.6 Hz), 7.04 (1H, d, J = 5.6, Hz), 5.98 (1H, br s), 4.29-4.23 (1H, m), 3.56-3.46 (2H, m), 1.81-1.74 (1H, m), 1.72-1.63 (1H, m), 1.10 (3H, t, J = 7.6 Hz).
[0217] Reference example 5 Preparation of (R)-2-fluoro-N-(2-hydroxybutyl)benzenesulfonamide
[0218] [ka]
[0219] To a solution of (R)-1-aminobutan-2-ol (127.6 mg, 1.4 mmol) in THF / water (4 / 1) (2.0 mL) were added potassium carbonate (203.0 mg, 1.5 mmol) and 2,6-difluorobenzenesulfonyl chloride (150 μL, 1.1 mmol), and the mixture was stirred at room temperature for 2 hours. Water was added to the reaction solution, which was then extracted with ethyl acetate, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (318.1 mg, quant.) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.51 (1H, m), 7.04 (2H, t, J = 8.4 Hz), 3.73-3.67 (1H, m), 3.28 (1H, dd, J = 12.8, 3.2 Hz), 2.96 (1H, d, J = 12.8, 8.0 Hz), 1.55-1.41 (2H, m), 0.94 (3H, t, J =7.6 Hz).
[0220] Reference example 6 Preparation of (R)-4-ethyl-9-fluoro-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide
[0221] [ka]
[0222] A solution of (R)-2-fluoro-N-(2-hydroxybutyl)benzenesulfonamide (161.0 mg, 0.65 mmol) and potassium tert-butoxide (150.7 mg, 1.3 mmol) in DMSO (1.5 mL) was stirred at 100 °C for 2 hours using a microwave. The reaction solution was returned to room temperature, adjusted to pH 6 with 1 M hydrochloric acid, extracted with ethyl acetate, and the organic layer was washed with saturated brine, dried over sodium sulfate, and evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 73 / 27 → 52 / 48) to give the title compound (113.2 mg, 71%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.38-7.33 (1H, m), 6.93-6.88 (2H, m), 5.26 (1H, br t, J = 6.0 Hz), 4.34-4.27 (1H, m), 3.54 (1H, ddd, J = 14.0, 6.4, 4.0 Hz), 3.23 (1H, ddd, J= 14.0, 11.2, 6.8 Hz), 1.78-1.58 (2H, m), 1.07 (3H, t, J = 7.6 Hz).
[0223] Reference example 7 Preparation of [(but-3-en-1-yloxy)methyl]benzene
[0224] [ka]
[0225] To a solution of sodium hydride (60%) (2.36 g, 59 mmol) in THF (25 mL) was added 3-buten-1-ol (2.5 mL, 29.5 mmol) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 30 minutes. Benzyl bromide (3.85 mL, 32.4 mmol) was added to this solution at 0 °C, and the mixture was stirred at room temperature for 20 hours. The reaction was quenched by adding saturated aqueous ammonium chloride to the mixture at 0 °C, and the mixture was extracted with ethyl acetate. The combined organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 100 / 0 → 91 / 9) to give the title compound (3.95 g, 83%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 7.38-7.26 (5H, m), 5.91-5.79 (1H, m), 5.15-5.07 (1H, m), 5.08-5.02 (1H, m), 4.53 (2H, s), 3.54 (2H, t, J = 6.8 Hz), 2.43-2.35 (2H, m).
[0226] Reference example 8 Preparation of 2-[2-(benzyloxy)ethyl]oxirane
[0227] [ka]
[0228] To a solution of [(but-3-en-1-yloxy)methyl]benzene (3.95 g, 24.3 mmol) in dichloromethane (79 mL) was added mCPBA (approximately 77%) (7.09 g, 31.6 mmol) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 14 hours. The reaction mixture was diluted with water, and saturated aqueous sodium bicarbonate and saturated aqueous sodium thiosulfate were added to quench the reaction. The mixture was extracted with dichloromethane, and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 93 / 7 → 72 / 28) to give the title compound (4.11 g, 95%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 7.38-7.26 (5H, m), 4.54 (2H, s), 3.68-3.58 (2H, m), 3.12-3.06 (1H, m), 2.79 (1H, dd, J = 5.0, 4.2 Hz), 2.54 (1H, dd, J = 5.0, 3.7 Hz), 1.97-1.86 (1H, m), 1.84-1.73 (1H, m).
[0229] Reference example 9 Preparation of 1-amino-4-(benzyloxy)butan-2-ol
[0230] [ka]
[0231] 2-[2-(benzyloxy)ethyl]oxirane (4.11 g, 23.1 mmol) was added to aqueous ammonia (approximately 28%) (86 mL). The reaction mixture was stirred for 15 hours and then concentrated under reduced pressure to give the title compound (4.45 g, 99%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.37-7.26 (5H, m), 4.52 (2H, s), 3.77-3.63 (3H, m), 2.79 (1H, dd, J = 12.8, 3.6 Hz), 2.61 (1H, dd, J = 12.8, 7.6 Hz), 1.77-1.71 (2H, m).
[0232] Reference example 10 Preparation of 4-[2-(benzyloxy)ethyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide
[0233] [ka]
[0234] To a solution of 1-amino-4-(benzyloxy)butan-2-ol (4.4475 g, 22.8 mmol) in THF (29 mL) and water (7.3 mL) were added potassium carbonate (2.06 g, 14.9 mmol) and 2-fluorobenzenesulfonyl chloride (1.95 mL, 14.9 mmol). The reaction mixture was stirred for 1 hour and quenched with 1N hydrochloric acid. The mixture was extracted with ethyl acetate, and the organic layer was concentrated under reduced pressure. The resulting residue was dissolved in DMSO (135 mL), and to this solution was added potassium tert-butoxide (5.02 g, 44.7 mmol). The reaction mixture was stirred at 80 °C for 1 hour and quenched with 1N hydrochloric acid. The mixture was extracted with ethyl acetate, washed with saturated brine, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 91 / 9 → 60 / 40) to give the title compound (3.88 g, 78%) as a colorless solid. 1H NMR(400 MHz, CDCl3)δ 7.83 (1H, d,J = 7.6 Hz), 7.42 (1H, td, J = 7.6, 1.6 Hz), 7.33-7.26 (5H, m), 7.20 (1H, t, J = 7.6 Hz), 6.96 (1H, d, J= 7.6 Hz), 4.63 (1H, br s), 4.55 (1H, d,J = 12.0 Hz), 4.49 (1H, d, J = 12.0 Hz), 4.11 (1H, br t, J = 9.6 Hz), 3.85-3.63 (3H, m), 3.39-3.35 (1H, m), 2.00-1.86 (2H, m).
[0235] Reference example 11 Preparation of (5-bromo-2-methylphenyl)methanol
[0236] [ka]
[0237] To a solution of 5-bromo-2-methylbenzoic acid (5.0 g, 25.3 mmol) in THF (50 mL), borane-tetrahydrofuran complex (approximately 0.9 mmol / L THF solution) (38.8 mL, 34.9 mmol) was added dropwise at 0 °C over 10 minutes, followed by stirring at room temperature for 20 hours. Methanol (35 mL) was added to the resulting solution, and the mixture was stirred at room temperature for 2 hours. The solvent was then evaporated under reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with 1N hydrochloric acid. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (5.0 g, 98%) as a pale yellow oil. 1 H NMR(400 MHz, CDCl3)δ 7.53 (1H, d, J= 2.0 Hz), 7.32 (1H, dd, J = 8.0, 2.0 Hz), 7.03 (1H, d, J = 8.0 Hz), 4.66 (2H, d, J = 5.6 Hz), 2.27 (3H, s), 1.64 (1H, t, J = 5.6 Hz).
[0238] Reference example 12 Preparation of (R)-2-(5-bromo-2-methylbenzyl)-4-ethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide
[0239] [ka]
[0240] To a solution of (5-bromo-2-methylphenyl)methanol (2.0 g, 9.95 mmol), (R)-4-ethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (2.26 g, 9.95 mmol), and triphenylphosphine (2.61 g, 9.95 mmol) in THF (39 mL) was added 2.2 M DEAD toluene solution (5.1 mL, 11.2 mmol) with stirring at 0 °C. The solution was stirred at room temperature for 7 h, then diluted with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 95 / 5 → 85 / 15) to give the title compound (3.46 g, 85%) as a white solid. 1H NMR(400 MHz, CDCl3)δ 7.89 (1H, dd, J= 7.6, 1.6 Hz), 7.52 (1H, td, J = 7.6, 1.6 Hz), 7.39 (1H, d, J = 2.0 Hz), 7.35 (1H, dd, J = 8.0, 2.0 Hz), 7.26 (1H, td, J = 7.6, 1.2 Hz), 7.21 (1H, dd, J = 7.6, 1.2 Hz), 7.06 (1H, d, J = 8.0 Hz), 4.51 (1H, d, J = 14.4 Hz), 4.08-4.02 (1H, m), 3.85 (1H, d, J =14.4 Hz), 3.76 (1H, dd, J= 15.2, 10.8 Hz), 3.06 (1H, dd, J = 15.2, 2.0 Hz), 2.29 (3H, s), 1.79-1.70 (1H, m), 1.56-1.50 (1H, m), 1.11 (3H, t, J = 7.2 Hz).
[0241] Reference example 13 Preparation of (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide
[0242] [ka]
[0243] A 1,4-dioxane solution (36 mL) of (R)-2-(5-bromo-2-methylbenzyl)-4-ethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (3.4 g, 8.29 mmol), bis(pinacolato)diboron (3.15 g, 12.4 mmol), potassium acetate (2.44 g, 24.9 mmol), and PdCl(dppf)-CHCl (408 mg, 0.5 mmol) was stirred at 100 °C for 6 h. The reaction solution was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 95 / 5 → 85 / 15) to afford the title compound (3.28 g, 86%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.90 (1H, d, J= 7.6 Hz), 7.68 (1H, d, J = 7.6 Hz), 7.54 (1H, s), 7.52 (1H, t, J = 7.6 Hz), 7.25 (1H, t, J = 7.6 Hz), 7.22-7.20 (2H, m), 4.64 (1H, d, J = 13.6 Hz), 4.09-4.04 (1H, m), 3.83 (1H, d, J =13.6 Hz), 3.74 (1H, dd, J= 15.2, 10.8 Hz), 2.97 (1H, dd, J = 15.2, 1.2 Hz), 2.43 (3H, s), 1.77-1.70 (1H, m), 1.51-1.42 (1H, m), 1.32 (12H, s), 1.05 (3H, t, J = 7.2 Hz).
[0244] Reference example 14 Preparation of 4-bromo-2-{[(4-methoxybenzyl)oxy]methyl}-1-methylbenzene
[0245] [ka]
[0246] To a solution of (5-bromo-2-methylphenyl)methanol (2.16 g, 10.8 mmol) in DMF (16 mL) was added sodium hydride (472 mg, 11.8 mmol). The solution was stirred at room temperature for 30 minutes, then cooled to 0 °C, and 4-methoxybenzyl chloride (1.53 mL, 11.3 mmol) was added. The solution was stirred at room temperature for 2 hours, quenched with water, and extracted with diethyl ether. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 95 / 5 → 85 / 15) to give the title compound (1.77 g, 61%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.50 (1H, d, J= 2.0 Hz), 7.32-7.28 (3H, m), 7.02 (1H, d, J = 8.0 Hz), 6.90 (2H, d, J = 8.4 Hz), 4.51 (2H, s), 4.46 (2H, s), 3.81 (3H, s), 2.24 (3H, s).
[0247] Reference example 15 Preparation of 3-{[(4-methoxybenzyl)oxy]methyl}-4-methylbenzaldehyde
[0248] [ka]
[0249] To a solution of 4-bromo-2-{[(4-methoxybenzyl)oxy]methyl}-1-methylbenzene (600 mg, 1.87 mmol) in THF (6 mL) was added dropwise at -78 °C under an argon atmosphere. The reaction mixture was stirred at -78 °C for 1 hour, then DMF (290 μL, 3.75 mmol) was added. The mixture was warmed to room temperature and stirred for 1 hour. The reaction was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 99 / 1 → 90 / 10) to give the title compound (448.3 mg, 89%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 9.97 (1H, s), 7.87 (1H, d, J = 1.6 Hz), 7.72 (1H, dd, J= 8.0, 1.6 Hz), 7.33-7.26 (3H, m), 6.90 (2H, br d, J = 8.8 Hz), 4.56 (2H, s), 4.54 (2H, s), 3.82 (3H, s), 2.39 (3H, s).
[0250] Reference example 16 Preparation of 2-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
[0251] [ka]
[0252] A 1,4-dioxane solution (68 mL) of 4-bromo-2-{[(4-methoxybenzyl)oxy]methyl}-1-methylbenzene (6.67 g, 20.77 mmol), bis(pinacolato)diboron (5.54 g, 21.81 mmol), potassium acetate (6.12 g, 62.31 mmol), and PdCl(dppf)-CHCl (848.1 mg, 1.04 mmol) was stirred at 100 °C for 6 h. The reaction solution was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 95 / 5 → 85 / 15) to give the title compound (6.63 g, 87%) as a pale yellow oil. 1 H NMR(400 MHz, CDCl3)δ 7.73 (1H, s), 7.65 (1H, dd, J = 7.2, 1.2 Hz), 7.27 (2H, d, J= 8.8 Hz), 7.18 (1H, d, J = 7.2 Hz), 6.88 (2H, br d, J = 8.8 Hz), 4.52 (2H, s), 4.47 (2H, s), 3.81 (3H, s), 2.36 (3H, s), 1.34 (12H, s).
[0253] Reference example 17 Preparation of methyl 3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate
[0254] [ka]
[0255] To a solution of methyl (E)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate (3.30 g, 13.0 mmol), 2-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.39 g, 6.49 mmol), and [RhCl(cod)]2 (160 mg, 0.32 mmol) in 1,4-dioxane / water (9.6 mL / 960 μL) was added triethylamine (2.7 mL, 19.5 mmol). The reaction mixture was stirred at 50 °C for 2.5 h. Water was added to the mixture, which was then extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 9 / 1 → 7 / 3) to give the title compound (1.52 g, 47%) as a pale yellow oil. 1 H NMR(400 MHz, CDCl3)δ 7.28-7.24 (3H, m), 7.11-7.10 (2H, m), 6.88 (2H, br d, J= 8.4 Hz), 6.81 (1H, d, J = 3.6 Hz), 6.65 (1H, dd, J = 3.6, 0.8 Hz), 4.67 (1H, t, J = 7.6 Hz), 4.48 (2H, s), 4.46 (2H, s), 4.00-3.95 (2H, m), 3.94-3.89 (2H, m), 3.81 (3H, s), 3.59 (3H, s), 3.08 (1H, dd, J = 15.6, 7.6 Hz), 2.99 (1H, dd, J = 15.6, 7.6 Hz), 2.28 (3H, s), 1.71 (3H, s).
[0256] Reference example 18 Preparation of methyl 3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2-methyl-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate
[0257] [ka]
[0258] To a solution of methyl 3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate (1.40 g, 2.82 mmol) in THF (18 mL) was added 2M LDA in THF / heptane / ethylbenzene (1.83 mL, 3.67 mmol) at -78 °C under an argon atmosphere. The reaction mixture was stirred at -78 °C for 30 minutes and then at -40 °C for 20 minutes. Iodomethane (2.6 mL, 42.3 mmol) was added, and the mixture was warmed to room temperature and stirred for 4 hours. Water was added to the mixture to quench the reaction, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 8%) to give the title compound. The title compound could be separated into two isomer mixtures: isomer 1 (505.7 mg, 31%) with a shorter retention time and isomer 2 (853.3 mg, 52%) with a longer retention time, both of which were obtained as pale yellow oils. Isomer 1: 1H NMR(400 MHz, CDCl3)δ 7.28-7.26 (3H, m), 7.16 (1H, dd, J = 8.0, 2.0 Hz), 7.06 (1H, d,J = 8.0 Hz), 6.89 (2H, br d, J = 8.8 Hz), 6.82 (1H, d, J = 3.6 Hz), 6.74 (1H, d, J = 3.6 Hz), 4.47 (2H, s), 4.43 (2H, s), 4.25 (1H, d, J = 10.8 Hz), 4.01-3.97 (2H, m), 3.96-3.90 (2H, m), 3.81 (3H, s), 3.43 (3H, s), 3.24-3.16 (1H, m), 2.25 (3H, s), 1.71 (3H, s), 1.20 (3H, d, J = 6.8 Hz). Isomer 2: 1 H NMR(400 MHz, CDCl3)δ 7.28-7.23 (3H, m), 7.11-7.10 (2H, m), 6.89 (2H, br d, J = 8.8 Hz), 6.77 (1H, d, J = 3.6 Hz), 6.71 (1H, dd, J = 3.6 Hz), 4.48 (2H, s), 4.47 (2H, s), 4.27 (1H, d, J = 11.2 Hz), 3.99-3.95 (2H, m), 3.93-3.82 (2H, m), 3.82 (3H, s), 3.58 (3H, s), 3.21-3.16 (1H, m), 2.28 (3H, s), 1.69 (3H, s), 1.05 (3H, d, J= 6.8 Hz).
[0259] Reference Example 19 メチル3-(5-アセチルチオフェン-2-イル)-3-(3-{[(4-メトキシベManufacturing
[0260]
change
[0261] To a solution of methyl 3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2-methyl-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate (isomer 1) (489 mg, 0.96 mmol) in tetrahydrofuran (2.8 mL) was added 2N hydrochloric acid (1.4 mL) and stirred at room temperature for 3 hours. The mixture was neutralized with 1N aqueous sodium hydroxide solution and extracted with dichloromethane. The organic layer was washed with water, dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give isomer 2 of the title compound (390.8 mg, 87%) as a pale yellow oil. Isomer 1 of the title compound was obtained in the same manner as isomer 2. Isomer 1: 1 H NMR(400 MHz, CDCl3)δ 7.49 (1H, d, J = 4.0 Hz), 7.28-7.24 (3H, m), 7.17 (1H, dd, J = 8.0, 2.0 Hz), 7.07 (1H, d, J = 8.0 Hz), 6,94-6.88 (3H, m), 4.46 (2H, s), 4.44 (2H, s), 4.36 (1H, d, J = 11.2 Hz), 3.81 (3H, s), 3.45 (3H, s), 3.29-3.21 (1H, m), 2.45 (3H, s), 2.24 (3H, s), 1.21 (3H, d, J = 6.8 Hz). Isomer 2: 1 H NMR(400 MHz, CDCl3)δ 7.46 (1H, d, J = 4.0 Hz), 7.29-7.24 (3H, m), 7.11 (2H, s), 6,92-6.89 (3H, m), 4.49 (2H, s), 4.48 (2H, s), 4.36 (1H, d, J = 11.2 Hz), 3.82 (3H, s), 3.60 (3H, s), 3.25-3.21 (1H, m), 2.46 (3H, s), 2.26 (3H, s), 1.08 (3H, d, J = 6.8 Hz).
[0262] Reference example 20 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2-methylpropanoate
[0263] [ka]
[0264] To a solution of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2-methylpropanoate (700.9 mg, 1.5 mmol) in dichloromethane / water (10 / 1) (18.2 mL) was added DDQ (681 mg, 3.0 mmol) at 0 °C. The mixture was stirred at room temperature for 2.5 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, which was then extracted with dichloromethane. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 6 / 4 → 4 / 6) to obtain isomer 2 of the title compound (436.3 mg, 84%) as a pale yellow oil. Isomer 1 of the title compound was obtained by the same method as isomer 2. Isomer 1: 1 H NMR(400 MHz, CDCl3)δ 7.50 (1H, d, J = 4.0 Hz), 7.30 (1H, br s), 7.16 (1H, dd, J = 7.6, 2.0 Hz), 7.08 (1H, d, J = 7.6 Hz), 6.95 (1H, d, J = 4.0 Hz), 4.63 (2H, d, J = 14.4 Hz), 4.36 (1H, d, J = 10.8 Hz), 3.47 (3H, s), 3.31-3.21 (1H, m), 2.45 (3H, s), 2.26 (3H, s), 1.21 (3H, d, J = 7.2 Hz). Isomer 2: 1H NMR(400 MHz, CDCl3)δ 7.46 (1H, d, J = 4.0 Hz), 7.28 (1H, br s), 7.13 (2H, br s), 6.93 (1H, d, J = 4.0 Hz), 4.68 (2H, d, J = 5.6 Hz), 4.37 (1H, d, J = 11.2 Hz), 3.60 (3H, s), 3.27-3.23 (1H, m), 2.46 (3H, s), 2.30 (3H, s), 1.09 (3H, d, J = 6.8 Hz).
[0265] Reference example 21 Preparation of 1-(5-bromothiophen-2-yl)ethan-1-ol
[0266] [ka]
[0267] Sodium borohydride (458.2 mg, 12 mmol) was added to a methanol solution (40 mL) of 2-acetyl-5-bromothiophene (1.16 g, 5.6 mmol) at 10°C, and the mixture was stirred at 10°C for 1 hour and 20 minutes. Water was added to the reaction solution, and the mixture was stirred at 0°C for 15 minutes. The reaction solution was concentrated under reduced pressure, and then ethyl acetate was added. The mixture was washed with water and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure to obtain the title compound (1.16 g, 99%) as a colorless, transparent oil. 1 H NMR (400 MHz, CDCl3) δ 6.90 (1H, d, J = 3.6 Hz), 6.72 (1H, d, J= 3.6 Hz), 5.04 (1H, dq, J = 5.6, 6.4 Hz), 1.97 (1H, d, J = 4.8 Hz), 1.57 (3H, d, J = 6.4 Hz).
[0268] Reference example 22 Preparation of [1-(5-bromothiophen-2-yl)ethoxy](tert-butyl)dimethylsilane
[0269] [ka]
[0270] A solution of 1-(5-bromothiophen-2-yl)ethan-1-ol (1.16 g, 5.6 mmol) in dichloromethane (12 mL) was added with a solution of 4-dimethylaminopyridine (76.8 mg, 0.6 mmol), triethanolamine (3.2 mL, 23 mmol), and tert-butyldimethylchlorosilane (1.66 g, 11 mmol) in dichloromethane (5.0 mL) at 0 °C and stirred overnight at room temperature. 4-Dimethylaminopyridine (305.6 mg, 2.5 mmol) and tert-butyldimethylchlorosilane (981.6 mg, 6.5 mmol) were further added to the reaction solution, and the mixture was stirred at room temperature for 3 hours and 45 minutes. Ethyl acetate was added to the reaction solution, which was washed with water and saturated brine. The resulting organic layer was dried over sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 1 / 0 → 95 / 5) to obtain the title compound (1.28 g, 71%) as a colorless, transparent oil. 1 H NMR (400 MHz, CDCl3), δ 6.86 (1H, d, J = 4.0 Hz), 6.58 (1H, d, J= 4.0 Hz), 5.01 (1H, q, J = 6.4 Hz), 1.47 (3H, d, J = 6.4 Hz), 0.91 (9H, s), 0.09 (3H, s), 0.06 (3H, s).
[0271] Reference example 23 Preparation of (5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}thiophen-2-yl)(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)methanol
[0272] [ka]
[0273] A solution of [1-(5-bromothiophen-2-yl)ethoxy](tert-butyl)dimethylsilane (540.9 mg, 1.7 mmol) in anhydrous THF (5.0 mL) was cooled to -78 °C, and then 2.5 M n-butyllithium (0.75 mL, 1.9 mmol) was added dropwise and stirred at -78 °C for 30 min. A solution of 3-{[(4-methoxybenzyl)oxy]methyl}-4-methylbenzaldehyde (478.1 mg, 1.8 mmol) in THF (5 mL) was added dropwise to the reaction solution, and the mixture was stirred at -78 °C for 1 h and then at room temperature for 30 min. The reaction was quenched with saturated aqueous ammonium chloride, extracted with ethyl acetate, and the organic layer was washed with saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The resulting crude product was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 90 / 10 → 69 / 31) to obtain the title compound (740.4 mg, 86%) as a yellow, transparent oil. 1 H NMR (400 MHz, CDCl3) δ 7.41 (1H, s), 7.29-7.26 (3H, m), 7.16 (1H, d, J = 7.6 Hz), 6.88 (1H, d, J = 8.4 Hz), 6.67 (2H, d, J = 4.4 Hz), 5.96 (1H, d, J = 4.0 Hz), 5.17 (1H, q, J = 6.4 Hz), 4.51 (2H, s), 4.48 (2H, s), 3.81 (3H, s), 2.32 (3H, s), 2.29 (1H, d, J = 4.0 Hz), 1.47 (3H, d, J = 6.4 Hz), 0.90 (9H, s), 0.07 (3H, s), 0.03 (3H, br s).
[0274] Reference example 24 Preparation of methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}thiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0275] [ka]
[0276] To a solution of ((5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}thiophen-2-yl)(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)methanol (110.7 mg, 0.2 mmol) in acetonitrile (2.0 mL), trichloroacetonitrile (40 μL, 0.4 mmol) and DBU (6 μL, 0.1 mmol) were added and stirred at room temperature for 30 min. Dimethylketene methyl trimethylsilyl acetal (120 μL, 0.6 mmol) and bis(trifluoromethanesulfonyl)imide (8.2 mg, 0.03 mmol) were added and stirred at room temperature for 1 h. The reaction was quenched by adding saturated aqueous sodium bicarbonate solution, and the reaction was extracted with dichloromethane. The organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = The product was purified by elution with a solvent mixture of 95 / 5 and 74 / 26 to give the title compound (824.8 mg, 73%) as a yellow, transparent oil. 1H NMR (400 MHz, CDCl3) δ 7.32 (1H, dd, J = 4.4, 1.2 Hz), 7.29-7.26 (2H, m), 7.21 (1H, td, J = 7.6, 1.6 Hz), 7.08 (1H, d, J = 7.6 Hz), 6.90 (1H, s), 6.88 (1H, s), 6.76-6.74 (1H, m), 6.64-6.63 (1H, m), 5.00 (1H, q, J = 6.4 Hz), 4.63-4.62 (1H, m), 4.49 (2H, s), 4.47 (2H, br s), 3.81 (3H, s), 3.56 (3H, s), 2.27 (3H, s), 1.45 (3H, d, J = 6.4 Hz), 1.29 (3H, s), 1.22 (3H, s), 0.89 (9H, br s), 0.05 (3H, s), 0.002 (3H, s).
[0277] Reference example 25 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2,2-dimethylpropanoate
[0278] [ka]
[0279] To a solution of methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}thiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate (773 mg, 1.3 mmol) in a mixture of dichloromethane (16 mL) and water (1.2 mL), DDQ (612.2 mg, 2.7 mmol) was added at 0 °C and the mixture was stirred at 0 °C for 1 hour and 20 minutes. The reaction solution was quenched by adding saturated aqueous sodium bicarbonate solution, extracted with dichloromethane, and the organic layer was dried over sodium sulfate. The solvent was then removed by evaporation under reduced pressure. The crude product was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 93 / 7 → 72 / 28 → 50 / 50) to give the title compound (204.1 mg, 44%) as a colorless, transparent oil. 1 H NMR (400 MHz, CDCl3) δ 7.50 (1H, d, J = 4.0 Hz), 7.34 (1H, d, J = 1.6 Hz), 7.20 (1H, dd, J = 7.6, 1.6 Hz), 7.11 (1H, d, J = 7.6 Hz), 6.97 (1H, d, J = 4.0 Hz), 4.17 (1H, s), 4.68 (2H, d, J = 5.6 Hz), 3.61 (3H, s), 2.49 (3H, s), 2.31 (3H, s), 1.32 (3H, s), 1.24 (3H, s).
[0280] Reference example 26 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]-2,2-dimethylpropanoate
[0281] [ka]
[0282] To a suspension of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2,2-dimethylpropanoate (204.1 mg, 0.57 mmol) and lithium chloride (123.1 mg, 2.9 mmol) in dichloromethane (6.0 mL) was added DIPEA (300 μL, 1.7 mmol) and methanesulfonyl chloride (88 μL, 1.1 mmol), and the mixture was stirred at room temperature for 4.5 hours. Ethyl acetate was added to the reaction solution, which was then washed with 10% aqueous citric acid, saturated aqueous sodium bicarbonate, and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (218.3 mg, quant.) as a light brown, transparent oil. 1 H NMR (400 MHz, CDCl3) δ 7.51 (1H, d, J = 4.0 Hz), 7.31-7.24 (2H, m), 7.14 (1H, d, J = 8.0 Hz), 6.87 (1H, d, J = 4.0 Hz), 4.70 (1H, s), 4.57 (2H, s), 3.60 (3H, s), 2.50 (3H, s), 2.38 (3H, s), 1.31 (3H, s), 1.24 (3H, s).
[0283] Reference example 27 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0284] [ka]
[0285] A solution of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]-2,2-dimethylpropanoate (29.8 mg, 0.079 mmol), (R)-4-ethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (27.8 mg, 0.12 mmol), potassium carbonate (33.9 mg, 0.25 mmol), and tetrabutylammonium iodide (5.7 mg, 0.015 mmol) in DMF (0.50 mL) was stirred at 70 °C for 3 hours and 10 minutes. The reaction solution was cooled to room temperature, and ethyl acetate was added. The mixture was washed with water and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The obtained crude product was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 73 / 27 → 52 / 48) to obtain the title compound (43.1 mg, 96%) as a white solid. 1 H NMR (400 Mz, CDCl3) δ 7.87 (1H, dt, J = 7.6, 1.2 Hz), 7.55-7.50 (1H, m), 7.49 (1H, d, J = 4.0 Hz), 7.27-7.11 (5H, m), 6.97-6.95 (1H, m), 4.69 (1H, br s), 4.56-4.55 (1H, m), 3.83-3.80 (1H, m), 4.04-3.97 (1H, m), 3.73-3.71 (1H, m), 3.60 (3H, br s), 2.96-2.93 (1H, m), 2.49-2.48 (3H, m), 2.33 (3H, s), 1.81-1.56 (1H, m), 1.51-1.35 (1H, m), 1.29 (3H, br s), 1.23-1.21 (3H, m), 1.10-1.08 (3H, m).
[0286] Reference example 28 Preparation of methyl 2-amino-5-bromo-3-nitrobenzoate
[0287] [ka]
[0288] To a solution of methyl 2-amino-3-nitrobenzoate (5.30 g, 27 mmol) in acetic acid (30 mL), a solution of bromine (5.0 g, 32 mmol) in acetic acid (5.0 mL) was added and stirred at room temperature for 1 hour. Crushed ice and water were added to the reaction solution, and the mixture was stirred at room temperature for 10 minutes. The precipitated solid was filtered, washed with water, dissolved in ethyl acetate, washed with 1 M aqueous sodium hydroxide solution and saturated brine, and dried over sodium sulfate. The solvent was removed by evaporation under reduced pressure to give the title compound (7.37 g, 99%) as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 8.51 (1H, d, J = 2.4 Hz), 8.44 (2H, br s), 8.32 (1H, d, J = 2.4 Hz), 3.93 (3H, s).
[0289] Reference example 29 Preparation of methyl 2,3-diamino-5-bromobenzoate
[0290] [ka]
[0291] Tin(II) chloride (13.6 g, 72 mmol) was added to a solution of methyl 2-amino-5-bromo-3-nitrobenzoate (3.97 g, 14 mmol) in methanol (100 mL) and stirred at 75 °C for 1.5 hours. The reaction solution was returned to room temperature and concentrated under reduced pressure. Water was added, and the pH was adjusted to 9 with 1 M aqueous sodium hydroxide (100 mL) and solid sodium bicarbonate. The resulting organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 70 / 30 → 49 / 51) to give the title compound (2.60 g, 73%) as a brown solid. 1H NMR (400 MHz, CDCl3) δ 7.58 (1H, d, J = 1.6 Hz), 6.94 (1H d, J= 1.6 Hz), 5.55 (2H, br s), 3.87 (3H, s), 3.39 (2H, br s).
[0292] Reference example 30 Preparation of methyl 6-bromo-1H-benzo[d]imidazole-4-carboxylate
[0293] [ka]
[0294] A solution of methyl 2,3-diamino-5-bromobenzoate (1.02 g, 4.2 mmol) in formic acid (10 mL) was stirred at 100 °C for 1 hour. The reaction solution was returned to room temperature, and 1 M aqueous sodium hydroxide and solid sodium bicarbonate were added to adjust the pH to 9, followed by extraction with ethyl acetate. The resulting organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (1.06 g, 99%) as a purple solid. 1 H NMR (400 MHz, CDCl3) δ 10.5 (1H, br s), 8.18 (1H, d, J = 0.8 Hz), 8.14 (1H, s), 8.07 (1H, d, J = 0.8 Hz), 4.02 (3H, s).
[0295] Reference example 31 Preparation of (6-bromo-1-trityl-1H-benzo[d]imidazol-4-yl)methanol
[0296] [ka]
[0297] To a solution of methyl 6-bromo-1H-benzo[d]imidazole-4-carboxylate (854.6 mg, 3.4 mmol) in dichloromethane (16 mL), N-methylmorpholine (550 μL, 5.3 mmol) and trityl chloride (1.17 g, 4.2 mmol) were added and the mixture was stirred at 55 °C for 2 hours. The reaction solution was returned to room temperature, ethyl acetate was added, washed with saturated aqueous sodium carbonate and saturated brine, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The resulting residue was dissolved in THF (12 mL), and 2 M lithium borohydride in THF (3.4 mL, 6.8 mmol) was added, followed by stirring at room temperature for 1 hour. Water was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate. The resulting organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 72 / 28 → 7 / 93 → CH2Cl2 / MeOH = 100 / 0 → 95 / 5) to obtain the title compound (1.17 g, 74%) as a pale purple solid. 1 H NMR (400 MHz, CDCl3) δ 7.85 (1H, s), 7.36-7.31 (9H, m), 7.21 (1H, s), 7.17-7.14 (6H, m), 6.50 (1H, s), 5.09 (2H, d, J = 6.4 Hz), 3.67 (1H, t, J = 6.4 Hz), Reference example 32 Preparation of (R)-2-[(6-bromo-1-trityl-1H-benzo[d]imidazol-4-yl)methyl]-4-ethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide
[0298] [ka]
[0299] To a solution of (6-bromo-1-trityl-1H-benzo[d]imidazol-4-yl)methanol (343.7 mg, 0.73 mmol) and lithium chloride (126.3 mg, 3.0 mmol) in dichloromethane (2.5 mL) were added DIPEA (0.77 mL, 4.4 mmol) and methanesulfonyl chloride (115 μL, 1.5 mmol), and the mixture was stirred at 25 °C for 12 hours. The reaction solution was diluted with ethyl acetate, washed with water and saturated brine, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The resulting residue was dissolved in a mixed solvent of DMF (3.0 mL) and dichloromethane (1.0 mL), and (R)-4-ethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (173.9 mg, 0.77 mmol), tetrabutylammonium iodide (55.8 mg, 0.15 mmol), and potassium carbonate (315.6 mg, 2.3 mmol) were added to the reaction solution. The reaction solution was stirred at 40 °C for 5.5 hours, cooled to room temperature, diluted with a mixed solvent of ethyl acetate / hexane (1 / 1), washed with water and saturated brine, dried over sodium sulfate, and evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 69 / 31 → 48 / 52) to obtain the title compound (471.8 mg, 95%) as a pale orange solid. 1H NMR (400 MHz, CDCl3) δ 7.89 (1H, dd, J = 7.6, 1.6 Hz), 7.78 (1H, s), 7.49 (1H, td, J = 7.6, 1.6 Hz), 7.46 (1H, s), 7.34-7.30 (9H, m), 7.23 (1H, t, J = 8.0 Hz), 7.17-7.11 (7H, m), 6.50 (1H, d, J = 1.6 Hz), 4.77 (1H, d, J = 16.0 Hz), 4.55 (1H, d, J = 16.0 Hz), 4.05-3.96 (2H, m), 3.30 (1H, dt, J = 13.6, 6.8 Hz), 1.78-1.67 (1H, m), 1.54-1.44 (1H, m), 1.08 (3H, t, J= 7.2 Hz).
[0300] Reference example 33 Preparation of (R)-4-ethyl-2-{[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-benzo[d]imidazol-4-yl]methyl}-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide
[0301] [ka]
[0302] A solution of (R)-2-[(6-bromo-1-trityl-1H-benzo[d]imidazol-4-yl)methyl]-4-ethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (202.2 mg, 0.30 mmol), bis(pinacolato)diboron (83.0 mg, 0.33 mmol), PdCl(dppf)-CHCl (12.8 mg, 0.016 mmol), and potassium acetate (90.8 mg, 0.93 mmol) in anhydrous 1,4-dioxane (2.0 mL) was stirred at 90 °C for 15.5 h under an argon atmosphere. The reaction mixture was cooled to room temperature, filtered through Celite, and the solvent in the filtrate was removed by evaporation under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 76 / 24 → 55 / 45) to obtain the compound (170.6 mg), approximately half of which was unreacted. A solution of the resulting compound (0.13 mmol), bis(pinacolato)diboron (83.0 mg, 0.33 mmol), PdCl2(dppf)2-CHCl2 (12.8 mg, 0.016 mmol), and potassium acetate (90.8 mg, 0.93 mmol) in anhydrous 1,4-dioxane (2.0 mL) was stirred at 90 °C for 15.5 h. The reaction solution was returned to room temperature and filtered through Celite. The solvent in the filtrate was removed by evaporation under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 76 / 24 → 55 / 45) to obtain the title compound (138.9 mg, 64%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.92 (1H, d, J = 7.6 Hz), 7.84 (1H, s), 7.71 (1H, s), 7.46 (1H, t, J = 7.6 Hz), 7.32-7.28 (9H, m), 7.21 (1H, t, J = 7.6 Hz), 7.16-7.14 (7H, m). 6.77 (1H, s), 4.81 (1H, d, J = 14.8 Hz), 4.58 (1H, d, J = 14.8 Hz), 4.06-3.94 (2H, m), 3.27 (1H, d, J = 14.0 Hz), 1.72-1.62 (1H, m), 1.49-1.40 (1H, m), 1.20 (12H, s), 1.03 (3H, t, J = 7.2 Hz).
[0303] Reference example 34 Preparation of 5-bromo-3-methylthiophene-2-carbaldehyde
[0304] [ka]
[0305] To a solution of 3-methylthiophene-2-carboxaldehyde (3.75 g, 30 mmol) in dichloromethane (25 mL) was added bromine (5.0 g, 31 mmol) at 0 °C and the mixture was stirred at 65 °C for 1 hour. The reaction solution was returned to room temperature, diluted with dichloromethane, and washed with aqueous sodium thiosulfate, water, and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The resulting residue was purified by silica gel chromatography (hexane / ethyl acetate (v / v) = 98 / 2 → 90 / 10) and then recrystallized from ethyl acetate / hexane to give the title compound (2.06 g, 33%) as pale yellow crystals. The filtrate was further concentrated, hexane was added, and the precipitate was collected by filtration to give the title compound (1.41 g, 23%) as a pale brown solid. 1H NMR (400 MHz, CDCl3) δ 9.90 (1H, s), 6.96 (1H, s), 2.53 (3H, s).
[0306] Reference example 35 Preparation of 5-bromo-3-methylthiophene-2-carboxylic acid
[0307] [ka]
[0308] A solution of 5-bromo-3-methylthiophene-2-carbaldehyde (317.1 mg, 1.6 mmol) in acetone (3.0 mL) was cooled to 0 °C, and 2.5 M Jones reagent (3.75 mL, 3.8 mmol) (CrO 1.01 g, H SO 1.0 mL, HO 3.0 mL) was added. The mixture was stirred at 0 °C for 5 minutes, followed by stirring at 25 °C for 2 hours and 15 minutes. Water was added to the reaction solution to quench the reaction. Ethyl acetate was added, and the organic and aqueous layers were separated. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water and saturated brine, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (304.2 mg, 89%) as an orange solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.20 (1H, s), 2.43 (3H, s).
[0309] Reference example 36 Preparation of 5-bromo-N-methylfuran-2-carboxamide
[0310] [ka]
[0311] To a solution of 5-bromofuran-2-carboxylic acid (500 mg, 2.6 mmol), methylamine hydrochloride (212.3 mg, 3.1 mmol), EDCI (603 mg, 3.1 mmol), and HOBt (106.2 mg, 0.79 mmol) in acetonitrile (3.3 mL) was added TEA (439 μL, 3.1 mmol). The reaction mixture was stirred at room temperature for 14 hours, followed by addition of water and extraction with dichloromethane. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 70 / 30 → 50 / 50) to afford the title compound (391.3 mg, 73%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.04 (1H, d, J= 3.6 Hz), 6.62 (1H, s), 6.42 (1H, d, J= 3.6 Hz), 2.96 (3H, d, J = 4.8 Hz).
[0312] Reference example 37 Preparation of (5-bromofuran-2-yl)(pyrrolidin-1-yl)methanone
[0313] [ka]
[0314] 5-Bromofuran-2-carboxylic acid (1.0 g, 5.2 mmol), pyrrolidine (517 μL, 6.3 mmol), EDCI (1.2 g, 6.3 mmol), HOBt (212 mg, 1.6 mmol), acetonitrile (6.6 mL), and TEA (878 μL, 6.3 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (748.8 mg, 58%) as a white solid. 1H NMR(400 MHz, CDCl3)δ 7.04 (1H, d, J = 3.6 Hz), 6.43 (1H, d, J = 3.6 Hz), 3.82 (2H, t, J = 6.8 Hz), 3.63 (2H, t, J = 6.8 Hz), 2.01 (2H, quin, J = 6.8 Hz), 1.90 (2H, quin, J = 6.8 Hz).
[0315] Reference example 38 Preparation of 5-bromo-N-isopropylfuran-2-carboxamide
[0316] [ka]
[0317] 5-Bromofuran-2-carboxylic acid (1.0 g, 5.24 mmol), isopropylamine (540 μL, 6.3 mmol), EDCI (1.2 g, 6.3 mmol), HOBt (212 mg, 1.57 mmol), acetonitrile (6.6 mL), and TEA (878 μL, 6.3 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (714.3 mg, 59%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.04 (1H, d, J = 3.2 Hz), 6.43 (1H, d, J = 3.2 Hz), 6.09 (1H, br s), 4.24 (1H, septd, J = 6.4, 1.2 Hz), 1.26 (6H, d, J = 6.4 Hz).
[0318] Reference example 39 Preparation of 5-bromo-N-methylthiophene-2-carboxamide
[0319] [ka]
[0320] 5-Bromothiophene-2-carboxylic acid (500 mg, 2.4 mmol), methylamine hydrochloride (325 mg, 4.8 mmol), EDCI (554 mg, 2.9 mmol), HOBt (97.7 mg, 0.72 mmol), acetonitrile (5.0 mL), and TEA (1.0 mL, 7.2 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (239.8 mg, 45%) as a white solid. 1 H NMR(400 MHz, CD3OD)δ 7.40 (1H, d, J = 4.0 Hz), 7.13 (1H, d, J = 4.0 Hz), 2.86 (3H, s).
[0321] Reference example 40 Preparation of 5-bromo-N-(2-methoxyethyl)furan-2-carboxamide
[0322] [ka]
[0323] 5-Bromofuran-2-carboxylic acid (300 mg, 1.6 mmol), 2-methoxyethylamine (340 μL, 5.2 mmol), EDCI (602 mg, 3.1 mmol), HOBt (212 mg, 1.6 mmol), acetonitrile (3.0 mL), and TEA (500 μL, 6.8 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (339.9 mg, 87%) as a pale yellow oil. 1 H NMR(400 MHz, CDCl3)δ 7.06 (1H, d, J= 3.6 Hz), 6.63 (1H, br s), 6.43 (1H, d, J= 3.6 Hz), 3.63-3.59 (2H, m), 3.55-3.53 (2H, m), 3.40 (3H, s).
[0324] Reference example 41 Preparation of N,3-dimethylfuran-2-carboxamide
[0325] [ka]
[0326] 3-Methylfuran-2-carboxylic acid (720 mg, 5.7 mmol), methylamine hydrochloride (581 mg, 8.6 mmol), EDCI (1.3 g, 6.8 mmol), HOBt (459 mg, 3.4 mmol), acetonitrile (10 mL), and TEA (2.4 mL, 17 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (693.6 mg, 87%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 6.32 (1H, s), 6.28 (1H, br s), 2.95 (3H, d, J = 5.2 Hz), 2.40 (3H, s).
[0327] Reference example 42 Preparation of 4-bromo-N-methylthiophene-2-carboxamide
[0328] [ka]
[0329] 4-Bromothiophene-2-carboxylic acid (1.0 g, 4.83 mmol), methylamine hydrochloride (652 mg, 9.7 mmol), EDCI (1.1 g, 5.8 mmol), HOBt (392 mg, 2.9 mmol), acetonitrile (15 mL), and TEA (2.0 mL, 15 mmol) were used as raw materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (789.1 mg, 74%) as a white solid. 1H NMR(400 MHz, CDCl3)δ 7.37 (1H, d,J = 1.2 Hz), 7.35 (1H, d, J = 1.2 Hz), 5.93 (1H, br s), 3.00 (3H, d, J= 4.8 Hz).
[0330] Reference example 43 Preparation of N,4-dimethylthiophene-2-carboxamide
[0331] [ka]
[0332] Using 4-methylthiophene-2-carboxylic acid (1.0 g, 7.0 mmol), methylamine hydrochloride (945.3 mg, 14 mmol), EDCI (1.61 g, 8.4 mmol), HOBt (662 mg, 4.9 mmol), acetonitrile (5.0 mL), dichloromethane (5.0 mL), and TEA (2.94 mL, 21 mmol) as starting materials, the title compound (880.5 mg, 81%) was obtained as a white solid by the procedure described in Reference Example 36. 1 H NMR(400 MHz, CDCl3)δ 7.45 (1H, d, J= 1.2 Hz), 7.29 (1H, br s), 7.00 (1H, br s), 2.96 (3H, d, J = 4.8 Hz), 2.20 (3H, d, J= 0.8 Hz).
[0333] Reference example 44 Preparation of N-methoxy-N,4-dimethylthiophene-2-carboxamide
[0334] [ka]
[0335] Using 4-methylthiophene-2-carboxylic acid (700 mg, 4.9 mmol), N,O-dimethylhydroxylamine hydrochloride (1.44 g, 15 mmol), EDCI (1.88 g, 9.8 mmol), HOBt (1.32 g, 9.8 mmol), dichloromethane (20 mL), and DIPEA (2.6 mL, 15 mmol) as starting materials, and operating in the same manner as in Reference Example 36, the title compound (831.5 mg, 91%) was obtained as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ 7.75 (1H, d, J= 1.6 Hz), 7.14 (1H, d, J = 1.6 Hz), 3.76 (3H, s), 3.36 (3H, s), 2.28 (3H, s).
[0336] Reference example 45 Preparation of 3-fluoro-N-methoxy-N-methylthiophene-2-carboxamide
[0337] [ka]
[0338] 3-Fluorothiophene-2-carboxylic acid (500 mg, 3.4 mmol), N,O-dimethylhydroxylamine hydrochloride (1.0 g, 10 mmol), EDCI (1.31 g, 6.8 mmol), and HOBt (924.3 mg, 6.8 mmol), dichloromethane (20 mL), and DIPEA (1.84 mL, 10 mmol) were used as raw materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (604.6 mg, 94%) as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ 7.38 (1H, dd, J= 5.6, 4.0 Hz), 6.84 (1H, d, J = 5.6 Hz), 3.74 (3H, s), 3.33 (3H, s).
[0339] Reference example 46 Preparation of 5-bromo-N-(2,4-dimethoxybenzyl)thiophene-2-carboxamide
[0340] [ka]
[0341] 5-Bromothiophene-2-carboxylic acid (400 mg, 1.9 mmol), 2,4-dimethoxybenzylamine (582 μL, 3.9 mmol), EDCI (1.31 g, 6.8 mmol), HOBt (924.3 mg, 6.8 mmol), dichloromethane (20 mL), and DIPEA (1.84 mL, 10 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (860.9 mg, quant.) as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ 7.21 (1H, d, J= 8.0 Hz), 7.19 (1H, d, J = 4.0 Hz), 6.98 (1H, d, J = 4.0 Hz), 6.48 (1H, br s), 6.46 (1H, d, J = 2.4 Hz), 6.43 (1H, dd, J = 8.0, 2.4 Hz), 4.49 (2H, d, J = 5.6 Hz), 3.84 (3H, s), 3.79 (3H, s).
[0342] Reference example 47 Preparation of 5-bromo-N-methoxy-N-3-dimethylthiophene-2-carboxamide
[0343] [ka]
[0344] To a solution of 5-bromo-3-methylthiophene-2-carboxylic acid (302.3 mg, 1.4 mmol), N,O-dimethylhydroxylamine hydrochloride (267.4 mg, 2.7 mmol), and EDCI (397.6 mg, 2.1 mmol) in dichloromethane (5.0 mL) was added TEA (0.57 mL, 4.1 mmol) and stirred at 25 °C for 18 hours. The reaction solution was diluted with ethyl acetate, washed with 1 M hydrochloric acid and saturated brine, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (315.3 mg, 87%) as a brown oil. 1 H NMR (400 MHz, CDCl3) δ 6.87 (1H, s), 3.70 (3H, s), 3.29 (3H, s), 2.51 (3H, s).
[0345] Reference example 48 Bromo-N-methoxy-N-methylthiazole-5-carboxamide
[0346] [ka]
[0347] To a solution of 2-bromothiazole-5-carboxylic acid (707.9 mg, 3.4 mmol), N,O-dimethylhydroxylamine hydrochloride (667.5 mg, 6.8 mmol), and EDCI (977.9 mg, 5.1 mmol) in dichloromethane (17 mL) and DMF (3.0 mL) was added TEA (1.5 mL, 11 mmol), and the mixture was stirred at 25 °C for 13 hours. Ethyl acetate was added to the reaction solution, which was then washed with 1 M hydrochloric acid and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (519.1 mg, 61%) as a pale yellow solid. 1 H NMR (400 MHz, CDCl3) δ 8.32 (1H, s), 3.78 (3H, s), 3.36 (3H, s).
[0348] Reference example 49 Preparation of 2-bromo-N-methoxy-N-4-dimethylthiazole-5-carboxamide
[0349] [ka]
[0350] To a solution of 2-bromo-4-methylthiazole-5-carboxylic acid (500.2 mg, 2.3 mmol), N,O-dimethylhydroxyamine hydrochloride (452.8 mg, 4.6 mmol), and EDCI (654.6 mg, 3.4 mmol) in dichloromethane (8.0 mL) and DMF (2.0 mL) was added TEA (1.0 mL, 7.2 mmol) and stirred at 25 °C for 8 hours. The reaction solution was diluted with ethyl acetate and washed with 1 M hydrochloric acid and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (473.5 mg, 79%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 3.66 (3H, s), 3.26 (3H, s), 2.68 (3H, s).
[0351] Reference example 50 Preparation of 4-bromo-N-methoxy-N-methylthiophene-2-carboxamide
[0352] [ka]
[0353] Using 4-bromothiophene-2-carboxylic acid (500 mg, 2.4 mmol), NO-dimethylhydroxylamine hydrochloride (470 mg, 4.8 mmol), EDCI (924 mg, 4.8 mmol), HOBt (708 mg, 5.2 mmol), dichloromethane (20 mL), and DIPEA (1.29 mL, 7.2 mmol) as starting materials, and operating in the same manner as in Reference Example 36, the title compound (510.5 mg, 85%) was obtained as a colorless oily substance. 1H NMR(400 MHz, CDCl3)δ 7.83 (1H, d, J = 1.6 Hz), 7.44 (1H, d, J = 1.6 Hz), 3.78 (3H, s), 3.37 (3H, s).
[0354] Reference example 51 Preparation of 2-bromo-N-methoxy-N-methylthiophene-3-carboxamide
[0355] [ka]
[0356] 2-Bromothiophene-3-carboxylic acid (500 mg, 2.4 mmol), N,O-dimethylhydroxylamine hydrochloride (470 mg, 4.8 mmol), EDCI (924 mg, 4.8 mmol), HOBt (326 mg, 4.8 mmol), dichloromethane (20 mL), and DIPEA (1.29 mL, 7.2 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (606.7 mg, quant.) as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ 7.25 (1H, d, J= 6.0 Hz), 7.04 (1H, d, J = 6.0 Hz), 3.60 (3H, s), 3.34 (3H, s).
[0357] Reference example 52 Preparation of 5-bromo-N-methoxy-N-methylfuran-2-carboxamide
[0358] [ka]
[0359] 5-Bromofuran-2-carboxylic acid (500 mg, 2.6 mmol), N,O-dimethylhydroxylamine hydrochloride (767 mg, 7.9 mmol), EDCI (1.0 g, 5.2 mmol), HOBt (708 mg, 5.2 mmol), dichloromethane (20 mL), and DIPEA (1.4 mL, 7.9 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 36 to obtain the title compound (555.3 mg, 90%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.08 (1H, d,J = 3.6 Hz), 6.44 (1H, d, J = 3.6 Hz), 3.77 (3H, s), 3.33 (3H, s).
[0360] Reference example 53 Preparation of N-[(5-bromofuran-2-yl)methyl]propan-2-amine
[0361] [ka]
[0362] To a solution of 5-bromofuran-2-carbaldehyde (700 mg, 4.0 mmol) in methanol (7.0 mL), isopropylamine (514 μL, 6.0 mmol) and acetic acid (50 μL, 0.79 mmol) were added and stirred at room temperature for 2 hours. Sodium borohydride (227 mg, 6.0 mmol) was added to this mixture, and the mixture was stirred at room temperature for 16 hours. This mixture was diluted with 1N aqueous sodium hydroxide and extracted with dichloromethane. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (785.4 mg, 90%) as a pale yellow oil. 1H NMR(400 MHz, CDCl3)δ 6.21 (1H, d, J= 3.2 Hz), 6.15 (1H, d, J = 3.2 Hz), 3.75 (2H, s), 2.82 (1H, septd, J = 6.4 Hz), 1.38 (1H, br s), 1.06 (6H, d, J= 6.4 Hz).
[0363] Reference example 54 Preparation of 5-(tert-butyl)-4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-one
[0364] [ka]
[0365] To a solution of 2,3-thiophenedicarboxaldehyde (4.14 g, 30 mmol) in anhydrous dichloromethane (260 mL), tert-butylamine (4.0 mL, 38 mmol) and acetic acid (8.5 mL, 149 mmol) were added at 0 °C. The mixture was stirred at 0 °C for 15 minutes and then at room temperature for 3.5 hours. After completion of the reaction, the reaction solution was washed with 1 M hydrochloric acid and saturated aqueous sodium bicarbonate. The resulting organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 84 / 16 → 63 / 37) to give the title compound (4.03 g, 70%) as a pale orange solid. 1 H NMR (400 MHz, CDCl3) δ 7.56 (1H, d, J = 4.8 Hz), 6.99 (1H, d, J= 4.8 Hz), 4.36 (2H, s), 1.54 (9H, s) Reference example 55 Preparation of 2-bromo-1,5,6,7-tetrahydro-4H-indol-4-one
[0366] [ka]
[0367] To a solution of 1,5,6,7-tetrahydro-4H-indol-4-one (300 mg, 2.2 mmol) in DMF (3.0 mL), N-bromosuccinimide (475.2 mg, 2.7 mmol) was added and stirred at room temperature for 14 hours. 4N aqueous sodium hydroxide solution was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 6 / 4 → 5 / 5) to afford the title compound (220.5 mg, 76%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 8.49 (1H, br s), 6.51 (1H, d, J = 2.4 Hz), 2.79 (2H, t, J= 6.4 Hz), 2.48 (2H, t, J = 6.4 Hz), 2.15 (2H, quin, J = 6.4 Hz).
[0368] Reference example 56 Preparation of 5-bromo-N,3-dimethylfuran-2-carboxamide
[0369] [ka]
[0370] N,3-Dimethylfuran-2-carboxamide (310 mg, 2.2 mmol), DMF (2.3 mL), N-bromosuccinimide (477 mg, 2.7 mmol), and TFA (341 μL, 4.5 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 55 to obtain the title compound (205.3 mg, 42%) as a yellow oil. 1 H NMR(400 MHz, CDCl3)δ 6.28 (1H, br s), 6.27 (1H, s), 2.95 (3H, d, J = 4.8 Hz), 2.37 (3H, s).
[0371] Reference example 57 Preparation of 5-bromo-N,4-dimethylthiophene-2-carboxamide
[0372] [ka]
[0373] N,4-Dimethylthiophene-2-carboxamide (600 mg, 3.9 mmol), dimethylformamide (6.0 mL), N-bromosuccinimide (822 mg, 4.6 mmol), and TFA (588 μL, 7.7 mmol) were used as raw materials, and the procedure was performed in the same manner as in Reference Example 55 to obtain the title compound (763.8 mg, 84%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.19 (1H, s), 6.23 (1H, br s), 2.95 (3H, d, J = 4.8 Hz), 2.18 (3H, s).
[0374] Reference example 58 Preparation of 1-(5-bromo-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one
[0375] [ka]
[0376] 1-(2,4-Dimethyl-1H-pyrrol-3-yl)ethan-1-one (500 mg, 3.6 mmol), DMF (5.0 mL), and N-bromosuccinimide (778 mg, 4.4 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 55 to obtain the title compound (538.9 mg, 68%) as a red solid. 1 H NMR (400 MHz, CDCl3)δ 8.16 (1H, br s), 2.49 (3H, s), 2.42 (3H, s), 2.22 (3H, s).
[0377] Reference example 59 Preparation of 1-(5-bromo-4-methylthiophen-2-yl)ethan-1-one
[0378] [ka]
[0379] 1-(4-Methylthiophen-2-yl)ethan-1-one (100 mg, 0.71 mmol), DMF (1.0 mL), N-bromosuccinimide (152.4 mg, 0.86 mmol), and TFA (110 μL, 1.4 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 55 to obtain the title compound (118.6 mg, 76%) as a pale yellow solid. 1 H NMR (400 MHz, CDCl3)δ 7.36 (1H, s), 2.48 (3H, s), 2.22 (3H, s).
[0380] Reference example 60 Preparation of 5-bromo-3-fluoro-N-methoxy-N-methylthiophene-2-carboxamide
[0381] [ka]
[0382] To a solution of 3-fluoro-N-methoxy-N-methylthiophene-2-carboxamide (620 mg, 3.3 mmol) in DMF (6.0 mL) were added N-bromosuccinimide (1.17 g, 6.6 mmol) and TFA (1.0 mL, 13 mmol). The reaction mixture was stirred at room temperature for 24 hours, followed by the addition of 1N aqueous sodium hydroxide solution and extraction with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 100 / 0 → 80 / 20) to afford the title compound (425.5 mg, 48%) as a colorless oil. 1H NMR (400 MHz, CDCl3)δ 6.89 (1H, s), 3.75 (3H, s), 3.30 (3H, s).
[0383] Reference example 61 Preparation of 1-(5-bromo-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one
[0384] [ka]
[0385] 1-(2,4-Dimethyl-1H-pyrrol-3-yl)ethan-1-one (500 mg, 3.6 mmol), DMF (5.0 mL), and N-bromosuccinimide (778 mg, 4.4 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 55 to obtain the title compound (538.9 mg, 68%) as a red solid. 1 H NMR (400 MHz, CDCl3)δ 8.16 (1H, br s), 2.49 (3H, s), 2.42 (3H, s), 2.22 (3H, s).
[0386] Reference example 62 Preparation of 1-(5-bromo-1-ethyl-1H-pyrrol-2-yl)ethan-1-one
[0387] [ka]
[0388] 1-(1-ethyl-1H-pyrrol-2-yl)ethan-1-one (600 μL, 4.3 mmol), DMF (6.0 mL), and N-bromosuccinimide (925 mg, 5.2 mmol) were used as starting materials, and the procedure was carried out in the same manner as in Reference Example 55 to obtain the title compound (752 mg, 80%) as a colorless oil. 1H NMR(400 MHz, CDCl3)δ 6.91 (1H, d, J= 1.6 Hz), 6.85 (1H, d, J = 1.6 Hz), 4.33 (2H, q, J = 7.2 Hz), 2.40 (3H, s), 1.35 (3H, t, J = 7.2 Hz).
[0389] Reference example 63 Preparation of (5-bromothiophen-2-yl)(cyclopropyl)methanone
[0390] [ka]
[0391] Cyclopropyl(thiophen-2-yl)methanone (593 μL, 4.6 mmol), DMF (5.8 mL), N-bromosuccinimide (979 mg, 5.5 mmol), and TFA (704 μL, 9.2 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 55 to obtain the title compound (56.8 mg, 5%) as a pale red oil. 1 H NMR(400 MHz, CDCl3)δ 7.55 (1H, d, J= 4.0 Hz), 7.12 (1H, d, J = 4.0 Hz), 2.47-2.41 (1H, m), 1.25-1.21 (2H, m), 1.05-1.01 (2H, m).
[0392] Reference example 64 Preparation of 2-bromo-5-(tert-butyl)-4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-one
[0393] [ka]
[0394] To a solution of 5-(tert-butyl)-4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-one (4.03 g, 21 mmol) in DMF (100 mL) was added N-bromosuccinimide (7.37 g, 41 mmol) and acetic acid (1.3 mL, 23 mmol) at 0 °C and stirred at room temperature for 8 h. The reaction solution was quenched with saturated aqueous sodium bicarbonate and extracted with ethyl acetate / hexane (1 / 1). The resulting organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 96 / 4 → 75 / 25) to give the title compound (4.27 g, 76%) as a pale yellow solid. 1 H NMR (400 MHz, CDCl3) δ 7.01(1H, s), 4.33 (2H, s), 1.53 (9H, s).
[0395] Reference example 65 Preparation of 4-bromo-1-methyl-1H-pyrrole-2-carbonitrile
[0396] [ka]
[0397] 1-Methyl-1H-pyrrole-2-carbonitrile (300 mg, 2.8 mmol), DMF (7.0 mL), and N-bromosuccinimide (604.5 mg, 3.4 mmol) were used as raw materials, and the procedure was performed in the same manner as in Reference Example 55 to obtain the title compound (212.5 mg, 41%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 6.81 (1H, d, J= 1.6 Hz), 6.75 (1H, d, J = 1.6 Hz), 3.76 (3H, s).
[0398] Reference example 66 Preparation of 2-bromo-1-methyl-1,5,6,7-tetrahydro-4H-indol-4-one
[0399] [ka]
[0400] A solution of 2-bromo-1,5,6,7-tetrahydro-4H-indol-4-one (200 mg, 0.93 mmol) and potassium tert-butoxide (113.6 mg, 1.0 mmol) in DMSO (4.0 mL) was stirred at 60 °C for 30 min. Iodomethane (86 μL, 1.4 mmol) was added, and the mixture was stirred at 60 °C for 7 h. 1N hydrochloric acid was added to the mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 7 / 3 → 1 / 1) to give the title compound (170.1 mg, 80%) as a pale yellow solid. 1 H NMR(400 MHz, CDCl3)δ 6.52 (1H, s), 3.50 (3H, s), 2.73 (2H, t, J = 6.4 Hz), 2.41 (2H, t, J = 6.4 Hz), 2.14 (2H, quin, J = 6.4 Hz).
[0401] Reference example 67 Preparation of 1-(5-bromo-1,2,4-trimethyl-1H-pyrrol-3-yl)ethan-1-one
[0402] [ka]
[0403] To a solution of sodium hydride (50.4 mg, 1.7 mmol) in DMF (4.0 mL) was added 1-(5-bromo-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one (300 mg, 1.4 mmol). The mixture was stirred at room temperature for 1 hour, and then iodomethane (105 μL, 1.7 mmol) was added and stirred for 20 hours. Further iodomethane (86 μL, 1.4 mmol) was added, and the mixture was stirred at 60 °C for 7 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 0→9 / 1) to give the title compound (152.8 mg, 48%) as a pale red solid. 1 H NMR(400 MHz, CDCl3)δ 3.50 (3H, s), 2.50 (3H, s), 2.41 (3H, s), 2.24 (3H, s).
[0404] Reference example 68 Preparation of 1-(5-bromo-3-fluorothiophen-2-yl)ethan-1-one
[0405] [ka]
[0406] To a solution of 5-bromo-3-fluoro-N-methoxy-N-methylthiophene-2-carboxamide (425 mg, 1.6 mmol) in THF (8.0 mL) was added a solution of methylmagnesium bromide (3 M, 2-methyltetrahydrofuran solution) (0.80 mL, 2.4 mmol) at 0 °C. After stirring at room temperature for 7.5 hours, the reaction was quenched with saturated aqueous ammonium chloride and extracted with diethyl ether. The organic layer was washed with saturated aqueous ammonium chloride, dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (190.8 mg, 54%) as a colorless oil. 1H NMR (400 MHz, CDCl3)δ 6.90 (1H, d, J= 0.8 Hz), 2.52 (3H, d, J = 3.2 Hz).
[0407] Reference example 69 Preparation of 1-(4-methylthiophen-2-yl)ethan-1-one
[0408] [ka]
[0409] N-Methoxy-N,4-dimethylthiophene-2-carboxamide (400 mg, 2.2 mmol), THF (11 mL), and a solution of methylmagnesium bromide (3 M, 2-methyltetrahydrofuran solution) (1.1 mL, 3.2 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 68 to obtain the title compound (275.1 mg, 91%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.50 (1H, d, J= 0.8 Hz), 7.22 (1H, br d, J = 0.8 Hz), 2.53 (3H, s), 2.29 (3H, d, J = 0.8 Hz).
[0410] Reference example 70 Preparation of 1-(5-bromo-3-methylthiophen-2-yl)ethan-1-one
[0411] [ka]
[0412] 5-Bromo-N-methoxy-N,3-dimethylthiophene-2-carboxamide (368 mg, 1.4 mmol), THF (7.0 mL), and a solution of methylmagnesium bromide (3 M, 2-methyltetrahydrofuran solution) (0.70 mL, 2.1 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 68 to obtain the title compound (216.1 mg, 71%) as a yellow oily substance. 1 H NMR (400 MHz, CDCl3)δ 6.93 (1H, s), 2.51 (3H, s), 2.47 (3H, s).
[0413] Reference example 71 Preparation of 1-(2-bromothiazol-5-yl)ethan-1-one
[0414] [ka]
[0415] To a solution of 2-bromo-N-methoxy-N-methylthiazole-5-carboxamide (507.5 mg, 2.0 mmol) in THF (7.0 mL) was added a solution of methylmagnesium bromide (3 M, 2-methyltetrahydrofuran solution) (0.68 mL, 2.0 mmol), and the mixture was stirred at 25 °C for 1 hour. Further, methylmagnesium bromide (3 M, 0.15 mL, 0.45 mmol) was added, and the mixture was stirred at room temperature for 5 minutes. A saturated aqueous solution of ammonium chloride was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (278 mg, 67%) as a pale yellow solid. 1 H NMR (400 MHz, CDCl3) δ 8.05, (1H, s), 2.56 (3H, s).
[0416] Reference example 72 Preparation of 1-(2-bromo-4-methylthiazol-5-yl)ethan-1-one
[0417] [ka]
[0418] To a solution of 2-bromo-N-methoxy-N-4-dimethylthiazole-5-carboxamide (209.0 mg, 0.8 mmol) in THF (2.0 mL) was added methylmagnesium bromide (3 M, 2-methyltetrahydrofuran solution) (0.3 mL, 0.9 mmol) at 0 °C and stirred at room temperature for 10 min. The reaction solution was quenched by adding saturated aqueous ammonium chloride solution, extracted with ethyl acetate, washed with saturated brine, dried over sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 82 / 18 → 61 / 39) to give the title compound (146.8 mg, 85%) as a clear yellow oil. 1 H NMR (400 MHz, CDCl3) δ 2.72 (3H, s), 2.51 (3H, s).
[0419] Reference example 73 Preparation of 1-(4-bromothiophen-2-yl)ethan-1-one
[0420] [ka]
[0421] Using 4-bromo-N-methoxy-N-methylthiophene-2-carboxamide (510 mg, 2.0 mmol), THF (10 mL), and a solution of methylmagnesium bromide (3 M, 2-methyltetrahydrofuran solution) (1.0 mL, 3.0 mmol) as starting materials, and operating in the same manner as in Reference Example 68, the title compound (406.9 mg, 97%) was obtained as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ 7.58 (1H, d, J = 1.2 Hz), 7.53 (1H, d, J = 1.2 Hz), 2.55 (3H, s).
[0422] Reference example 74 Preparation of 1-(2-bromothiophen-3-yl)ethan-1-one
[0423] [ka]
[0424] 2-Bromo-N-methoxy-N-methylthiophene-3-carboxamide (550 mg, 2.2 mmol), THF (10 mL), and a solution of methylmagnesium bromide (3 M, 2-methyltetrahydrofuran solution) (1.1 mL, 3.3 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 68 to obtain the title compound (128.8 mg, 29%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.35 (1H, d, J = 5.6 Hz), 7.23 (1H, d, J = 5.6 Hz), 2.62 (3H, s).
[0425] Reference example 75 Preparation of 1-(5-bromofuran-2-yl)ethan-1-one
[0426] [ka]
[0427] 5-Bromo-N-methoxy-N-methylfuran-2-carboxamide (332.6 mg, 1.4 mmol), THF (7.0 mL), and methylmagnesium bromide (3 M, 2-methyltetrahydrofuran solution) (0.7 mL, 2 mmol) were used as raw materials, and the procedure was performed in the same manner as in Reference Example 68 to obtain the title compound (223.3 mg, 78%) as a white solid. 1H NMR(400 MHz, CDCl3)δ 7.12 (1H, d,J = 3.6 Hz), 6.49 (1H, d, J = 3.6 Hz), 2.46 (3H, s).
[0428] Reference example 76 Preparation of 2-(5-bromothiophen-2-yl)-2-methyl-1,3-dioxolane
[0429] [ka]
[0430] To a solution of 1-(5-bromothiophen-2-yl)ethan-1-one (500 mg, 2.4 mmol) in toluene (34 mL), ethylene glycol (0.95 mL, 17 mmol) and p-TsOH-HO (130 mg, 0.68 mmol) were added and the mixture was stirred under reflux for 25 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 95 / 5 → 9 / 1) to afford the title compound (183.7 mg, 30%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 6.90 (1H, d, J= 4.0 Hz), 6.79 (1H, d, J = 4.0 Hz), 4.06-4.00 (m, 2H), 3.99-3.93 (m, 2H), 1.73(s, 3H).
[0431] Reference example 77 Preparation of 2-(5-bromo-3-methylthiophen-2-yl)-2-methyl-1,3-dioxolone
[0432] [ka]
[0433] To a solution of 1-(5-bromo-3-methylthiophen-2-yl)ethan-1-one (491.5 mg, 2.2 mmol) in toluene (20 mL), ethylene glycol (1.2 mL, 22 mmol) and p-TsOH-HO (0.11 mmol) were added and the mixture was stirred under reflux for 10 hours. The reaction solution was returned to room temperature, saturated aqueous sodium bicarbonate was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (577.9 mg, 98%) as a clear yellow oil. 1 H NMR (400 MHz, CDCl3) δ 6.74 (1H, s), 4.06-3.99 (2H, m), 3.96-3.90 (2H, m), 2.23 (3H, s), 1.71 (3H, s).
[0434] Reference example 78 Preparation of 2-bromo-5-(2-methyl-1,3-dioxolan-2-yl)thiazole
[0435] [ka]
[0436] To a solution of 1-(2-bromothiazol-5-yl)ethan-1-one (278 mg, 1.3 mmol) in toluene (8.0 mL), ethylene glycol (800 μL) and p-TsOH-HO (12.7 mg, 0.067 mmol) were added and the mixture was stirred under reflux for 14 hours. The reaction solution was returned to room temperature, and saturated aqueous sodium bicarbonate and ethyl acetate were added, separating the organic and aqueous layers. The organic layer was washed with saturated aqueous sodium bicarbonate, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (313.6 mg, 93%) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ 7.49 (1H, s), 4.13-4.03 (2H, m), 3.99-3.91 (2H, m), 1.75 (3H, s).
[0437] Reference example 79 Preparation of 2-bromo-4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiazole
[0438] [ka]
[0439] To a solution of 1-(2-bromo-4-methylthiazol-5-yl)ethan-1-one (146.8 mg, 0.67 mmol) in toluene (8.0 mL), ethylene glycol (0.40 mL) and p-TsOH-HO (6.3 mg, 0.033 mmol) were added, and the mixture was heated under reflux for 21 hours. The reaction mixture was returned to room temperature, saturated aqueous sodium bicarbonate solution was added, extracted with ethyl acetate, washed with saturated brine, and the solvent was removed by evaporation under reduced pressure. Since the reaction had not proceeded completely, toluene (8.0 mL), ethylene glycol (0.80 mL), and p-TsOH-HO (5.7 mg, 0.030 mmol) were added to the residue, and the mixture was heated under reflux for 13 hours. The reaction mixture was returned to room temperature, saturated aqueous sodium bicarbonate solution was added, extracted with ethyl acetate, washed with saturated brine, and the solvent was removed by evaporation under reduced pressure to give the title compound (172.2 mg, 98%) as an orange oil. 1 H NMR (400 MHz, CDCl3) δ 4.09-4.01 (2H, m), 3.94-3.88 (2H, m), 2.43 (3H, s), 1.71 (3H, s).
[0440] Reference example 80 Preparation of 2-(5-bromofuran-2-yl)-2-methyl-1,3-dioxolane
[0441] [ka]
[0442] 1-(5-Bromofuran-2-yl)ethan-1-one (533.5 mg, 2.8 mmol), ethylene glycol (1.7 mL, 31 mmol), p-TsOH-HO (27 mg, 0.14 mmol), and toluene (32 mL) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 76 to obtain the title compound (496.3 mg, 76%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 6.29 (1H, d,J = 3.2 Hz), 6.23 (1H, d, J = 3.2 Hz), 4.07-4.03 (2H, m), 4.01-3.97 (2H, m), 1.71 (3H, s).
[0443] Reference example 81 Preparation of 2-(5-bromothiophen-3-yl)-2-methyl-1,3-dioxolane
[0444] [ka]
[0445] 1-(5-Bromothiophen-3-yl)ethan-1-one (398 mg, 1.9 mmol), ethylene glycol (1.08 mL, 19. mmol), p-TsOH-HO (18.5 mg, 0.097 mmol), and toluene (22 mL) were used as starting materials, and the procedure was carried out in the same manner as in Reference Example 76 to obtain the title compound (322.2 mg, 67%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.17 (1H, d, J= 1.6 Hz), 7.02 (1H, d, J = 1.6 Hz), 4.07-3.98 (2H, m), 3.91-3.82 (2H, m), 1.64 (3H, s).
[0446] Reference example 82 Preparation of 1-(5-bromothiophen-3-yl)ethan-1-ol
[0447] [ka]
[0448] To a solution of 5-bromothiophene-3-carbaldehyde (200 μL, 1.8 mmol) in THF (8.0 mL) was added methylmagnesium bromide (3 M, 2-methyltetrahydrofuran solution) (907 μL, 2.7 mol) at 0 °C, and the mixture was stirred at room temperature for 1.5 hours. Saturated aqueous ammonium chloride solution was added to this mixture to quench the reaction, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous ammonium chloride solution, dried over sodium sulfate, and the solvent was evaporated under reduced pressure to obtain the title compound (503.8 mg, quant.) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 6.97 (1H, d, J= 0.8 Hz), 6.94 (1H, br s), 4.76 (1H, q, J= 6.4 Hz), 2.20 (1H, br s), 1.38 (3H, d, J= 6.4 Hz).
[0449] Reference example 83 Preparation of 1-(5-bromothiophen-3-yl)ethan-1-one
[0450] [ka]
[0451] To a solution of 1-(5-bromothiophen-3-yl)ethan-1-ol (503.8 mg, 1.8 mmol) in DMSO (8.0 mL), TEA (868 μL, 6.2 mmol) and pyridine-sulfur trioxide complex (832 mg, 5.2 mmol) were added and stirred at room temperature for 6 hours. This mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 95 / 5 → 80 / 20) to obtain the title compound (397.2 mg, quant.) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.91 (1H, d, J= 1.6 Hz), 7.49 (1H, d, J = 1.6 Hz), 2.49 (3H, s).
[0452] Reference example 84 Preparation of 5-(2-methyl-1,3-dioxolan-2-yl)thiazole-2-carbaldehyde
[0453] [ka]
[0454] A solution of 2-bromo-5-(2-methyl-1,3-dioxolan-2-yl)thiazole (215.2 mg, 0.86 mmol) in anhydrous THF (2.5 mL) was cooled to -78 °C, and n-butyllithium (1.6 M hexane solution) (0.6 mL, 0.96 mmol) was added and stirred at -78 °C for 30 min. Anhydrous DMF (240 μL, 3.1 mmol) was added to the reaction solution, and the mixture was stirred at -78 °C for 15 min. After that, the mixture was heated to -60 °C and stirred for an additional 50 min. Saturated aqueous ammonium chloride solution was added to the reaction solution at -60 °C, and the mixture was extracted with diethyl ether, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (96.0 mg, 56%) as a yellow, transparent oil. 1H NMR (400 MHz, CDCl3) δ 9.93 (1H, s), 8.01 (1H, s), 4.12-4.06 (2H, m), 3.99-3.93 (2H, m), 1.80 (3H, s).
[0455] Reference example 85 Preparation of 2-bromo-4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-one
[0456] [ka]
[0457] A solution of 2-bromo-5-(tert-butyl)-4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-one (3.78 g, 14 mmol) in TFA (50 mL) and water (5.0 mL) was stirred at 105 °C for 19 hours. The reaction solution was cooled to room temperature and concentrated by evaporation under reduced pressure. A saturated aqueous solution of sodium bicarbonate was added to the resulting residue, which was extracted with ethyl acetate. The resulting organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (3.25 g, quant.) as a brown solid. 1 H NMR (400 MHz, CDCl3) δ 7.08 (1H, s), 6.16 (1H, br s), 4.36 (2H, s).
[0458] Reference example 86 Preparation of 1-(5-bromo-3-fluorothiophen-2-yl)ethan-1-ol
[0459] [ka]
[0460] To a solution of 1-(5-bromo-3-fluorothiophen-2-yl)ethan-1-one (600.7 mg, 2.7 mmol) in methanol (3.6 mL), sodium borohydride (203.5 mg, 5.4 mmol) was added and stirred at room temperature for 1.5 hours. The reaction mixture was concentrated under reduced pressure. The reaction was quenched with 4N aqueous sodium hydroxide and extracted with dichloromethane. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (588.5 mg, 86%) as a pale red oil. 1 H NMR(400 MHz, CDCl3)δ 6.75 (1H, br s), 5.22-5.17 (1H, m), 2.00 (1H, d, J = 4.0 Hz), 1.54 (1H, d, J = 6.4 Hz).
[0461] Reference example 87 Preparation of [1-(5-bromo-3-fluorothiophen-2-yl)ethoxy](tert-butyl)dimethylsilane
[0462] [ka]
[0463] A solution of 1-(5-bromo-3-fluorothiophen-2-yl)ethan-1-ol (588.5 mg, 2.3 mmol) and imidazole (204.4 mg, 3.0 mmol) in DMF (1.5 mL) was added to a solution of tert-butyldimethylsilyl chloride (417.5 mg, 2.8 mmol) in DMF (4.1 mL) at 0 °C and stirred at room temperature for 23 hours. The reaction mixture was diluted with water and extracted with diethyl ether. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 1 / 0 → 95 / 5) to afford the title compound (581 mg, 74%) as a colorless oil. 1H NMR(400 MHz, CDCl3)δ 6.70 (1H, br s), 5.13 (1H, qd, J = 6.4, 1.2 Hz), 1.45 (3H, d, J = 6.4 Hz), 0.91 (9H, s), 0.082 (3H, s), 0.036 (3H, s).
[0464] Reference example 88 Preparation of methyl (E)-3-[5-(methylcarbamoyl)furan-2-yl]acrylate
[0465] [ka]
[0466] To a solution of 5-bromo-N-methylfuran-2-carboxamide (163.3 mg, 0.80 mmol), tetrabutylammonium chloride (32.7 mg, 0.04 mmol), and PdCl(dppf)-CHCl (22.2 mg, 0.08 mmol) in DMA (1.4 mL) was added methyl acrylate (215 μL, 2.4 mmol) and N,N-dicyclohexylmethylamine (515 μL, 2.4 mmol) and stirred at 110 °C for 17 h. The resulting solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 3 / 2 → 2 / 3) to give the title compound (103.8 mg, 62%) as a pale yellow solid. 1 H NMR(400 MHz, CDCl3)δ 7.41 (1H, d, J= 16.0 Hz), 7.13 (1H, d, J = 3.6 Hz), 6.67 (1H, d, J = 3.6 Hz), 6.52 (1H, br s), 6.41 (1H, d, J = 16.0 Hz), 3.80 (3H, s), 3.01 (3H, d, J = 4.8 Hz).
[0467] Reference example 89 Preparation of methyl (E)-3-[5-(pyrrolidine-1-carbamoyl)furan-2-yl]acrylate
[0468] [ka]
[0469] Using (5-bromofuran-2-yl)(pyrrolidin-1-yl)methanone (583 mg, 2.4 mmol), tetrabutylammonium chloride (66.7 mg, 0.24 mmol), PdCl(dppf)-CHCl (98 mg, 0.12 mmol), DMA (4.8 mL), methyl acrylate (643 μL, 7.2 mmol), and N,N-dicyclohexylmethylamine (761 μL, 3.6 mmol) as starting materials, and operating in a similar manner to Reference Example 88, the title compound (478.2 mg, 80%) was obtained as a brown solid. 1 H NMR(400 MHz, CDCl3)δ 7.44 (1H, d, J= 16.0 Hz), 7.14 (1H, d, J = 3.6 Hz), 6.71 (1H, d, J = 3.6 Hz), 6.37 (1H, d, J = 16.0 Hz), 3.90 (2H, t, J = 6.8 Hz), 3.80 (3H, s), 3.65 (2H, t, J = 6.8 Hz), 2.05 (2H, quin, J = 6.8 Hz), 1.92 (2H, quin, J = 6.8 Hz).
[0470] Reference example 90 Preparation of methyl (E)-3-[5-(isopropylcarbamoyl)furan-2-yl]acrylate
[0471] [ka]
[0472] Using 5-bromo-N-isopropylfuran-2-carboxamide (546.2 mg, 2.4 mmol), tetrabutylammonium chloride (65.3 mg, 0.24 mmol), PdCl(dppf)-CHCl (98 mg, 0.12 mmol), DMA (4.5 mL), methyl acrylate (632 μL, 7.1 mmol), and N,N-dicyclohexylmethylamine (748 μL, 3.5 mmol) as starting materials, and operating as in Reference Example 88, the title compound (411.6 mg, 74%) was obtained as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.43 (1H, d, J= 16.0 Hz), 7.13 (1H, d, J = 3.6 Hz), 6.68 (1H, d, J = 3.6 Hz), 6.43 (1H, d, J = 16.0 Hz), 6.15 (1H, br s), 4.27 (1H, septd, J = 6.4, 1.2 Hz), 3.82 (3H, s), 1.28 (6H, d, J = 6.4 Hz). Reference example 91 Preparation of methyl (E)-3-[5-(methylcarbamoyl)thiophen-2-yl]acrylate
[0473] [ka]
[0474] 5-Bromo-N-methylthiophene-2-carboxamide (239 mg, 1.1 mmol), tetrabutylammonium chloride (30.6 mg, 0.11 mmol), PdCl(dppf)-CHCl (44.5 mg, 0.05 mmol), DMA (2.2 mL), methyl acrylate (296 μL, 3.3 mmol), and N,N-dicyclohexylmethylamine (347 μL, 1.6 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 88 to give the title compound (16.1 mg, 7%) as a white solid. 1H NMR(400 MHz, CDCl3)δ 7.72 (1H, d,J = 15.6 Hz), 7.39 (1H, d, J = 3.6 Hz), 7.19 (1H, d, J = 3.6 Hz), 6.31 (1H, d, J = 15.6 Hz), 5.96 (1H, br s), 3.80 (3H, s), 3.01 (3H, d, J = 4.8 Hz).
[0475] Reference example 92 Preparation of methyl (E)-3-{5-[(2-methoxyethyl)carbamoyl]furan-2-yl}acrylate
[0476] [ka]
[0477] Using 5-bromo-N-(2-methoxyethyl)furan-2-carboxamide (270 mg, 1.1 mmol), tetrabutylammonium chloride (27 mg, 0.097 mmol), PdCl(dppf)-CHCl (40 mg, 0.049 mmol), DMA (2.2 mL), methyl acrylate (411 μL, 4.6 mmol), and N,N-dicyclohexylmethylamine (310 μL, 1.5 mmol) as starting materials, and operating as in Reference Example 88, the title compound (221.6 mg, 88%) was obtained as a brown oil. 1 H NMR(400 MHz, CDCl3)δ 7.42 (1H, d, J = 16.0 Hz), 7.14 (1H, d, J = 3.6 Hz), 6.88 (1H, br s), 6.69 (1H, d, J = 3.6 Hz), 6.46 (1H, d, J = 16.0 Hz), 3.81 (3H, s), 3.66-3.62 (2H, m), 3.58-3.55 (2H, m), 3.41 (3H, s).
[0478] Reference example 93 Preparation of methyl (E)-3-(5-acetylthiophen-2-yl)acrylate
[0479] [ka]
[0480] 1-(5-Bromothiophen-2-yl)ethan-1-one (700 mg, 3.4 mmol), tetrabutylammonium chloride (95 mg, 0.34 mmol), PdCl2(dppf)2-CHCl2 (139.0 mg, 0.17 mmol), DMA (7.0 mL), methyl acrylate (457 μL, 0.17 mmol), and N,N-dicyclohexylmethylamine (1.1 mL, 5.1 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 88 to obtain the title compound (304.8 mg, 43%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.73 (1H, d, J= 16.0 Hz), 7.60 (1H, d, J = 4.0 Hz), 7.24 (1H, d, J = 4.0 Hz), 6.39 (1H, d, J = 16.0 Hz), 3.81 (3H, s), 2.56 (3H, s).
[0481] Reference example 94 Preparation of methyl (E)-3-[4-methyl-5-(methylcarbamoyl)furan-2-yl]acrylate
[0482] [ka]
[0483] Using 5-bromo-N,3-dimethylfuran-2-carboxamide (200 mg, 0.92 mmol), tetrabutylammonium chloride (26 mg, 0.092 mmol), PdCl(dppf)-CHCl (38 mg, 0.046 mmol), DMA (1.5 mL), methyl acrylate (165 μL, 1.8 mmol), and N,N-dicyclohexylmethylamine (292 μL, 1.4 mmol) as starting materials, the title compound (99.6 mg, 48%) was obtained as a white solid by the procedure described in Reference Example 88. 1 H NMR(400 MHz, CDCl3)δ7.36 (1H, d, J = 15.6 Hz), 6.53 (1H, s), 6.36 (1H, d, J = 15.6 Hz), 6.34 (1H, br s), 3.80 (3H, s), 2.98 (3H, d, J = 5.2 Hz), 2.39 (3H, s).
[0484] Reference example 95 Preparation of methyl (E)-3-(5-sulfamoylthiophen-2-yl)acrylate
[0485] [ka]
[0486] Using 5-bromothiophene-2-sulfonamide (593.2 mg, 2.5 mmol), tetrabutylammonium chloride (68.1 mg, 0.25 mmol), PdCl(dppf)-CHCl (100 mg, 0.12 mmol), DMA (4.0 mL), methyl acrylate (439 μL, 4.9 mmol), and N,N-dicyclohexylmethylamine (780 μL, 3.7 mmol) as starting materials, and operating as in Reference Example 88, the title compound (163.7 mg, 27%) was obtained as a yellow solid. 1H NMR(400 MHz, CD3OD)δ 7.80 (1H, d, J = 16.0 Hz), 7.55 (1H, d, J = 4.0 Hz), 7.37 (1H, d, J = 4.0 Hz), 6.42 (1H, d, J = 16.0 Hz), 3.81 (3H, s).
[0487] Reference example 96 Preparation of methyl (E)-3-(thiophen-2-yl)acrylate
[0488] [ka]
[0489] Using 2-bromothiophene (235 μL, 2.5 mmol), tetrabutylammonium chloride (68.1 mg, 0.25 mmol), PdCl(dppf)-CHCl (100 mg, 0.12 mmol), DMA (4.0 mL), methyl acrylate (439 μL, 4.9 mmol), and N,N-dicyclohexylmethylamine (780 μL, 3.7 mmol) as starting materials, the title compound (332.9 mg, 81%) was obtained as a white solid by the procedure described in Reference Example 88. 1 H NMR(400 MHz, CDCl3)δ 7.79 (1H, d, J = 16.0 Hz), 7.37 (1H, d, J = 5.2 Hz), 7.25 (1H, d, J = 3.6 Hz), 7.05 (1H, dd, J= 5.2, 3.6 Hz), 6.24 (1H, d, J = 16.0 Hz), 3.79 (3H, s).
[0490] Reference example 97 Preparation of methyl (E)-3-[5-(methylcarbamoyl)thiophen-3-yl]acrylate
[0491] [ka]
[0492] Using 4-bromo-N-methylthiophene-2-carboxamide (500 mg, 2.3 mmol), tetrabutylammonium chloride (64 mg, 0.23 mmol), PdCl(dppf)-CHCl (93.0 mg, 0.11 mmol), DMA (4.0 mL), methyl acrylate (407 μL, 4.5 mmol), and N,N-dicyclohexylmethylamine (723 μL, 3.4 mmol) as starting materials, and operating as in Reference Example 88, the title compound (213.7 mg, 42%) was obtained as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.63 (1H, s), 7.60 (1H, d, J = 16.0 Hz), 7.58 (1H, s), 6.27 (1H, d, J = 16.0 Hz), 6.04 (1H, br s), 3.80 (3H, s), 3.01 (3H, d, J = 4.8 Hz).
[0493] Reference example 98 Preparation of methyl (E)-3{-[5-(isopropylamino)methyl]furan-2-yl}acrylate
[0494] [ka]
[0495] N-[(5-bromofuran-2-yl)methyl]propan-2-amine (600 mg, 2.8 mmol), tetrabutylammonium chloride (78 mg, 0.28 mmol), PdCl(dppf)-CHCl (112 mg, 0.14 mmol), DMA (4.5 mL), methyl acrylate (493 μL, 5.5 mmol), and N,N-dicyclohexylmethylamine (875 μL, 4.1 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 88 to give the title compound (158 mg, 26%) as a brown oil. 1H NMR(400 MHz, CDCl3)δ 7.38 (1H, d, J = 15.6 Hz), 6.54 (1H, d, J = 3.2 Hz), 6.27 (1H, d, J = 15.6 Hz), 6.26 (1H, d, J = 3.2 Hz), 3.81 (2H, s), 3.78 (3H, s), 2.85 (1H, septd, J = 6.4 Hz), 1.09 (6H, d, J = 6.4 Hz).
[0496] Reference example 99 Preparation of methyl (E)-3-[3-methyl-5-(methylcarbamoyl)thiophen-2-yl]acrylate
[0497] [ka]
[0498] Using 5-bromo-N,4-dimethylthiophene-2-carboxamide (200 mg, 0.85 mmol), tetrabutylammonium chloride (24 mg, 0.085 mmol), PdCl(dppf)-CHCl (34.7 mg, 0.043 mmol), DMA (1.2 mL), methyl acrylate (152.5 μL, 1.7 mmol), and N,N-dicyclohexylmethylamine (270 μL, 1.3 mmol) as starting materials, and operating as in Reference Example 88, the title compound (171.5 mg, 84%) was obtained as a yellow solid. 1 H NMR(400 MHz, CDCl3)δ 7.76 (1H, d, J= 16.0 Hz), 7.34 (1H, s), 6.94 (1H, br s), 6.20 (1H, d, J = 16.0 Hz), 3.79 (3H, s), 2.98 (3H, d, J = 4.8 Hz), 2.28 (3H, s).
[0499] Reference example 100 Preparation of methyl (E)-3-(1-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-2-yl)acrylate
[0500] [ka]
[0501] 2-Bromo-1-methyl-1,5,6,7-tetrahydro-4H-indol-4-one (170 mg, 2.3 mmol), tetrabutylammonium chloride (21 mg, 0.085 mmol), PdCl2(dppf)2-CHCl2 (31 mg, 0.038 mmol), DMA (0.90 mL), methyl acrylate (135 μL, 1.5 mmol), and N,N-dicyclohexylmethylamine (240 μL, 1.1 mmol) were used as starting materials, and the procedure was carried out in the same manner as in Reference Example 88 to obtain the title compound (154.6 mg, 88%) as a brown solid. 1 H NMR(400 MHz, CDCl3)δ 7.56 (1H, d, J= 15.6 Hz), 7.00 (1H, s), 6.23 (1H, d, J= 15.6 Hz), 3.78 (3H, s), 3.61 (3H, s), 2.79 (2H, t, J = 6.4 Hz), 2.47 (2H, t, J= 6.4 Hz), 2.17 (2H, quin, J = 6.4 Hz).
[0502] Reference example 101 Preparation of methyl (E)-3-(5-acetyl-1-methyl-1H-pyrrol-2-yl)acrylate
[0503] [ka]
[0504] 1-(5-Bromo-1-methyl-1H-pyrrol-2-yl)ethan-1-one (402.7 mg, 1.8 mmol), tetrabutylammonium chloride (66 mg, 0.24 mmol), PdCl2(dppf)2-CHCl2 (96.4 mg, 0.12 mmol), dimethylacetamide (1.8 mL), methyl acrylate (423 μL, 4.7 mmol), and N,N-dicyclohexylmethylamine (750 μL, 3.5 mmol) were used as starting materials, and the procedure was carried out in the same manner as in Reference Example 88 to obtain the title compound (153.1 mg, 17%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.64 (1H, d, J= 15.6 Hz), 6.95 (1H, d, J = 4.4 Hz), 6.60 (1H, d, J = 4.4 Hz), 6.37 (1H, d, J = 15.6 Hz), 4.01 (3H, s), 3.81 (3H, s), 2.46 (3H, s).
[0505] Reference example 102 Preparation of methyl (E)-3-(5-acetyl-3-methylthiophen-2-yl)acrylate
[0506] [ka]
[0507] 1-(5-Bromo-4-methylthiophen-2-yl)ethan-1-one (200 mg, 0.91 mmol), tetrabutylammonium chloride (25.4 mg, 0.091 mmol), PdCl2(dppf)2-CHCl2 (37.6 mg, 0.046 mmol), DMA (1.6 mL), methyl acrylate (164 μL, 1.8 mmol), and N,N-dicyclohexylmethylamine (290 μL, 1.4 mmol) were used as starting materials, and the procedure was carried out in the same manner as in Reference Example 88 to obtain the title compound (176.2 mg, 87%) as a yellow solid. 1H NMR(400 MHz, CDCl3)δ 7.76 (1H, d, J = 15.6 Hz), 7.43 (1H, s), 6.29 (1H, d, J = 15.6 Hz), 3.80 (3H, s), 2.52 (3H, s), 2.34 (3H, s).
[0508] Reference example 103 Preparation of methyl (E)-3-(5-acetyl-4-fluorothiophen-2-yl)acrylate
[0509] [ka]
[0510] 1-(5-Bromo-3-fluorothiophen-2-yl)ethan-1-one (140 mg, 0.46 mmol), tetrabutylammonium chloride (12.8 mg, 0.046 mmol), PdCl(dppf)-CHCl (18.8 mg, 0.023 mmol), DMA (1.0 mL), methyl acrylate (82.5 μL, 0.92 mmol), and N,N-dicyclohexylmethylamine (146 μL, 0.69 mmol) were added to the mixture and heated at 120 °C for 1.5 h in a microwave oven. The resulting solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 9 / 1 → 7 / 3) to give the title compound (51.3 mg, 49%) as a brown powder. 1 H NMR(400 MHz, CDCl3)δ 7.60 (1H, d, J= 16.0 Hz), 7.00 (1H, s), 6.39 (1H, d, J= 16.0 Hz), 3.81 (3H, s), 2.58 (3H, d, J= 2.8 Hz).
[0511] Reference example 104 Preparation of methyl (E)-3-{5-[(2,4-dimethoxybenzyl)carbamoyl]thiophen-2-yl}acrylate
[0512] [ka]
[0513] Using 5-bromo-N-(2,4-dimethoxybenzyl)thiophene-2-carboxamide (400 mg, 1.1 mmol), tetrabutylammonium chloride (31 mg, 0.11 mmol), PdCl(dppf)-CHCl (45.7 mg, 0.11 mmol), DMA (2.0 mL), methyl acrylate (201 μL, 2.2 mmol), and N,N-dicyclohexylmethylamine (356 μL, 1.7 mmol) as starting materials, the title compound (99.4 mg, 25%) was obtained as a white solid by the procedure described in Reference Example 103. 1 H NMR(400 MHz, CDCl3)δ 7.67 (1H, d, J= 16.0 Hz), 7.41 (1H, d, J = 4.0 Hz), 7.19 (1H, d, J = 8.4 Hz), 7.13 (1H, d, J = 4.0 Hz), 6.85 (1H, t, J = 5.6 Hz), 6.43 (1H, d, J = 2.4 Hz), 6.41 (1H, dd, J = 8.0, 2.4 Hz), 6.26 (1H, d, J = 16.0 Hz),4.49 (2H, d, J = 5.6 Hz), 3.81 (3H, s), 3.77 (3H, s), 3.76 (3H, s).
[0514] Reference example 105 Preparation of methyl (E)-3-(5-acetyl-4-methylthiophen-2-yl)acrylate
[0515] [ka]
[0516] 1-(5-Bromo-3-methylthiophen-2-yl)ethan-1-one (216 mg, 0.99 mmol), tetrabutylammonium chloride (14 mg, 0.049 mmol), PdCl2(dppf)2-CHCl2 (81 mg, 0.099 mmol), DMA (2.0 mL), methyl acrylate (177 μL, 2.0 mmol), and N,N-dicyclohexylmethylamine (314 μL, 1.5 mmol) were used as raw materials, and the procedure was carried out in the same manner as in Reference Example 103 to obtain the title compound (120.9 mg, 55%) as a yellow solid. 1 H NMR(400 MHz, CDCl3)δ 7.66 (1H, d, J= 16.0 Hz), 7.07 (1H, s), 6.35 (1H, d, J= 16.0 Hz), 3.81 (3H, s), 2.53 (3H, s), 2.52 (3H, s).
[0517] Reference example 106 Preparation of methyl (E)-3-(4-acetyl-1,3,5-trimethyl-1H-pyrrol-2-yl)acrylate
[0518] [ka]
[0519] 1-(5-Bromo-1,2,4-trimethyl-1H-pyrrol-3-yl)ethan-1-one (120 mg, 0.52 mmol), tetrabutylammonium chloride (14.5 mg, 0.052 mmol), PdCl2(dppf)2-CHCl2 (21.2 mg, 0.026 mmol), DMA (0.70 mL), methyl acrylate (93.3 μL, 1.0 mmol), and N,N-dicyclohexylmethylamine (165 μL, 0.78 mmol) were used as raw materials, and the procedure was carried out in the same manner as in Reference Example 103 to obtain the title compound (35.2 mg, 29%) as a pale yellow solid. 1H NMR(400 MHz, CDCl3)δ 7.68 (1H, d, J= 16.0 Hz), 6.03 (1H, d, J = 16.0 Hz), 3.80 (3H, s), 3.59 (3H, s), 2.51 (3H, s), 2.46 (3H, s), 2.40 (3H, s).
[0520] Reference example 107 Preparation of methyl (E)-3-(5-acetyl-1-ethyl-1H-pyrrol-2-yl)acrylate
[0521] [ka]
[0522] 1-(5-Bromo-1-ethyl-1H-pyrrol-2-yl)ethan-1-one (500 mg, 2.3 mmol), tetrabutylammonium chloride (64 mg, 0.23 mmol), PdCl2(dppf)2-CHCl2 (94.3 mg, 0.12 mmol), DMA (3.5 mL), methyl acrylate (414 μL, 4.6 mmol), and N,N-dicyclohexylmethylamine (733 μL, 3.5 mmol) were used as starting materials, and the procedure was carried out in the same manner as in Reference Example 103 to obtain the title compound (23.2 mg, 5%) as a pale yellow solid. 1 H NMR(400 MHz, CDCl3)δ 7.54 (1H, d, J= 16.0 Hz), 7.12 (1H, d, J = 1.6 Hz), 7.08 (1H, d, J = 1.6 Hz), 6.16 (1H, d, J = 16.0 Hz), 4.35 (2H, q, J = 7.2 Hz), 3.77 (3H, s), 2.46 (3H, s), 1.37 (3H, t, J = 7.2 Hz).
[0523] Reference example 108 Preparation of methyl (E)-3-[5-(cyclopropanecarbonyl)thiophen-2-yl]acrylate
[0524] [ka]
[0525] Using (5-bromothiophen-2-yl)(cyclopropyl)methanone (56 mg, 0.24 mmol), tetrabutylammonium chloride (3.4 mg, 0.012 mmol), PdCl(dppf)-CHCl (20 mg, 0.024 mmol), DMA (0.60 mL), methyl acrylate (43.4 μL, 0.48 mmol), and N,N-dicyclohexylmethylamine (77 μL, 0.36 mmol) as starting materials, the title compound (34 mg, 60%) was obtained as a pale yellow solid by the procedure described in Reference Example 103. 1 H NMR(400 MHz, CDCl3)δ 7.74 (1H, d, J= 16.0 Hz), 7.72 (1H, d, J = 4.0 Hz), 7.27 (1H, d, J = 4.0 Hz), 6.39 (1H, d, J = 16.0 Hz), 3.81 (3H, s), 2.51 (1H, tt, J = 8.0, 4.4 Hz), 1.28-1.25 (2H, m), 1.08-1.04 (2H, m).
[0526] Reference example 109 Preparation of methyl (E)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate
[0527] [ka]
[0528] Using 2-(5-bromothiophen-2-yl)-2-methyl-1,3-dioxolane (180 mg, 0.72 mmol), tetrabutylammonium chloride (20 mg, 0.072 mmol), PdCl(dppf)-CHCl (29.4 mg, 0.036 mmol), DMA (1.1 mL), methyl acrylate (129 μL, 1.4 mmol), and N,N-dicyclohexylmethylamine (232 μL, 1.1 mmol) as starting materials, the title compound (135.5 mg, 74%) was obtained as a white solid by the procedure described in Reference Example 103. 1 H NMR(400 MHz, CDCl3)δ 7.71 (1H, d, J= 15.6 Hz), 7.10 (1H, d, J = 3.6 Hz), 6.97 (1H, d, J = 3.6 Hz), 6.18 (1H, d, J = 15.6 Hz), 4.08-4.02 (m, 2H), 3.98-3.95 (m, 2H), 3.78 (3H, s), 1.76 (s, 3H).
[0529] Reference example 110 Preparation of methyl (E)-3-(5-cyanothiophen-2-yl)acrylate
[0530] [ka]
[0531] Using 5-bromothiophene-2-carbonitrile (289 μL, 2.7 mmol), tetrabutylammonium chloride (74 mg, 0.27 mmol), PdCl(dppf)-CHCl (109 mg, 0.13 mmol), DMA (3.3 mL), methyl acrylate (477 μL, 5.3 mmol), and N,N-dicyclohexylmethylamine (845 μL, 4.0 mmol) as starting materials, the title compound (77.6 mg, 15%) was obtained as a white solid by the procedure described in Reference Example 103. 1H NMR(400 MHz, CDCl3)δ 7.71 (1H, d, J= 16.0 Hz), 7.55 (1H, d, J = 4.0 Hz), 7.23 (1H, d, J = 4.0 Hz), 6.36 (1H, d, J = 16.0 Hz), 3.82 (3H, s).
[0532] Reference example 111 Preparation of methyl (E)-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate
[0533] [ka]
[0534] A flask was charged with 2-(5-bromo-3-methylthiophen-2-yl)-2-methyl-1,3-dioxolone (306.1 mg, 1.2 mmol), PdCl(dppf)-CHCl (48.8 mg, 0.0060 mmol), tetrabutylammonium chloride (27.8 mg, 0.12 mmol), DMA (1.7 mL), N,N-dicyclohexylmethylamine (500 μL, 2.4 mmol), and methyl acrylate (210 μL, 2.3 mmol). The mixture was heated at 130 °C for 3 h in a microwave oven. The mixture was further heated at 130 °C for 1 h in a microwave oven, and then the temperature was returned to room temperature. The reaction solution was diluted with ethyl acetate, washed with water and saturated brine, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 98 / 2 → 77 / 23) to obtain the title compound (160.8 mg, 52%) as a yellow, transparent oil. 1H NMR (400 MHz, CDCl3) δ 7.61 (1H, d, J = 15.6 Hz), 6.92 (1H, s), 6.11 (1H, d, J = 15.6 Hz), 4.07-3.98 (2H, m), 3.94-3.88 (2H, m), 3.74 (3H, s), 2.23 (3H, s), 1.70 (3H, s).
[0535] Reference example 112 Preparation of methyl (E)-3-(6-oxo-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl)acrylate
[0536] [ka]
[0537] A solution of 2-bromo-4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-one (301.3 mg, 1.4 mmol), PdCl(dppf) CHCl (59.4 mg, 0.073 mmol), and tetrabutylammonium chloride (40.3 mg, 0.15 mmol) in DMA (1.8 mL) was added with methyl acrylate (250 μL, 2.8 mmol) and N,N-dicyclohexylamine (600 μL, 2.8 mmol) and heated at 130 °C for 3 h in a microwave oven. The reaction mixture was cooled to room temperature, and ethyl acetate and 1 M hydrochloric acid were added. The organic and aqueous layers were separated, the aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with saturated brine and dried over sodium sulfate. After removing the solvent by evaporation under reduced pressure, the residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 19 / 81 → 0 / 100) to obtain the title compound (171 mg, 55%) as an orange solid. 1 H NMR (400 MHz, CDCl3) δ 7.77 (1H, d, J = 15.6 Hz), 7.18 (1H, s), 6.54 (1H, br s), 6.37 (1H, d, J = 15.6 Hz), 4.38 (2H, s), 3.81 (3H, s).
[0538] Reference example 113 Preparation of methyl (E)-3-(5-acetylfuran-2-yl)acrylate
[0539] [ka]
[0540] 1-(5-Bromofuran-2-yl)ethan-1-one (220 mg, 1.16 mmol), tetrabutylammonium chloride (16 mg, 0.058 mmol), PdCl2(dppf)2-CHCl2 (94 mg, 0.115 mmol), DMA (2.0 mL), methyl acrylate (206 μL, 2.3 mmol), and N,N-dicyclohexylmethylamine (364 μL, 1.72 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 103 to obtain the title compound (90.0 mg, 40%) as a pale yellow solid. 1 H NMR(400 MHz, CDCl3)δ 7.43 (1H, d, J= 16.0 Hz), 7.17 (1H, d, J = 3.6 Hz), 6.69 (1H, d, J = 3.6 Hz), 6.54 (1H, d, J = 16.0 Hz), 3.79 (1H, s), 2.49 (3H, s).
[0541] Reference example 114 Preparation of methyl (E)-3-(5-acetylthiophen-3-yl)acrylate
[0542] [ka]
[0543] 1-(4-Bromothiophen-2-yl)ethan-1-one (200 mg, 0.98 mmol), tetrabutylammonium chloride (13.6 mg, 0.049 mmol), PdCl2(dppf)2-CHCl2 (80 mg, 0.098 mmol), DMA (2.0 mL), methyl acrylate (176 μL, 2.0 mmol), and N,N-dicyclohexylmethylamine (310 μL, 1.47 mmol) were used as raw materials, and the procedure was carried out in the same manner as in Reference Example 103 to obtain the title compound (114.3 mg, 56%) as an orange solid. 1 H NMR(400 MHz, CDCl3)δ 7.82 (1H, d, J = 1.2 Hz), 7.74 (1H, d, J = 1.2 Hz), 7.62 (1H, d, J = 16.0 Hz), 6.32 (1H, d, J= 16.0 Hz), 3.81 (3H, s), 2.59 (3H, s).
[0544] Reference example 115 Preparation of methyl (E)-3-(4-acetylthiophen-2-yl)acrylate
[0545] [ka]
[0546] 1-(5-Bromothiophen-3-yl)ethan-1-one (380 mg, 1.9 mmol), tetrabutylammonium chloride (25.7 mg, 0.093 mmol), PdCl2(dppf)2-CHCl2 (151 mg, 0.19 mmol), DMA (3.8 mL), methyl acrylate (344 μL, 3.7 mmol), and N,N-dicyclohexylmethylamine (586 μL, 2.8 mmol) were used as starting materials, and the procedure was carried out in the same manner as in Reference Example 103 to obtain the title compound (151.8 mg, 39%) as a pale green powder. 1H NMR(400 MHz, CDCl3)δ 8.03 (1H, s), 7.73 (1H, d, J = 16.0 Hz), 7.64 (1H, br s), 6.27 (1H, d, J = 16.0 Hz), 3.80 (3H, s), 2.52 (3H, s).
[0547] Reference example 116 Preparation of methyl (E)-3-(5-cyano-1-methyl-1H-pyrrol-3-yl)acrylate
[0548] [ka]
[0549] Using 4-bromo-1-methyl-1H-pyrrole-2-carbonitrile (131.9 mg, 0.71 mmol), tetrabutylammonium chloride (19.7 mg, 0.071 mmol), PdCl(dppf)-CHCl (58 mg, 0.071 mmol), DMA (1.2 mL), methyl acrylate (128 μL, 1.4 mmol), and N,N-dicyclohexylmethylamine (227 μL, 1.1 mmol) as starting materials, the title compound (33.5 mg, 25%) was obtained as a pale yellow solid by the procedure described in Reference Example 103. 1 H NMR(400 MHz, CDCl3)δ 7.48 (1H, d,J = 16.0 Hz), 7.01 (1H, d, J = 1.6 Hz), 6.96 (1H, d, J = 1.6 Hz), 6.13 (1H, d, J = 16.0 Hz), 3.80 (3H, s), 3.77 (3H, s).
[0550] Reference example 117 Preparation of methyl (E)-3-(3-acetylthiophen-2-yl)acrylate
[0551] [ka]
[0552] 1-(2-Bromothiophen-3-yl)ethan-1-one (128.8 mg, 0.63 mmol), tetrabutylammonium chloride (8.8 mg, 0.032 mmol), PdCl2(dppf)2-CHCl2 (51.4 mg, 0.065 mmol), DMA (1.3 mL), methyl acrylate (113 μL, 1.3 mmol), and N,N-dicyclohexylmethylamine (200 μL, 0.95 mmol) were used as raw materials, and the procedure was performed in the same manner as in Reference Example 103 to obtain the title compound (62.1 mg, 47%) as a pale yellow solid. 1 H NMR(400 MHz, CDCl3)δ 8.51 (1H, d, J= 16.0 Hz), 7.40 (1H, d, J = 5.6 Hz), 7.28 (1H, d, J = 5.6 Hz), 6.34 (1H, d, J = 16.0 Hz), 3.78 (3H, s), 2.54 (3H, s).
[0553] Reference example 118 Preparation of methyl (E)-3-[5-(2-methyl-1,3-dioxolan-2-yl)furan-2-yl]acrylate
[0554] [ka]
[0555] Using 2-(5-bromofuran-2-yl)-2-methyl-1,3-dioxolane (200 mg, 0.86 mmol), tetrabutylammonium chloride (12 mg, 0.043 mmol), PdCl(dppf)-CHCl (70.1 mg, 0.086 mmol), DMA (2.0 mL), methyl acrylate (160 μL, 1.7 mmol), and N,N-dicyclohexylmethylamine (272 μL, 1.3 mmol) as starting materials, the title compound (168.8 mg, 83%) was obtained as a yellow oily substance by the procedure described in Reference Example 103. 1 H NMR(400 MHz, CDCl3)δ 7.39 (1H, d, J= 15.6 Hz), 6.52 (1H, d, J = 3.6 Hz), 6.39 (1H, d, J = 3.6 Hz), 6.32 (1H, d, J = 15.6 Hz), 4.09-4.05 (2H, m), 4.04-4.00 (2H, m), 3.78 (3H, s), 1.75 (3H, s).
[0556] Reference example 119 Preparation of methyl (E)-3-[4-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate
[0557] [ka]
[0558] Using 2-(5-bromothiophen-3-yl)-2-methyl-1,3-dioxolane (160 mg, 0.64 mmol), tetrabutylammonium chloride (8.9 mg, 0.032 mmol), PdCl(dppf)-CHCl (52.4 mg, 0.064 mmol), DMA (1.3 mL), methyl acrylate (115 μL, 1.3 mmol), and N,N-dicyclohexylmethylamine (203 μL, 0.96 mmol) as starting materials, the title compound (137.7 mg, 84%) was obtained as a colorless oily substance by the procedure described in Reference Example 103. 1 H NMR(400 MHz, CDCl3)δ 7.72 (1H, d, J= 15.6 Hz), 7.31 (1H, s), 7.21 (1H, s), 6.22 (1H, d, J = 15.6 Hz), 4.06-4.02 (2H, m), 3.89-3.86 (2H, m), 3.79 (3H, s), 1.66 (3H, s).
[0559] Reference example 120 Preparation of ethyl (E)-3-(thiazol-5-yl)acrylate
[0560] [ka]
[0561] A solution of potassium tert-butoxide (123.4 mg, 1.1 mmol) and triethyl phosphonoacetate (220 μL, 1.1 mmol) in THF (2.0 mL) was stirred at -5 °C for 30 minutes. Thiazole-5-carbaldehyde (100 mg, 0.88 mmol) was then added, and the mixture was stirred at -5 °C for 2 hours and then at room temperature for 21 hours. The reaction solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 9 / 1 → 7 / 3) to give the title compound (143.5 mg, 89%) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 8.80 (1H, s), 8.01 (1H, s), 7.82 (1H, d, J = 15.6 Hz), 6.26 (1H, d, J = 15.6 Hz), 4.26 (2H, q, J = 7.2 Hz), 1.33 (3H, t, J = 7.2 Hz).
[0562] Reference example 121 Preparation of methyl (E)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiazol-2-yl]acrylate
[0563] [ka]
[0564] To a solution of 5-(2-methyl-1,3-dioxolan-2-yl)thiazole-2-carbaldehyde (85.2 mg, 0.42 mmol) in toluene (1.5 mL), methyl(triphenylphosphoranylidene)acetate (424.2 mg, 1.3 mmol) was added and the mixture was stirred at 120 °C for 1 hour. The reaction solution was returned to room temperature, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 81 / 19 → 62 / 38) to give the title compound (111.5 mg, quant.) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.79 (1H, s), 7.70 (1H, d, J = 15.6 Hz), 6.65 (1H, d, J = 15.6 Hz), 4.14-4.04 (2H, m), 3.99-3.91 (2H, m), 3.82 (3H, s), 1.78 (3H, s).
[0565] Reference example 122 Preparation of methyl (E)-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiazol-2-yl]acrylate
[0566] [ka]
[0567] To a solution of 4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiazole-2-carbaldehyde (32.5 mg, 0.15 mmol) in toluene (1.0 mL), methyl(triphenylphosphoranylidene)acetate (160.7 mg, 0.48 mmol) was added and the mixture was stirred at 120 °C for 1.5 hours. The reaction solution was returned to room temperature, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 86 / 14 → 65 / 35) to give the title compound (34.6 mg, 85%) as a clear orange oil. 1H NMR (400 MHz, CDCl3) δ 7.63 (1H, d, J = 15.6 Hz), 6.60 (1H, d, J= 15.6 Hz), 4.08-4.02 (2H, m), 3.94-3.86 (2H, m), 3.80 (3H, s), 2.49 (3H, s), 1.74 (3H, s).
[0568] Reference example 123 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(methylcarbamoyl)furan-2-yl]propanoate
[0569] [ka]
[0570] To a solution of (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (165 mg, 0.36 mmol), methyl (E)-3-[5-(methylcarbamoyl)furan-2-yl]acrylate (50 mg, 0.24 mmol), and [RhCl(cod)]2 (5.9 mg, 0.012 mmol) in 1,4-dioxane / water (3 / 1) (1.0 mL) was added TEA (168 μL, 1.2 mmol) and stirred under reflux for 14 hours. The resulting solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 3 / 2 → 2 / 3) to give the title compound (22.9 mg, 18%) as a colorless oil. 1H NMR(400 MHz, CDCl3)δ 7.88 (1H, d,J = 8.0 Hz), 7.53 (1H, td, J = 8.0, 1.6 Hz), 7.28-7.21 (3H, m), 7.14-7.07 (2H, m), 6.98 (1H, d, J = 3.2 Hz), 6.37 (1H, br s), 6.15 (1H, t, J = 3.2 Hz), 4.55-4.49 (2H, m), 4.04-3.99 (1H, m), 3.87-3.84 (1H, m), 3.80-3.73 (1H, m), 3.62 (3H, br s), 3.12-3.00 (3H, m), 2.95-2.94 (3H, m), 2.30 (3H, br s), 1.76-1.66 (1H, m), 1.53-1.41 (1H, m), 1.09 (3H, t, J = 7.2 Hz).
[0571] Reference example 124 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(pyrrolidine-1-carbonyl)furan-2-yl]propanoate
[0572] [ka]
[0573] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (240 mg, 0.52 mmol), methyl (E)-3-[5-(pyrrolidine-1-carbonyl)furan-2-yl]acrylate (84 mg, 0.34 mmol), [RhCl(cod)]2 (17.4 mg, 0.035 mmol), 1,4-dioxane / DMA / water (3 / 3 / 1) (0.7 mL), and TEA (74 μL, 0.53 mmol) as starting materials, the title compound (85.0 mg, 50%) was obtained as a colorless oily substance by the procedure described in Reference Example 123. 1 H NMR(400 MHz, CDCl3)δ 7.88(1H, d,J = 7.6 Hz), 7.52 (1H, t, J = 7.6 Hz), 7.29-7.12 (5H, m), 6.97 (1H, d, J= 3.2 Hz), 6.11 (1H, d, J = 3.2 Hz), 4.57-4.53 (2H, m), 4.03-3.98 (1H, m), 3.81 (1H, d, J = 14.4 Hz), 3.78-3.67 (3H, m), 3.61-3.58 (5H, m), 3.14-3.10 (1H, m), 2.99-2.87 (2H, m), 2.32 (3H, s), 1.99-1.95 (2H, m), 1.88-1.85 (2H, m), 1.74-1.64 (1H, m), 1.50-1.42 (1H, m), 1.08 (3H, t, J = 7.2 Hz).
[0574] Reference example 125 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(isopropylcarbamoyl)furan-2-yl]propanoate
[0575] [ka]
[0576] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (206 mg, 0.45 mmol), methyl (E)-3-[5-(isopropylcarbamoyl)furan-2-yl]acrylate (70 mg, 0.3 mmol), [RhCl(cod)]2 (15 mg, 0.030 mmol), 1,4-dioxane / water (6 / 1) (0.7 mL), and TEA (152 μL, 1.5 mmol) as starting materials, the title compound (38.2 mg, 22%) was obtained as a pale yellow oily substance, as in Reference Example 123. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 8.0, 1.6 Hz), 7.53 (1H, td, J= 8.0, 1.6 Hz), 7.26 (1H, t, J = 8.0 Hz), 7.21 (1H, d, J = 8.0 Hz), 7.16-7.08 (3H, m), 6.98 (1H, d, J = 3.6 Hz), 6.14-6.10 (1H, m), 6.05 (1H, br s), 4.56-4.51 (2H, m), 4.26-4.19 (1H, m), 4.03-4.00 (1H, m), 3.87-3.74 (2H, m), 3.64 (3H, s), 3.07-2.99 (2H, m), 2.88-2.85 (1H, m), 2.33 (3H, br s), 1.76-1.65 (1H, m), 1.51-1.42 (1H, m), 1.26-1.22 (6H, m), 1.09-1.08 (3H, m).
[0577] Reference example 126 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(methylcarbamoyl)thiophen-2-yl]propanoate
[0578] [ka]
[0579] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (240 mg, 0.52 mmol), methyl (E)-3-[5-(methylcarbamoyl)thiophen-2-yl]acrylate (79 mg, 0.35 mmol), [RhCl(cod)]2 (17.4 mg, 0.035 mmol), 1,4-dioxane / DMA / water (3 / 3 / 1) (0.7 mL), and TEA (74 μL, 0.53 mmol) as raw materials, the title compound (48.7 mg, 25%) was obtained as a pale yellow oily substance by the procedure described in Reference Example 123. 1H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 8.0, 1.6 Hz), 7.52 (1H, br t, J= 8.0 Hz), 7.29-7.19 (3H, m), 7.14 (2H, br s), 7.07 (1H, d, J = 6.8 Hz), 6.78-6.77 (1H, m), 5.99 (1H, br s), 4.69 (1H, t, J = 7.6 Hz), 4.56 (1H, dd, J = 14.0, 5.2 Hz), 4.02-3.95 (1H, m), 3.82-3.69 (2H, m), 3.60 (3H, s), 3.09 (1H, dd, J = 16.0, 7.6 Hz), 3.01-2.90 (5H, m), 2.34 (3H, br s), 1.69-1.62 (1H, m), 1.46-1.38 (1H, m), 1.06 (3H, t,J = 7.2 Hz).
[0580] Reference example 127 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-{5-[(2-methoxyethyl)carbamoyl]furan-2-yl}propanoate
[0581] [ka]
[0582] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (192 mg, 0.42 mmol), methyl (E)-3-{5-[(2-methoxyethyl)carbamoyl]furan-2-yl}acrylate (70 mg, 0.28 mmol), [RhCl(cod)]2 (13.8 mg, 0.028 mmol), 1,4-dioxane / water (6 / 1) (0.7 mL), and TEA (60 μL, 0.42 mmol) as starting materials, the title compound (11.1 mg, 7%) was obtained as a pale yellow oily substance, as in Reference Example 123. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 8.0, 1.6 Hz), 7.52 (1H, td, J= 8.0, 1.6 Hz), 7.26 (1H, t, J = 8.0 Hz), 7.23 (1H, d, J = 8.0 Hz), 7.16-7.09 (3H, m), 6.99 (1H, d, J = 3.6 Hz), 6.55 (1H, br s), 6.12 (1H, t, J= 3.6 Hz), 4.57-4.51 (2H, m), 4.04-4.00 (1H, m), 3.87-3.71 (2H, m), 3.63 (3H, s), 3.60-3.51 (4H, m), 3.37 (3H, s), 3.11-2.85 (3H, m), 2.33 (3H, br s), 1.78-1.67 (1H, m), 1.51-1.41 (1H, m), 1.08 (3H, t, J = 7.6 Hz).
[0583] Reference example 128 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0584] [ka]
[0585] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (274.4 mg, 0.6 mmol), methyl (E)-3-(5-acetylthiophen-2-yl)acrylate (105 mg, 0.5 mmol), [RhCl(cod)]2 (12.3 mg, 0.025 mmol), 1,4-dioxane / water (7 / 1) (1.0 mL), and TEA (210 μL, 1.5 mmol) as starting materials, and operating in a similar manner to Reference Example 123, the title compound (138.0 mg, 50%) was obtained as a pale yellow oil. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd, J= 8.0, 1.6 Hz), 7.52 (1H, td, J = 8.0, 1.6 Hz), 7.50 (1H, d, J = 4.0 Hz), 7.27-7.20 (2H, m), 7.17-7.12 (2H, m), 7.08 (1H, d, J = 8.4 Hz), 6.87 (1H, br t, J= 2.4 Hz), 4.72 (1H, t, J = 7.6 Hz), 4.58-4.56 (1H, m), 4.03-3.96 (1H, m), 3.83-3.69 (2H, m), 3.61 (3H, s), 3.13-2.91 (3H, m), 2.48 (3H, br s), 2.34 (3H, br s), 1.73-1.63 (1H, m), 1.47-1.39 (1H, m), 1.07 (3H, t, J = 7.6 Hz).
[0586] Reference example 129 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-methyl-5-(methylcarbamoyl)furan-2-yl]propanoate
[0587] [ka]
[0588] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (247 mg, 0.54 mmol), methyl (E)-3-[4-methyl-5-(methylcarbamoyl)furan-2-yl]acrylate (100 mg, 0.45 mmol), [RhCl(cod)]2 (11.3 mg, 0.023 mmol), 1,4-dioxane / water (6 / 1) (1.0 mL), and TEA (189 μL, 1.4 mmol) as starting materials, the title compound (48.2 mg, 19%) was obtained as a pale yellow oily substance, as in Reference Example 123. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 7.6, 1.6 Hz), 7.53 (1H, td, J= 7.6, 1.6 Hz), 7.27-7.19 (3H, m), 7.13 (1H, d, J = 7.6 Hz), 7.10-7.06 (1H, m), 6.27 (1H, br s), 5.98 (1H, d, J = 3.2 Hz), 4.49-4.44 (2H, m), 4.05-3.98 (1H, m), 3.89-3.72 (2H, m), 3.63 (3H, s), 3.09-2.84 (6H, m), 2.34-2.30 (6H, m), 1.78-1.59 (1H, m), 1.52-1.41 (1H, m), 1.09 (3H, t, J = 7.2 Hz).
[0589] Reference example 130 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl)-4-methylphenyl}-3-(5-sulfamoylthiophen-2-yl)propanoate
[0590] [ka]
[0591] To a solution of (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (137.2 mg, 0.3 mmol), methyl (E)-3-(5-sulfamoylthiophen-2-yl)acrylate (50 mg, 0.2 mmol), and [RhCl(cod)]2 (9.9 mg, 0.02 mmol) in 1,4-dioxane / water (1 / 1) (0.8 mL) was added TEA (84 μL, 0.6 mmol) and stirred at 120 °C for 1 h in a microwave oven. The resulting solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 4 / 1 → 3 / 2) to obtain the title compound (98.9 mg, 85%) as a white solid. 1H NMR(400 MHz, CDCl3)δ 7.84 (1H, br d,J = 8.0 Hz), 7.51 (1H, td, J = 8.0, 1.6 Hz), 7.42 (1H, d, J = 4.0 Hz), 7.27-7.19 (2H, m), 7.15-7.11 (3H, m), 6.78 (1H, d, J = 4.0 Hz), 4.71 (1H, t, J= 8.0 Hz), 4.51 (1H, d, J = 14.4 Hz), 4.03-3.97 (1H, m), 3.83-3.82 (1H, m), 3.77-3.69 (1H, m), 3.61 (3H, s), 3.11-2.95 (3H, m), 2.30 (3H, s), 1.74-1.63 (1H, m), 1.51-1.43 (1H, m), 1.08-1.07 (3H, m).
[0592] Reference example 131 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-(thiophen-2-yl)propanoate
[0593] [ka]
[0594] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (247 mg, 0.54 mmol), methyl (E)-3-(thiophen-2-yl)acrylate (76 mg, 0.45 mmol), [RhCl(cod)]2 (11.3 mg, 0.023 mmol), 1,4-dioxane / water (3 / 1) (1.0 mL), and TEA (189 μL, 1.4 mmol) as raw materials, and operating in a similar manner to Reference Example 123, the title compound (133 mg, 60%) was obtained as a white solid. 1 H NMR(400 MHz, CDCl3)δ7.88 (1H, dd,J = 8.0, 1.6 Hz), 7.51 (1H, td, J= 8.0, 1.6 Hz), 7.26-7.12 (5H, m), 7.03 (1H, d, J = 14.4 Hz), 6.89 (1H, br t,J = 4.0 Hz), 6.81 (1H, br t, J = 4.0 Hz), 4.71 (1H, t, J = 7.6 Hz), 4.60-4.57 (1H, m), 4.01-3.92 (1H, m), 3.80-3.68 (2H, m), 3.59 (3H, br s), 3.13-3.06 (1H, m), 3.02-2.87 (2H, m), 2.36 (3H, br s), 1.71-1.59 (1H, m), 1.44-1.32 (1H, m), 1.07-1.06 (3H, m).
[0595] Reference example 132 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(methylcarbamoyl)thiophen-3-yl]propanoate
[0596] [ka]
[0597] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (137.2 mg, 0.3 mmol), methyl (E)-3-[5-(methylcarbamoyl)thiophen-3-yl]acrylate (45.1 mg, 0.2 mmol), [RhCl(cod)]2 (9.9 mg, 0.02 mmol), 1,4-dioxane / water (1 / 1) (0.8 mL), and TEA (84 μL, 0.6 mmol) as raw materials, the title compound (77.5 mg, 70%) was obtained as a white solid by the procedure described in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.85 (1H, dd,J = 8.0, 1.6 Hz), 7.52 (1H, td, J= 8.0, 1.6 Hz), 7.31-7.30 (1H, m), 7.25 (1H, t, J = 8.0 Hz), 7.21 (1H, d, J= 8.0 Hz), 7.11-7.05 (4H, m), 6.37 (1H, br s), 4.51-4.47 (2H, m), 4.02-3.95 (1H, m), 3.84-3.70 (2H, m), 3.58 (3H, s), 3.05-2.92 (3H, m), 2.89 (3H, d, J = 4.8 Hz), 2.28 (3H, s), 1.74-1.61 (1H, m), 1.50-1.39 (1H, m), 1.08-1.07 (3H, m).
[0598] Reference example 133 Preparation of methyl 3-(3-(((R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl)methyl)-4-methylphenyl)-3-(3-methyl-5-(methylcarbamoyl)thiophen-2-yl)propanoate
[0599] [ka]
[0600] Using (R)-4-ethyl-2-(2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (226.4 mg, 0.5 mmol), methyl (E)-3-[3-methyl-5-(methylcarbamoyl)thiophen-2-yl]acrylate (80 mg, 0.3 mmol), [RhCl(cod)]2 (16.3 mg, 0.03 mmol), 1,4-dioxane / water (1 / 1) (1.6 mL), and TEA (138.4 μL, 1.0 mmol) as raw materials, and operating as in Reference Example 130, the title compound (148.1 mg, 78%) was obtained as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.87 (1H, br d,J = 8.0 Hz), 7.52 (1H, br t, J = 8.0 Hz), 7.26 (1H, d, J = 8.0 Hz), 7.23-7.19 (1H, m), 7.17 (1H, br s), 7.14-7.11 (2H, m), 7.05 (1H, br d, J = 5.6 Hz), 6.08 (1H, br s), 4.72 (1H, t, J = 8.0 Hz), 4.56-4.55 (1H, m), 4.00-3.95 (1H, m), 3.78-3.68 (2H, m), 3.59 (3H, s), 2.99 (2H, dd, J = 7.6, 7.6 Hz), 2.94-2.90 (4H, m), 2.33 (3H, br s), 2.10 (3H, s), 1.73-1.60 (1H, m), 1.45-1.38 (1H, m), 1.07-1.06 (3H, m).
[0601] Reference example 134 Preparation of ethyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-(thiazol-5-yl)propanoate
[0602] [ka]
[0603] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (206 mg, 0.45 mmol), ethyl (E)-3-(thiazol-5-yl)acrylate (55 mg, 0.3 mmol), [RhCl(cod)]2 (15 mg, 0.03 mmol), 1,4-dioxane / water (1 / 1) (1.0 mL), and TEA (126 μL, 0.9 mmol) as raw materials, and operating in a similar manner to Reference Example 130, the title compound (97.3 mg, 63%) was obtained as a pale red solid. 1H NMR(400 MHz, CDCl3)δ 8.80 (1H, s), 7.88 (1H, dd, J = 7.6, 1.6 Hz), 7.63 (1H, d, J= 3.6 Hz), 7.52 (1H, td, J = 7.6, 2.0 Hz), 7.25 (1H, td, J = 7.6, 1.2 Hz), 7.20 (1H, dd, J = 8.0, 0.8 Hz), 7.17-7.12 (2H, m), 7.08 (1H, d, J = 7.6 Hz), 4.77 (1H, t, J = 8.0 Hz), 4.57 (1H, dd, J = 14.0, 5.2 Hz), 4.09-3.98 (3H, m), 3.83-3.69 (2H, m), 3.11-2.91 (3H, m), 2.34 (3H, br s), 1.71-1.65 (1H, m), 1.46-1.40 (1H, m), 1.16 (3H, t, J = 7.2 Hz), 1.09-1.05 (3H, m).
[0604] Reference example 135 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-(1-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-2-yl)propanoate
[0605] [ka]
[0606] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (206 mg, 0.5 mmol), methyl (E)-3-(1-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-2-yl)acrylate (70 mg, 0.3 mmol), [RhCl(cod)]2 (15 mg, 0.03 mmol), 1,4-dioxane / water (1 / 1) (1.0 mL), and TEA (126 μL, 0.9 mmol) as starting materials, the title compound (149.8 mg, 91%) was obtained as a pale yellow oily substance, as in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.87-7.82 (1H, m), 7.55-7.50 (1H, m), 7.28-7.19 (2H, m), 7.13-7.10 (1H, m), 7.06-7.01 (1H, m), 6.96 (1H, s), 6.48 (1H, d, J = 4.0 Hz), 4.52-4.51 (1H, m), 4.41 (1H, t, J = 8.0 Hz), 4.00-3.95 (1H, m), 3.80-3.72 (2H, m), 3.61 (1H, s), 3.23 (3H, br s), 3.04-2.87 (2H, m), 2.80-2.73 (1H, m), 2.67-2.62 (2H, m), 2.46-2.42 (2H, m), 2.34 (3H, br s), 2.14-2.10 (2H, m), 1.75-1.62 (1H, m), 1.50-1.39 (1H, m), 1.11-1.04 (3H, m).
[0607] Reference example 136 Preparation of methyl 3-(5-acetyl-1-methyl-1H-pyrrol-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0608] [ka]
[0609] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (206 mg, 0.5 mmol), methyl (E)-3-(5-acetyl-1-methyl-1H-pyrrol-2-yl)acrylate (62.2 mg, 0.3 mmol), [RhCl(cod)]2 (15 mg, 0.03 mmol), 1,4-dioxane / water (1 / 1) (1.0 mL), and TEA (126 μL, 0.9 mmol) as starting materials, the title compound (129.3 mg, 80%) was obtained as a colorless oily substance by the procedure described in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 7.6, 1.6 Hz), 7.52 (1H, t, J= 7.6 Hz), 7.25 (1H, t, J = 7.6 Hz), 7.20 (1H, d, J = 7.6 Hz), 7.12-7.10 (1H, m), 7.02-6.92 (3H, m), 6.13 (1H, d,J = 4.4 Hz), 4.57-4.46 (2H, m), 4.00-3.93 (1H, m), 3.80-3.73 (1H, m), 3.68-3.65 (4H, m), 3.63 (3H, br s), 3.05-2.81 (3H, m), 2.39 (3H, s), 2.34-2.31 (3H, m), 1.74-1.61 (1H, m), 1.47-1.40 (1H, m), 1.09-1.05 (3H, m).
[0610] Reference example 137 Preparation of methyl 3-(5-acetyl-3-methylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0611] [ka]
[0612] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (206 mg, 0.5 mmol), methyl (E)-3-(5-acetyl-3-methylthiophen-2-yl)acrylate (67.3 mg, 0.3 mmol), [RhCl(cod)]2 (15 mg, 0.03 mmol), 1,4-dioxane / water (1 / 1) (2.0 mL), and TEA (126 μL, 0.9 mmol) as starting materials, the title compound (123.3 mg, 74%) was obtained as a pale yellow oily substance by the procedure described in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ7.87 (1H, dt,J = 8.0, 2.0 Hz), 7.52 (1H, br t, J= 8.0 Hz), 7.38 (1H, s), 7.28-7.20 (2H, m), 7.17-7.12 (2H, m), 7.05 (1H, d, J = 8.0 Hz), 4.74-4.73 (1H, m), 4.58-4.55 (1H, m), 4.03-3.95 (1H, m), 3.80-3.66 (2H, m), 3.60 (3H, br s), 3.07-2.86 (3H, m), 2.46 (3H, br s), 2.35 (3H, br s), 2.16 (3H, s), 1.74-1.60 (1H, m), 1.46-1.36 (1H, m), 1.08-1.07 (3H, m).
[0613] Reference example 138 Preparation of methyl 3-(5-acetyl-4-fluorothiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0614] [ka]
[0615] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (75.5 mg, 0.17 mmol), methyl (E)-3-(5-acetyl-4-fluorothiophen-2-yl)acrylate (51.3 mg, 0.23 mmol), [RhCl(cod)]2 (5.4 mg, 0.011 mmol), 1,4-dioxane / water (1 / 1) (0.9 mL), and TEA (69 μL, 0.49 mmol) as raw materials, and operating in a similar manner to Reference Example 130, the title compound (53.6 mg, 56%) was obtained as a pale yellow solid. 1H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 8.0, 1.6 Hz), 7.52 (1H, td, J= 8.0, 1.6 Hz), 7.26 (1H, td, J = 8.0, 1.2 Hz), 7.21 (1H, dd, J = 8.0, 1.2 Hz), 7.18-7.07 (3H, m), 6.64 (1H, s), 4.61-4.53 (2H, m), 4.06-3.98 (1H, m), 3.87-3.69 (2H, m), 3.63 (3H, s), 3.09-2.94 (3H, m), 2.50 (3H, br s), 2.35 (3H, br s), 1.74-1.65 (1H, m), 1.49-1.42 (1H, m), 1.08-1.07 (3H, m).
[0616] Reference example 139 Preparation of methyl 3-{5-[(2,4-dimethoxybenzyl)carbamoyl]thiophen-2-yl}-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0617] [ka]
[0618] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (150 mg, 0.328 mmol), methyl (E)-3-{5-[(2,4-dimethoxybenzyl)carbamoyl]thiophen-2-yl}acrylate (80 mg, 0.22 mmol), [RhCl(cod)]2 (10.8 mg, 0.022 mmol), 1,4-dioxane / water (1 / 1) (1.0 mL), and TEA (92.2 μL, 0.66 mmol) as starting materials, the title compound (112.4 mg, 74%) was obtained as a pale brown oily substance, as in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.86 (1H, dd,J = 8.0, 1.6 Hz), 7.51 (1H, br t, J= 8.0 Hz), 7.27-7.24 (2H, m), 7.22-7.18 (2H, m), 7.13 (2H, br s), 7.04 (1H, br d, J = 8.0 Hz), 6.76 (1H, br t, J = 3.6 Hz), 6.45-6.40 (3H, m), 4.67 (1H, t, J = 7.6 Hz), 4.56-4.55 (1H, m), 4.47 (2H, d, J = 5.6 Hz), 3.99-3.93 (1H, m), 3.84-3.67 (8H, m), 3.59 (3H, s), 3.09-2.88 (3H, m), 2.33 (3H, s), 1.67-1.58 (1H, m), 1.44-1.36 (1H, m), 1.04-1.03 (3H, m).
[0619] Reference example 140 Preparation of methyl 3-(5-acetyl-4-methylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0620] [ka]
[0621] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (150 mg, 0.3 mmol), methyl (E)-3-(5-acetyl-4-methylthiophen-2-yl)acrylate (50 mg, 0.2 mmol), [RhCl(cod)]2 (10.8 mg, 0.02 mmol), 1,4-dioxane / water (1 / 1) (1.0 mL), and TEA (92.2 μL, 0.7 mmol) as starting materials, the title compound (77.9 mg, 64%) was obtained as a pale yellow solid, by the procedure described in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.89-7.86 (1H, m), 7.52 (1H, br t, J = 8.0 Hz), 7.28-7.08 (5H, m), 6.69 (1H, br s), 4.66 (1H, t, J = 7.6 Hz), 4.60-4.48 (1H, m), 4.04-3.97 (1H, m), 3.85-3.70 (2H, m), 3.62-3.60 (3H, m), 3.12-2.87 (3H, m), 2.45-2.42 (3H, m), 2.35-2.31 (3H, m), 1.73-1.63 (1H, m), 1.47-1.39 (1H, m), 1.08-1.05 (3H, m).
[0622] Reference example 141 Preparation of methyl 3-(4-acetyl-1,3,5-trimethyl-1H-pyrrol-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0623] [ka]
[0624] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (93.3 mg, 0.20 mmol), methyl (E)-3-(4-acetyl-1,3,5-trimethyl-1H-pyrrol-2-yl)acrylate (30 mg, 0.14 mmol), [RhCl(cod)]2 (7.0 mg, 0.014 mmol), 1,4-dioxane / water (1 / 1) (0.8 mL), and TEA (57 μL, 0.41 mmol) as starting materials, the title compound (20.1 mg, 26%) was obtained as a colorless oily substance, as in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.89-7.85 (1H, m), 7.52 (1H, td, J = 8.0, 1.6 Hz), 7.25 (1H, t, J = 8.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 7.11 (1H, br d, J = 8.0 Hz), 7.01-6.93 (2H, m), 4.85-4.80 (1H, m), 4.55-4.51 (1H, m), 3.99-3.94 (1H, m), 3.80-3.69 (2H, m), 3.65 (3H, br s), 3.25-3.17 (4H, m), 2.99-2.88 (2H, m), 2.43-2.42 (6H, m), 2.34-2.32 (3H, m), 2.22 (3H, s), 1.75-1.61 (1H, m), 1.48-1.32 (1H, m), 1.07-1.05 (3H, m).
[0625] Reference example 142 Preparation of methyl 3-(5-acetyl-1-ethyl-1H-pyrrol-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0626] [ka]
[0627] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (123.5 mg, 0.27 mmol), methyl (E)-3-(5-acetyl-1-ethyl-1H-pyrrol-2-yl)acrylate (40 mg, 0.18 mmol), [RhCl(cod)]2 (9.0 mg, 0.018 mmol), 1,4-dioxane / water (1 / 1) (0.8 mL), and TEA (75.5 μL, 0.54 mmol) as starting materials, the title compound (37.2 mg, 37%) was obtained as a pale yellow oily substance by the procedure described in Reference Example 130. 1H NMR(400 MHz, CDCl3)δ 7.89 (1H, dd,J = 8.0, 1.6 Hz), 7.52 (1H, td, J= 8.0, 1.6 Hz), 7.25 (1H, t, J = 8.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 7.15-7.08 (3H, m), 6.70 (1H, dd, J = 4.8, 2.0 Hz), 6.62 (1H, dd, J = 4.8, 2.0 Hz), 4.55 (1H, d, J = 14.0 Hz), 4.35 (1H, t, J = 8.0 Hz), 4.26 (1H, q, J = 7.2 Hz), 4.03-3.99 (1H, m), 3.84-3.70 (2H, m), 3.60 (3H, s), 3.00-2.93 (2H, m), 2.90-2.82 (1H, m), 2.36 (3H, s), 2.33 (3H, s), 1.73-1.63 (1H, m), 1.47-1.39 (1H, m), 1.30 (3H, t, J = 7.2 Hz), 1.07 (3H, t, J = 7.2 Hz).
[0628] Reference example 143 Preparation of methyl 3-[5-(cyclopropanecarbonyl)thiophen-2-yl]-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0629] [ka]
[0630] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (99 mg, 0.2 mmol), methyl (E)-3-[5-(cyclopropanecarbonyl)thiophen-2-yl]acrylate (34 mg, 0.14 mmol), [RhCl(cod)]2 (7.1 mg, 0.014 mmol), 1,4-dioxane / water (1 / 1) (0.8 mL), and TEA (60 μL, 0.43 mmol) as starting materials, the title compound (45.5 mg, 56%) was obtained as a colorless oily substance by the procedure described in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 7.6, 1.6 Hz), 7.63 (1H, d, J= 3.6 Hz), 7.52 (1H, td, J = 7.6, 1.6 Hz), 7.25 (1H, dd, J = 7.6, 0.8 Hz), 7.22 (1H, br d, J = 7.6 Hz), 7.15 (2H, br s), 7.06 (1H, d, J = 10.4 Hz), 6.90-6.88 (1H, m), 4.73 (1H, t, J= 7.6 Hz), 4.60-4.54 (1H, m), 4.00-3.97 (1H, m), 3.81-3.77 (1H, m), 3.76-3.71 (1H, m), 3.61 (3H, s), 3.14-2.89 (3H, m), 2.47-2.43 (1H, m), 2.35 (3H, br s), 1.70-1.61 (1H, m), 1.44-1.39 (1H, m), 1.21-1.17 (2H, m), 1.06 (3H, t, J = 7.2 Hz), 1.00-0.96 (2H, m).
[0631] Reference example 144 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate
[0632] [ka]
[0633] A solution of (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (216 mg, 0.47 mmol), methyl (E)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate (80 mg, 0.32 mmol), and [RhCl(cod)] (15.5 mg, 0.032 mmol) in 1,4-dioxane / water (1 / 1) (1.7 mL) was added with triethyl ether (TEA) (132 μL, 0.95 mmol) under argon and heated at 140 °C for 2 h in a microwave oven. Water was added to the mixture, which was then extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 9 / 1 → 7 / 3) to give the title compound (90.9 mg, 49%) as a colorless oil. 1H NMR(400 MHz, CDCl3)δ 7.89 (1H, dd, J= 8.0, 1.6 Hz), 7.52 (1H, td, J = 8.0, 1.6 Hz), 7.26 (1H, br t, J = 8.0 Hz), 7.21 (1H, dd, J = 8.0, 1.6 Hz), 7.14 (2H, br s), 7.06 (1H, s), 6.81 (1H, d, J= 3.6 Hz), 6.62 (1H, d, J = 3.6 Hz), 4.63 (1H, t, J = 8.0 Hz), 4.58 (1H, d, J = 14.0 Hz), 4.03-3.96 (3H, m), 3.93-3.90 (2H, m), 3.81-3.77 (1H, m), 3.73 (1H, dd, J = 15.2, 10.8 Hz), 3.59 (3H, s), 3.10-3.07 (1H, m), 3.00-2.93 (2H, m), 2.35 (3H, s), 1.76-1.61 (1H, m), 1.70 (3H, s), 1.49-1.41 (1H, m), 1.11.06 (3H, m).
[0634] Reference example 145 Preparation of methyl 3-(5-cyanothiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0635] [ka]
[0636] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (137.2 mg, 0.3 mmol), methyl (E)-3-(5-cyanothiophen-2-yl)acrylate (38.6 mg, 0.2 mmol), [RhCl(cod)]2 (9.9 mg, 0.02 mmol), 1,4-dioxane / water (1 / 1) (0.8 mL), and TEA (83.9 μL, 0.6 mmol) as raw materials, the title compound (22.2 mg, 21%) was obtained as a white solid by the procedure described in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 7.6, 1.6 Hz), 7.53 (1H, td, J= 7.6, 1.6 Hz), 7.44 (1H, dd, J = 4.0, 0.8 Hz), 7.28-7.16 (3H, m), 7.13-7.10 (2H, m), 6.85 (1H, br d, J = 4.0 Hz), 4.73 (1H, t, J = 7.6 Hz), 4.58-4.52 (1H, m), 4.06-3.98 (1H, m), 3.88-3.81 (1H, m), 3.76-3.69 (1H, m), 3.63 (3H, s), 3.13-2.93 (3H, m), 2.34 (3H, br s), 1.77-1.64 (1H, m), 1.50-1.39 (1H, m), 1.12-1.06 (3H, m).
[0637] Reference example 146 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate
[0638] [ka]
[0639] (R)-4-Ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (499.7 mg, 1.1 mmol), methyl (E)-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate (146.8 mg, 1.1 mmol), and [RhCl(cod)]2 (17.1 mg, 0.035 mmol) were mixed in 1,4-dioxane / water (1 / 1) (1.2 mL) and triethyl ether (TEA) (250 μL, 1.8 mmol) under an argon atmosphere and heated at 120 °C for 1.5 h in a microwave oven. The reaction solution was cooled to room temperature, diluted with ethyl acetate, washed with water and saturated brine, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / hexane / TEA = 23 / 75 / 2) to give the title compound (204.3 mg, 62%) as a pale yellow solid. 1 H NMR (400 MHz, CDCl3) δ 7.89 (1H, dd, J = 8.0, 1.6 Hz), 7.52 (1H, t, J= 7.6 Hz), 7.28-7.24 (1H, m), 7.22 (1H, d, J= 8.0 Hz), 7.14 (2H, s), 7.06 (1H, s), 6.45 (1H, s), 4.60-4.53 (2H, m), 4.06-3.95 (3H, m), 3.92-3.86 (2H, m), 3.79 (1H, br d, J = 14.0 Hz), 3.74-3.72 (1H, m), 3.58 (3H, s), 3.05-3.01 (1H, m), 3.00-2.89 (2H, m), 2.35 (3H, s), 2.18 (3H, s), 1.74-1.64 (1H, m), 1.67 (3H, s), 1.52-1.42 (1H, m), 1.09-1.08 (3H, m).
[0640] Reference example 147 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiazol-2-yl]propanoate
[0641] [ka]
[0642] A solution of (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (56.7 mg, 0.13 mmol), methyl (E)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiazol-2-yl]acrylate (21.8 mg, 0.085 mmol), and [RhCl(cod)]2 (7.1 mg, 0.016 mmol) in 1,4-dioxane / water (2 / 1) (0.5 mL) was added with TEA (66 μL, 0.47 mmol) and heated at 50 °C for 4 h in a microwave oven. The reaction solution was cooled to room temperature, diluted with ethyl acetate, washed with water, dried over sodium sulfate, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 91 / 9 → 70 / 30) to give the title compound (23.7 mg, 47%) as a colorless, transparent oil. 1H NMR (400 MHz, CDCl3) δ 7.89 (1H, dd, J = 7.6, 1.2 Hz), 7.56 (1H, s), 7.52 (1H, td, J = 8.0, 1.2 Hz), 7.24-7.24 (1H, m), 7.22-7.15 (3H, m), 7.13-7.12 (1H, m), 4.72 (1H, t, J = 7.6 Hz), 4.58-4.57 (1H, d, J = 14.0 Hz), 4.05-3.98 (2H, m), 3.94-3.88 (2H, m), 3.81-3.79 (1H, m), 3.74-3.71 (1H, m), 3.61 (3H, s), 3..42-3.35 (1H, ), 3.01-2.92 (2H, m), 2.36 (3H, s), 1.74-1.63 (1H, m), 1.70 (3H, s), 1.53-1.38 (1H, m), 1.09 (3H, t, J = 7.6 Hz). Reference example 148 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiazol-2-yl]propanoate
[0643] [ka]
[0644] A solution of (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (62.6 mg, 0.1 mmol), methyl (E)-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiazol-2-yl]acrylate (13.7 mg, 0.05 mmol), and [RhCl(cod)]2 (6.3 mg, 0.01 mmol) in 1,4-dioxane / water (2 / 1) (0.5 mL) was added with TEA (70 μL, 0.5 mmol) and heated at 50 °C for 4 h in a microwave oven. The reaction solution was returned to room temperature, diluted with ethyl acetate, washed with water and saturated brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 68 / 32 → 47 / 53) to give the title compound (32.8 mg, quant.) as a colorless, transparent oil. 1 H NMR (400 MHz, CDCl3) δ 7.90 (1H, d, J = 7.6 Hz), 7.52 (1H t, J= 7.2 Hz), 7.28-7.20 (3H, m), 7.17-7.14 (2H, m), 4.68-4.63 (1H, m), 4.58 (1H, d, J = 14.0 Hz) 4.06-3.94 (3H, m), 3.88-3.79 (3H, m), 3.76-3.70 (1H, m), 3.60 (3H, s), 3.35 (1H, dt, J = 16.0, 6.0 Hz), 3.00-2.93 (2H, m), 2.41 (3H, s), 2.36 (3H, s), 1.74-1.66 (4H, m), 1.51-1.45 (1H, m), 1.09 (3H, t, J = 7.2 Hz).
[0645] Reference example 149 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-(6-oxo-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl)propanoate
[0646] [ka]
[0647] A solution of (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (64.6 mg, 0.1 mmol), methyl (E)-3-(oxo-5,6-dihydro-4H-thieno[2,3-c]pyrrolo-2-yl)acrylate (16.2 mg, 0.07 mmol), [RhCl(cod)]2 (7.6 mg, 0.02 mmol), and 1,4-dioxane / water (2 / 1) (0.7 mL) was added with TEA (100 μL, 0.7 mmol) and heated at 50 °C for 3 h in a microwave oven. The reaction solution was cooled to room temperature, diluted with ethyl acetate, washed with water and saturated brine, dried over sodium sulfate, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 9 / 1 → 0 / 100) to give the title compound (20.1 mg, 50%) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 7.88 (1H, d, J = 7.6 Hz), 7.52 (1H, t, J= 7.6 Hz), 7.27-7.18 (2H, m), 7.16 (2H, s), 7.11 (1H, d, J = 3.6 Hz), 6.80 (1H, s), 6.47 (1H, s), 4.75 (1H, t, J = 8.0 Hz), 4.56 (1H, d, J =14.4 Hz), 4.28 (2H, s), 4.04-3.97 (1H, m), 3.83-3.81 (1H, m), 3.75-3.68 (1H, m), 3.62 (3H, s), 3.12 (1H, dd, J = 15.6, 8.0 Hz), 3.03 (1H, dd, J = 15.6, 8.0 Hz), 2.96-2.94 (1H, m), 2.33 (3H, s), 1.73-1.64 (1H, m), 1.47-1.39 (1H, m), 1.07-1.06 (3H, m).
[0648] Reference example 150 Preparation of methyl 3-(5-acetylfuran-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0649] [ka]
[0650] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (120 mg, 0.3 mmol), methyl (E)-3-(5-acetylfuran-2-yl)acrylate (60.2 mg, 0.3 mmol), [RhCl(cod)]2 (6.4 mg, 0.01 mmol), 1,4-dioxane / water (3 / 1) (0.4 mL), and TEA (109 μL, 0.8 mmol) as starting materials, the title compound (29.9 mg, 22%) was obtained as a colorless oily substance, by the procedure described in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 7.6, 1.6 Hz), 7.52 (1H, td, J= 7.6, 1.6 Hz), 7.25 (1H, td, J = 7.6, 1.2 Hz), 7.20 (1H, d, J = 8.4 Hz), 7.16-7.11 (3H, m), 7.07 (1H, d, J= 3.6 Hz), 6.16 (1H, t, J = 3.6 Hz), 4.59-4.52 (2H, m), 4.05-3.99 (1H, m), 3.83-3.81 (1H, m), 3.76-3.69 (1H, m), 3.62 (3H, s), 3.17-3.11 (1H, m), 3.00-2.88 (2H, m), 2.40 (3H, s), 2.32 (3H, br s), 1.74-1.66 (1H, m), 1.50-1.41 (1H, m), 1.08-1.07 (3H, m).
[0651] Reference example 151 Preparation of methyl 3-(5-acetylthiophen-3-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0652] [ka]
[0653] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (150 mg, 0.33 mmol), methyl (E)-3-(5-acetylthiophen-3-yl)acrylate (102.5 mg, 0.39 mmol), [RhCl(cod)]2 (8.1 mg, 0.016 mmol), 1,4-dioxane / water (3 / 1) (0.7 mL), and TEA (138 μL, 0.98 mmol) as starting materials, the title compound (52.0 mg, 29%) was obtained as a pale yellow oily substance by the procedure described in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.87 (1H, dd,J = 8.0, 1.6 Hz), 7.51 (1H, td, J= 8.0, 1.6 Hz), 7.45 (1H, dd, J = 3.2, 1.2 Hz), 7.29 (1H, br s), 7.24 (1H, td,J = 8.0, 1.2 Hz), 7.20 (1H, br d, J= 8.0 Hz), 7.14-7.12 (1H, m), 7.09-7.06 (2H, m), 4.55-4.51 (2H, m), 4.03-3.96 (1H, m), 3.84-3.66 (2H, m), 3.60 (3H, s), 3.06-3.00 (1H, m), 2.98-2.90 (2H, m), 2.48 (3H, s), 2.31 (3H, br s), 1.72-1.62 (1H, m), 1.46-1.37 (1H, m), 1.06 (3H, t, J = 7.2 Hz).
[0654] Reference example 152 Preparation of methyl 3-(4-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0655] [ka]
[0656] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (150 mg, 0.33 mmol), methyl (E)-3-(4-acetylthiophen-2-yl)acrylate (102.5 mg, 0.39 mmol), [RhCl(cod)]2 (8.1 mg, 0.016 mmol), 1,4-dioxane / water (3 / 1) (0.7 mL), and TEA (138 μL, 0.98 mmol) as starting materials, the title compound (25.5 mg, 14%) was obtained as a brown oily substance by the procedure described in Reference Example 130. 1H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 8.0, 1.6 Hz), 7.84 (1H, d, J= 1.6 Hz), 7.52 (1H, br t, J = 8.0 Hz), 7.27-7.19 (3H, m), 7.16-7.11 (2H, m), 7.05 (1H, d, J = 10.4 Hz), 4.66 (1H, t, J= 7.6 Hz), 4.57-4.56 (1H, m), 4.00-3.97 (1H, m), 3.82-3.68 (2H, m), 3.61 (3H, s), 3.10 (1H, dd, J = 15.6, 7.6 Hz), 3.01-2.99 (2H, m), 2.46 (3H, s), 2.35 (3H, br s), 1.72-1.62 (1H, m), 1.48-1.36 (1H, m), 1.06 (3H, t, J = 7.6 Hz).
[0657] Reference example 153 Preparation of methyl 3-(5-cyano-1-methyl-1H-pyrrol-3-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0658] [ka]
[0659] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (150 mg, 0.33 mmol), methyl (E)-3-(5-cyano-1-methyl-1H-pyrrol-3-yl)acrylate (74 mg, 0.39 mmol), [RhCl(cod)]2 (8.1 mg, 0.016 mmol), 1,4-dioxane / water (3 / 1) (0.7 mL), and TEA (138 μL, 0.98 mmol) as starting materials, the title compound (52.4 mg, 30%) was obtained as a pale yellow oily substance by the procedure described in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 8.0, 1.6 Hz), 7.52 (1H, td, J= 8.0, 1.6 Hz), 7.25 (1H, td, J = 8.0, 1.2 Hz), 7.21 (1H, d, J = 8.0 Hz), 7.12 (1H, d, J = 8.0 Hz), 7.08-7.04 (2H, m), 6.56-6.53 (2H, m), 4.54-4.53 (1H, m), 4.33 (1H, t, J = 8.0 Hz), 4.05-3.98 (1H, m), 3.86-3.69 (2H, m), 3.68 (3H, s), 3.60 (3H, s), 2.99-2.79 (3H, m), 2.32 (3H, s), 1.75-1.66 (1H, m), 1.51-1.39 (1H, m), 1.09-1.08 (3H, m).
[0660] Reference example 154 Preparation of methyl 3-(3-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0661] [ka]
[0662] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (110 mg, 0.2 mmol), methyl (E)-3-(3-acetylthiophen-2-yl)acrylate (61 mg, 0.3 mmol), [RhCl(cod)]2 (5.9 mg, 0.01 mmol), 1,4-dioxane / water (9 / 1) (0.6 mL), and TEA (101 μL, 0.7 mmol) as starting materials, the title compound (24.6 mg, 19%) was obtained as a pale brown oily substance, as in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd,J = 8.0, 1.6 Hz), 7.52 (1H, br t, J= 8.0 Hz), 7.34 (1H, d, J = 5.6 Hz), 7.27-7.20 (3H, m), 7.16-7.10 (3H, m), 5.65 (1H, dd, J = 8.0, 8.0 Hz), 4.61-4.59 (1H, m), 4.04-3.99 (1H, m), 3.80-3.72 (2H, m), 3.56 (3H, s), 3.13-3.07 (1H, m), 3.02-2.90 (2H, m), 2.49 (3H, s), 2.35 (3H, br s), 1.71-1.59 (1H, m), 1.51-1.42 (1H, m), 1.13-1.06 (3H, m).
[0663] Reference example 155 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)furan-2-yl]propanoate
[0664] [ka]
[0665] Using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (115 mg, 0.25 mmol), methyl (E)-3-[5-(2-methyl-1,3-dioxolan-2-yl)furan-2-yl]acrylate (60 mg, 0.25 mmol), [RhCl(cod)]2 (6.2 mg, 0.013 mmol), 1,4-dioxane / water (9 / 1) (0.4 mL), and TEA (106 μL, 0.76 mmol) as starting materials, the title compound (13.5 mg, 9%) was obtained as a pale yellow oily substance, as in Reference Example 130. 1 H NMR(400 MHz, CDCl3)δ 7.89 (1H, dd,J = 8.0, 1.6 Hz), 7.52 (1H, t, J= 8.0 Hz), 7.25 (1H, t, J = 8.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 7.13-7.12 (2H, m), 7.06 (1H, s), 6.17 (1H, d, J= 3.2 Hz), 5.85 (1H, d, J = 3.2 Hz), 4.56 (1H, d, J = 14.0 Hz), 4.48 (1H, t, J = 8.0 Hz), 4.04-3.93 (5H, m), 3.81-3.69 (2H, m), 3.60 (3H, s), 3.07 (1H, d, J = 15.2, 7.2 Hz), 2.97 (1H, d,J = 15.2 Hz), 2.88-2.80 (1H, m), 2.34 (3H, s), 1.75-1.65 (4H, m), 1.50-1.43 (1H, m), 1.08 (3H, t, J = 7.2 Hz).
[0666] Reference example 156 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate
[0667] [ka]
[0668] The title compound (83.4 mg, 600 ml) was obtained in the same manner as in Reference Example 130 using (R)-4-ethyl-2-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (165 mg, 0.36 mmol), methyl (E)-3-[4-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate (137 mg, 0.54 mmol), [RhCl(cod)]2 (8.9 mg, 0.018 mmol), 1,4-dioxane / water (10 / 1) (0.77 mL), and TEA (151 μL, 1.08 mmol) as starting materials. 40%) as a colorless oil. 1H NMR(400 MHz, CDCl3)δ 7.89 (1H, dd, J= 8.0, 1.6 Hz), 7.51 (1H, td, J = 8.0, 1.6 Hz), 7.25 (1H, br t, J = 8.0 Hz), 7.20 (1H, br d, J = 8.0 Hz), 7.15-7.14 (2H, m), 7.07 (2H, br s), 6.77 (1H, dt, J = 4.8, 1.2 Hz), 4.64-4.62 (1H, m), 4.58-4.57 (1H, m), 4.03-3.96 (3H, m), 3.89-3.69 (4H, m), 3.59 (3H, s), 3.08 (1H, dd, J = 15.6, 6.8 Hz), 3.00-2.93 (2H, m), 2.35 (3H, br s), 1.73-1.70 (1H, m), 1.62 (3H, s), 1.45-1.41 (1H, m), 1.09-1.07 (3H, m).
[0669] Reference example 157 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methyl-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate
[0670] [ka]
[0671] To a solution of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate (49.5 mg, 0.085 mmol) in THF (0.6 mL) was added 1M LDA in THF / hexane (150 μL, 0.15 mmol) at −78°C under an argon atmosphere. The reaction mixture was stirred at −78°C for 30 minutes and then at −40°C for 20 minutes. Iodomethane (106 μL, 1.7 mmol) was added, and the mixture was warmed to room temperature and stirred for 3 hours. Water was added to the mixture to quench the reaction, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 9 / 1 → 7 / 3) to give the title compound (40.1 mg, 79%) as a colorless oil. The title compound could be separated into two isomers, isomer 1 with a short retention time and isomer 2 with a long retention time. Isomer 1: 1H NMR(400 MHz, CDCl3)δ 7.90 (1H, dd, J = 8.0, 1.6 Hz), 7.53 (1H, td, J = 8.0, 1.6 Hz), 7.26 (1H, br t, J = 8.0 Hz), 7.22 (1H, dd, J = 8.0, 1.6 Hz), 7.14 (2H, br s), 7.06 (1H, d, J = 11.2 Hz), 6.77 (1H, dd, J = 3.6, 0.8 Hz), 6.69 (1H, br d, J = 3.6 Hz), 4.60-4.57 (1H, m), 4.28-4.25 (1H, m), 4.02-3.88 (5H, m), 3.86-3.69 (2H, m), 3.59 (3H, s), 3.19-3.13 (1H, m), 2.95 (1H, dd, J = 15.2, 2.0 Hz), 2.36-2.34 (3H, m), 1.73-1.62 (4H, m), 1.46-1.38 (1H, m), 1.11-1.04 (6H, m)。 Isomer 2: 1 H NMR(400 MHz, CDCl3)δ 7.89 (1H, dd, J = 8.0, 1.6 Hz), 7.53 (1H, td, J = 8.0, 1.6 Hz), 7.26 (1H, br t, J = 8.0 Hz), 7.22 (1H, dd, J = 8.0, 1.6 Hz), 7.20-7.17 (1H, m), 7.11-7.07 (2H, m), 6.82 (1H, d, J = 3.6 Hz), 6.73 (1H, t, J = 3.6 Hz), 4.57 (1H, d, J = 14.0 Hz), 4.21 (1H, d, J = 11.2 Hz), 4.07-3.89 (5H, m), 3.79-3.68 (2H, m), 3.43 (3H, s), 3.21-3.10 (1H, m), 2.94 (1H, dd, J = 15.2, 8.8 Hz), 2.33 (3H, s), 1.73-1.65 (4H, m), 1.51-1.42 (1H, m), 1.20 (3H, d, J = 6.8 Hz), 1.15-1.07 (3H, m)。
[0672] Reference example 158 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methyl-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate
[0673] [ka]
[0674] A solution of diisopropylamine (30 μL, 0.21 mmol) in THF (200 μL) was cooled to −78°C and stirred for 10 minutes. A 1.6 M solution of n-butyllithium in hexane (110 μL, 0.18 mmol) was added at −78°C, the mixture was heated to −40°C, and then stirred for 30 minutes. The mixture was cooled to -78 °C again, and a solution of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate (41.5 mg, 0.069 mmol) in THF (400 μL) was added dropwise to the reaction solution. The mixture was stirred at -78 °C for 10 minutes, then heated to -40 °C and stirred for 10 minutes. Iodomethane (90 μL, 1.4 mmol) was added to the reaction solution, and the mixture was stirred at -40 °C for 15 minutes, then heated to room temperature and stirred for 2 hours. Water was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was dried over sodium sulfate and the solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / hexane / TEA (v / v) = 23 / 75 / 2) to give the title compound (31.2 mg, 74%) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 7.89 (1H, d, J = 7.6 Hz), 7.53 (1H, t, J= 7.6 Hz), 7.28-7.21 (2H, m), 7.18-7.04 (3H, m), 6.57-6.51 (1H, m), 4.59-4.57 (1H, m), 4.20-4.19 (1H, m), 4.07-3.94 (3H, m), 3.92-3.82 (3H, m), 3.78-3.69 (1H, m), 3.60-3.42 (3H, m), 3.16-3.08 (1H, m), 3.00-2.92 (1H, m), 2.37-2.33 (3H, m), 2.19-2.16 (3H, m), 1.74-1.62 (1H, m), 1.66-1.65 (3H, m), 1.53-1.37 (1H, m), 1.21-0.99 (6H, m).
[0675] Reference example 159 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methyl-3-[5-(2-methyl-1,3-dioxolan-2-yl)furan-2-yl]propanoate
[0676] [ka]
[0677] Methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)furan-2-yl]propanoate (55.7 mg, 0.098 mmol), 1M LDA THF / hexane solution (150 μL, 0.15 mmol), iodomethane (106 μL, 1.7 mmol), and THF (0.6 mL) were used as raw materials and operated in a similar manner to Reference Example 157 to obtain the title compound (40.1 mg, 79%) as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ 7.89 (1H, br d,J = 8.0 Hz), 7.52 (1H, br t, J = 8.0 Hz), 7.28-7.23 (1H, m), 7.22-7.04 (4H, m), 6.18-6.14 (1H, m), 6.01-5.92 (1H, m), 4.58-4.51 (1H, m), 4.15-4.08 (1H, m), 4.04-3.94 (5H, m), 3.85-3.71 (2H, m), 3.63-3.44 (3H, m), 3.23-3.16 (1H, m), 2.98-2.93 (1H, m), 2.35-2.31 (3H, m), 1.69-1.66 (4H, m), 1.52-1.48 (1H, m), 1.16-0.98 (6H, m).
[0678] Reference example 160 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methyl-3-[4-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate
[0679] [ka]
[0680] Methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate (83 mg, 0.14 mmol), THF (0.9 mL), 2M LDA THF / heptane / ethylbenzene solution (92 μL, 0.18 mmol), and iodomethane (133 μL, 2.1 mmol) were used as raw materials and operated in the same manner as in Reference Example 157 to obtain the title compound (58.0 mg, 81%) as a colorless oily substance. The title compound was separated into two isomers by silica gel column chromatography, yielding isomer 1 (17.0 mg) with a short retention time and isomer 2 (30.7 mg) with a long retention time as colorless oils. Isomer 1: 1 H NMR(400 MHz, CDCl3)δ 7.89 (1H, dd, J = 7.6, 1.6 Hz), 7.53 (1H, br t, J = 8.0 Hz), 7.28-7.25 (1H, m), 7.24-7.18 (2H, m), 7.11-7.08 (3H, m), 6.86 (1H, dd, J = 6.0, 1.2 Hz), 4.57-4.56 (1H, m), 4.24-4.23 (1H, m), 4.03-3.99 (3H, m), 3.85-3.68 (4H, m), 3.43 (3H, s), 3.19-3.12 (1H, m), 2.96-2.91 (1H, m), 2.32 (3H, s), 1.73-1.69 (1H, m), 1.62 (3H, s), 1.51-1.44 (1H, m), 1.20-1.19 (3H, m), 1.24-1.09 (3H, m). Isomer 2: 1H NMR(400 MHz, CDCl3)δ 7.89 (1H, br d, J = 8.0 Hz), 7.53 (1H, td, J = 8.0, 1.6 Hz), 7.28-7.24 (1H, m), 7.22-7.19 (1H, m), 7.16-7.14 (2H, m), 7.09-7.07 (1H, m), 7.03 (1H, br s), 6.83 (1H, br s), 4.60-4.57 (1H, m), 4.28-4.27 (1H, m), 4.04-3.97 (3H, m), 3.87-3.69 (4H, m), 3.58 (3H, br s), 3.19-3.12 (1H, m), 2.97-2.93 (1H, m), 2.36-2.34 (3H, m), 1.71-1.67 (1H, m), 1.62-1.61 (3H, m), 1.46-1.37 (1H, m), 1.11-1.03 (6H, m).
[0681] Reference example 161 Preparation of methyl 3-[5-(dimethylcarbamoyl)furan-2-yl]-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0682] [ka]
[0683] To a solution of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(methylcarbamoyl)furan-2-yl]propanoate (43 mg, 0.08 mmol) in THF (2.0 mL) was added 1M LDA in THF (96 μL, 0.096 mmol) at −78 °C. The reaction mixture was stirred at −78 °C for 20 minutes and at −40 °C for 15 minutes. Iodomethane (100 μL, 1.6 mmol) was added, and the mixture was stirred at room temperature for 3.5 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 3 / 7 → 1 / 1) to obtain the title compound (26.4 mg, 60%) as a pale yellow solid. 1 H NMR(400 MHz, CDCl3)δ 7.89 (1H, dd,J = 7.6, 1.6 Hz), 7.52 (1H, t, J= 7.6 Hz), 7.26 (1H, t, J = 7.6 Hz), 7.21 (1H, d, J = 7.6 Hz), 7.15-7.10 (3H, m), 6.90 (1H, d, J = 3.6 Hz), 6.10 (1H, d, J = 3.6 Hz), 4.56-4.52 (2H, m), 4.04-3.99 (1H, m), 3.82 (1H, d,J = 14 Hz), 3.76-3.69 (1H, m), 3.61 (3H, s), 3.13-2.86 (9H, m), 2.32 (3H, s), 1.75-1.65 (1H, m), 1.52-1.42 (1H, m), 1.08 (3H, t, J = 7.2 Hz).
[0684] Reference example 162 Preparation of methyl 3-(5-carbamoylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0685] [ka]
[0686] To a solution of methyl 3-{5-[(2,4-dimethoxybenzyl)carbamoyl]thiophen-2-yl}-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate (83.4 mg, 0.12 mmol) in dichloromethane (1 mL), TFA (750 μL, 9.8 mmol) was added under an argon atmosphere and stirred at room temperature for 2 hours. The solvent was concentrated under reduced pressure, and the residue was neutralized with 1N aqueous sodium hydroxide solution and extracted with methanol / dichloromethane (1 / 10). The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (99.4 mg, quant.) as a pale yellow solid. 1 H NMR(400 MHz, CDCl3)δ 7.87 (1H, dd,J = 8.0, 1.6 Hz), 7.52 (1H, br t, J= 8.0 Hz), 7.35 (1H, d, J = 3.6 Hz), 7.25 (1H, t, J = 8.0 Hz), 7.20 (1H, br d, J = 8.0 Hz), 7.14 (2H, br s), 7.08 (1H, d, J = 8.4 Hz), 6.81-6.79 (1H, m), 6.01 (2H, br s), 4.70 (1H, t, J = 8.0 Hz), 4.57-4.55 (1H, m), 4.02-3.95 (1H, m), 3.82-3.69 (2H, m), 3.60 (3H, s), 3.09 (1H, dd, J = 15.6, 7.6 Hz), 3.02-2.91 (2H, m), 2.33 (3H, s), 1.72-1.62 (1H, m), 1.46-1.38 (1H, m), 1.07-1.06 (3H, m).
[0687] Reference example 163 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0688] [ka]
[0689] A solution of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]-2,2-dimethylpropanoate (29.8 mg, 0.079 mmol), (R)-4-ethyl-3,4-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (27.8 mg, 0.12 mmol), potassium carbonate (33.9 mg, 0.25 mmol), and tetrabutylammonium iodide (5.7 mg, 0.015 mmol) in DMF (0.50 mL) was stirred at 70 °C for 3 h. The reaction solution was cooled to room temperature, and ethyl acetate was added. The mixture was washed with water and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 73 / 27 → 52 / 48) to obtain the title compound (43.1 mg, 96%) as a white solid. 1H NMR (400 Mz, CDCl3) δ 7.87 (1H, dt, J = 7.6, 1.2 Hz), 7.55-7.50 (1H, m), 7.49 (1H, d, J = 4.0 Hz), 7.27-7.11 (5H, m), 6.97-6.95 (1H, m), 4.69-4.67 (1H, m), 4.56-4.55 (1H, m), 4.04-3.97 (1H, m), 3.83-3.69 (2H, m), 3.60 (3H, brs), 2.97-2.90 (1H, m), 2.49-2.48 (3H, m), 2.33 (3H, s), 1.81-1.56 (1H, m), 1.51-1.35 (1H, m), 1.29 (3H, br s), 1.23 / -1.21 (3H, m), 1.10-1.08 (3H, m).
[0690] Reference example 164 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-9-fluoro-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0691] [ka]
[0692] Methyl 3-(5-acetylthiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]-2,2-dimethylpropanoate (23.4 mg, 0.062 mmol), (R)-4-ethyl-9-fluoro-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (18.3 mg, 0.075 mmol), potassium carbonate (27.2 mg, 0.20 mol), tetrabutylammonium iodide (5.3 mg, 0.014 mmol), and DMF (1.0 mL) were used as raw materials, and the procedure was performed in the same manner as in Reference Example 163 to obtain the title compound (31.8 mg, 88%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.51 (1H, dd, J = 4.0, 1.6 Hz), 7.44-7.39 (1H, m), 7.29 / 7.28 (1H, m), 7.25-7.22 (1H, m), 7.14 (1H, br d, J = 8.0 Hz), 7.00-6.94 (3H, m), 4.72 (1H, s), 4.58-4.55 (1H, m), 4.50-4.43 (1H, m), 4.31-4.28 (1H, m), 3.62 (3H, s), 3.33 (1H, d, J = 14.4, 4.0 Hz), 3.10 (1H, d, J= 14.4, 1.2 Hz), 2.49 (3H, br s), 2.34 (3H, br s), 1.68-1.56 (1H, m), 1.55-1.45 (1H, m), 1.32 (3H, br s), 1.25 (3H, s), 1.02-1.01 (3H, m).
[0693] Reference example 165 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0694] [ka]
[0695] Methyl 3-(5-acetylthiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2,2-dimethylpropanoate (50 mg, 0.139 mmol), (R)-4-ethyl-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepine 1,1-dioxide (38.1 mg, 0.167 mmol), triphenylphosphine (73 mg, 0.278 mmol), THF (0.4 mL), and a 2.2 M DEAD toluene solution (126 μL, 0.278 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 12 to obtain the title compound (39.4 mg, 50%) as a pale yellow oil. 1 H NMR(400 MHz, CDCl3)δ 8.51-8.49 (1H, m), 8.26 (1H, br d, J = 8.0 Hz), 7.51 (1H, d, J = 4.0 Hz), 7.30-7.24 (2H, m), 7.21 (1H, s), 7.14 (1H, d, J = 8.0 Hz), 6.98 (1H, t, J = 4.0 Hz), 4.69 (1H, d, J = 5.6 Hz), 4.47-4.42 (2H, m), 4.11-4.05 (1H, m), 3.62-3.59 (4H, m), 3.16 (1H, br d, J = 15.2 Hz), 2.50 (3H, s), 2.33 (3H, br s), 1.81-1.68 (1H, m), 1.60-1.52 (1H, m), 1.30 (3H, s), 1. 24 (3H, s), 1.09 (3H, t, J = 7.2 Hz).
[0696] Reference example 166 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-[3-({4-[2-(benzyloxy)ethyl]-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl}methyl)-4-methylphenyl]-2-methylpropanoate
[0697] [ka]
[0698] Methyl 3-(5-acetylthiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2,2-dimethylpropanoate (22 mg, 0.064 mmol), 4-[2-(benzyloxy)ethyl]-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (23 mg, 0.070 mmol), triphenylphosphine (20.1 mg, 0.077 mmol), THF (0.27 mL), and a 2.2 M DEAD toluene solution (38 μL, 0.083 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 12 to obtain the title compound (29.6 mg, 70%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, br d,J = 8.0 Hz), 7.49 (1H, br t, J = 8.0 Hz), 7.43 (1H, t, J = 4.0 Hz), 7.35-7.24 (6H, m), 7.14-7.09 (3H, m), 7.00 (1H, br t, J = 8.0 Hz), 6.89 (1H, br t,J = 4.0 Hz), 4.60-4.47 (3H, m), 4.36-4.31 (2H, m), 3.87-3.73 (3H, m), 3.66-3.61 (1H, m), 3.59 (3H, br s), 3.25-3.18 (1H, m), 2.93-2.88 (1H, m), 2.43 (3H, br s), 2.31 (3H, br s), 1.92-1.83 (1H, m), 1.67-1.60 (1H, m), 1.06 (3H, d, J = 7.2 Hz).
[0699] Reference example 167 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoate
[0700] [ka]
[0701] Methyl 3-(5-acetylthiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2-methylpropanoate (50 mg, 0.14 mmol), (R)-4-ethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepine 1,1-dioxide (38.1 mg, 0.17 mmol), triphenylphosphine (43.7 mg, 0.17 mmol), THF (3.7 mL), and a 2.2 M DEAD toluene solution (100 μL, 0.22 mmol) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 12 to obtain the title compound (24.8 mg, 31%) as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ 9.03 (1H, s), 8.66 (1H, dd, J = 5.6, 2.0 Hz), 7.47 (1H, dd,J = 4.0, 2.4 Hz), 7.17 (2H, s), 7.12-7.09 (2H, m), 6.93-6.92 (1H, m), 4.47-4.44 (1H, m), 4.38 (2H, d, J = 12.0 Hz), 4.21-4.09 (1H, m), 3.61 (3H, s), 3.51-3.41 (1H, m), 3.23-3.11 (2H, m), 2.47 (3H, br s), 2.33 (3H, s), 1.74-1.63 (1H, m), 1.56-1.47 (1H, m), 1.08-1.02 (6H, m).
[0702] Reference example 168 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[4-(2-hydroxyethyl)-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoate
[0703] [ka]
[0704] Palladium on carbon (35.7 mg) was added to a solution of methyl 3-(5-acetylthiophen-2-yl)-3-[3-({4-[2-(benzyloxy)ethyl]-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl}methyl)-4-methylphenyl]-2-methylpropanoate (126 mg, 0.19 mmol) in methanol / dichloromethane (0.6 mL / 0.4 mL) and stirred at room temperature for 32 hours. The mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 1 / 1 → 0 / 1) to afford the title compound (44.4 mg, 41%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.89 (1H, dd, J = 8.0, 1.6 Hz), 7.69-7.44 (3H, m), 7.29-7.22 (1H, m), 7.17-7.10 (3H, m), 6.93 (1H, d, J = 4.0 Hz), 4.77-4.59 (1H, m), 4.44-4.33 (2H, m), 4.02-3.80 (4H, m), 3.60-3.55 (3H, m), 3.31-3.09 (1H, m), 2.92-2.81 (1H, m), 2.49-2.34 (6H, m), 1.96-1.77 (1H, m), 1.62-1.45 (1H, m), 1.07-1.00 (3H, m).
[0705] Reference example 169 Preparation of (5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)methanol
[0706] [ka]
[0707] To a solution of [1-(5-bromo-3-fluorothiophen-2-yl)ethoxy](tert-butyl)dimethylsilane (200 mg, 0.59 mmol) in THF (2.0 mL) was added 2M n-butyllithium cyclohexane solution (354 μL, 0.71 mmol) at -78 °C. The mixture was stirred at -78 °C for 30 minutes, and then a solution of 3-{[(4-methoxybenzyl)oxy]methyl}-4-methylbenzaldehyde (135.1 mg, 0.50 mmol) in THF (1.5 mL) was added. The reaction mixture was stirred at -78 °C for 1.5 hours and then warmed to room temperature. After stirring for 1.5 hours, the reaction was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 1 / 0 → 95 / 5) to obtain the title compound (168.3 mg, 63%) as a colorless oil. 1H NMR(400 MHz, CDCl3)δ 7.31 (1H, br s), 7.22-7.16 (3H, m), 7.10 (1H, d, J = 7.6 Hz), 6.82 (2H, br d, J = 8.8 Hz), 6.40 (1H, d, J = 20.8 Hz), 5.76 (1H, br s), 5.09 (1H, q, J = 6.4 Hz), 4.44-4.43 (4H, m), 3.74 (3H, s), 2.32 (1H, br s), 2.25 (3H, s), 1.39-1.38 (3H, m), 0.82 (9H, br s), 0.01 (3H, br s), -0.05 (3H, br s).
[0708] Reference example 170 Preparation of methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0709] [ka]
[0710] To a solution of (5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)(3-{[(4-methoxybenzyl)oxy)]methyl}-4-methylphenyl)methanol (210 mg, 0.40 mmol) in acetonitrile (4.8 mL) was added trichloroacetonitrile (80 μL, 0.79 mmol) and DBU (3 μL, 0.020 mmol). The mixture was stirred at room temperature for 45 minutes, and then a solution of dimethylketene methyltrimethylsilyl acetal (201 μL, 0.99 mmol) and bis-(trifluoromethanesulfonyl)imide (11.1 mg, 0.040 mmol) in acetonitrile (111 μL) was added, followed by stirring at room temperature for 3.5 hours. A saturated aqueous solution of potassium carbonate was added to the mixture, which was then extracted with dichloromethane. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 1 / 0 → 85 / 15) to obtain the title compound (184.3 mg, 76%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.25-7.22 (3H, m), 7.13 (1H, br t, J = 8.0 Hz), 7.04 (1H, dd, J = 8.0, 3.2 Hz), 6.84 (2H, br d, J = 8.8 Hz), 6.55 (1H, d, J = 19.6 Hz), 5.07 (1H, q, J = 6.4 Hz), 4.45-4.41 (5H, m), 3.77 (3H, s), 3.54 (3H, s), 2.23 (3H, s), 1.39-1.36 (3H, m), 1.24 (3H, s), 1.15 (3H, s), 0.82 (9H, br s), 0.001 (3H, br s), -0.07 (3H, br s).
[0711] Reference example 171 Preparation of methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2,2-dimethylpropanoate
[0712] [ka]
[0713] Methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate (204 mg, 0.33 mmol), dichloromethane (2.9 mL), water (290 μL), and DDQ (82.6 mg, 0.36 mmol) were used as raw materials and operated in the same manner as in Reference Example 25 to obtain the title compound (109.3 mg, 66%) as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ7.31 (1H, s), 7.18 (1H, br t, J = 8.0 Hz), 7.10 (1H, dd, J= 8.0, 4.0 Hz), 6.60 (1H, d, J = 19.6 Hz), 5.12 (1H, q, J = 6.4 Hz), 4.67 (2H, br s), 4.50-4.47 (1H, m), 3.60 (3H, s), 2.31 (3H, s), 2.32 (3H, s), 1.59 (1H, br s), 1.43-1.42 (3H, m), 1.29 (3H, s), 1.20 (3H, br s), 0.87 (9H, br s), 0.054-0.051 (3H, m), 0.00--0.015 (3H, m).
[0714] Reference example 172 Preparation of methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0715] [ka]
[0716] Methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2,2-dimethylpropanoate (65 mg, 0.13 mmol), (R)-4-ethyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (33 mg, 0.15 mmol), triphenylphosphine (38 mg, 0.15 mmol), THF (0.4 mL), and a 2.2 M DEAD toluene solution (78 μL, 0.17 mmol) were used as starting materials, and the procedure was carried out in the same manner as in Reference Example 12 to obtain the title compound (66.2 mg, 71%) as a white solid. 1H NMR(400 MHz, CDCl3)δ 7.84 (1H, d,J = 8.0 Hz), 7.47 (1H, br t, J = 8.0 Hz), 7.23-7.13 (3H, m), 7.11-7.07 (2H, m), 6.57-6.50 (1H, m), 5.09-5.06 (1H, m), 4.52-4.49 (1H, m), 4.42-4.38 (1H, m), 3.99-3.95 (1H, m), 3.80-3.65 (2H, m), 3.55 (3H, br s), 2.95-2.89 (1H, m), 2.29 (3H, br s), 1.69-1.59 (1H, m), 1.39-1.36 (4H, m), 1.22-1.21 (3H, m), 1.14-1.13 (3H, m), 1.06-1.02 (3H, m), 0.82-0.79 (9H, m), 0.004--0.009 (3H, m), -0.052--0.091 (3H, m).
[0717] Reference example 173 Preparation of 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-fluoro-5-(1-hydroxyethyl)thiophen-2-yl]-2,2-dimethylpropanoic acid
[0718] [ka]
[0719] To a solution of methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate (87.2 mg, 0.12 mmol) in methanol / 1,4-dioxane (0.5 mL / 0.5 mL), 4N aqueous sodium hydroxide solution (310 μL, 1.2 mmol) was added and the mixture was stirred at 100°C for 1 hour using a microwave. 1N hydrochloric acid was added to the mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (90.7 mg, quant.) as a pale yellow oil. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, br d,J = 8.0 Hz), 7.52 (1H, br t, J = 8.0 Hz), 7.27-7.20 (4H, m), 7.13-7.11 (1H, m), 6.69-6.64 (1H, m), 5.13 (1H, q, J = 6.4 Hz), 4.58-4.48 (2H, m), 4.02-4.00 (1H, m), 3.86-3.73 (2H, m), 3.01-2.96 (1H, m), 2.32 (3H, s), 1.73-1.60 (1H, m), 1.52-1.48 (3H, m), 1.45-1.41 (1H, m), 1.29 (3H, s), 1.18 (3H, s), 1.10-1.06 (3H, m).
[0720] Reference example 174 Preparation of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-fluoro-5-(1-hydroxyethyl)thiophen-2-yl]-2,2-dimethylpropanoate
[0721] [ka]
[0722] To a solution of methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate (66 mg, 0.094 mmol) in THF (0.2 mL), 1N tetrabutylammonium fluoride THF solution (188 μL, 0.19 mmol) was added and stirred at room temperature for 2 hours. Saturated aqueous sodium bicarbonate solution was added to the mixture, which was then extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (62.1 mg, quant.) as a white solid. 1 H NMR(400 MHz, CDCl3)δ 7.88 (1H, dd, J= 8.0, 1.6 Hz), 7.52 (1H, br t, J = 8.0 Hz), 7.27-7.17 (4H, m), 7.12 (1H, d, J= 7.6 Hz), 6.63-6.61 (1H, m), 5.15 (1H, q, J= 6.4 Hz), 4.54-4.50 (1H, m), 4.48 (1H, br s), 4.05-4.01 (1H, m), 3.83 (1H, d, J = 14.0 Hz), 3.76-3.70 (1H, m), 3.62 (3H, br s), 3.39-3.35 (1H, m), 3.00-2.95 (1H, m), 2.33 (3H, s), 1.72-1.66 (1H, m), 1.52-1.50 (3H, m), 1.48-1.42 (1H, m), 1.28 (3H, s), 1.19 (3H, br s), 1.09 (3H, t, J = 7.2 Hz).
[0723] Reference example 175 Preparation of methyl 3-(5-acetyl-4-fluorothiophen-2-yl)3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0724] [ka]
[0725] To a solution of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-fluoro-5-(1-hydroxyethyl)thiophen-2-yl]-2,2-dimethylpropanoate (62.1 mg, 0.094 mmol) in DMSO (0.4 mL) was added TEA (47 μL, 0.34 mmol) and pyridine-sulfur trioxide complex (32.9 mg, 0.21 mmol). The reaction mixture was stirred at room temperature for 20 hours. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (48.1 mg, 87%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.89 (1H, dt, J= 8.0, 1.6 Hz), 7.53 (1H, br t, J = 8.0 Hz), 7.29-7.14 (5H, m), 6.75 (1H, br d, J= 6.8 Hz), 4.57-4.54 (2H, m), 4.06-4.00 (1H, m), 3.85-3.82 (1H, m), 3.77-3.71 (1H, m), 3.64 (3H, br s), 3.00-2.93 (1H, m), 2.51 (3H, br s), 2.34 (3H, s), 1.71-1.65 (1H, m), 1.50-1.38 (1H, m), 1.30 (3H, s), 1.20 (3H, s), 1.09-1.08 (3H, m).
[0726] Reference example 176 Preparation of methyl 3-(4-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-1-trityl-1H-benzo[d]imidazol-6-yl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate
[0727] [ka]
[0728] A flask was charged with (R)-4-ethyl-2-{[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-benzo[d]imidazol-4-yl]methyl}-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (126.9 mg, 0.17 mmol), methyl (E)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate (88.4 mg, 0.35 mmol), and [RhCl(cod)]2 (9.3 mg, 0.019 mmol), and the atmosphere was purged with argon. Then, 1,4-dioxane / water (1 / 1) (0.8 mL) and TEA (75 μL, 0.54 mmol) were added, and the mixture was heated in a microwave oven at 140 °C for 3 hours. The reaction solution was returned to room temperature, diluted with ethyl acetate, washed with water and saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 71 / 29 → 1 / 1) to give the title compound (86.6 mg, 58%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.88 (1H, d, J = 7.6 Hz), 7.78 (1H, s), 7.47-7.42 (1H, m), 7.31-7.26 (9H, m), 7.22-7.18 (1H, m), 7.15-7.11 (8H, m), 6.70 (1H, d, J = 2.0 Hz), 6.29-6.26 (2H, m), 4.77 (1H, d, J = 15.2 Hz), 4.55-4.54 (1H. m), 4.48 (1H, q, J = 7.2 Hz), 4.03-3.84 (6H, m), 3.53 (3H, s), 3.29-3.23 (1H, m),2.76-2.69 (1H, m), 2.59-2.51 (1H, m), 1.73-1.64 (1H, m), 1.68 (3H, s), 1.45-1.40 (1H, m), 1.03-1.02 (3H, m).
[0729] Reference example 177 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(4-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-1H-benzo[d]imidazol-6-yl)propanoate
[0730] [ka]
[0731] To a solution of methyl 3-(4-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-1-trityl-1H-benzo[d]imidazol-6-yl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate (49.8 mg, 0.058 mmol) in dichloromethane (0.9 mL), triethylsilane (0.1 mL) and TFA (1.0 mL) were added and stirred at room temperature for 30 minutes. The reaction solution was made basic with saturated aqueous sodium bicarbonate, extracted with ethyl acetate, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 0 → 95 / 5) and preparative thin-layer chromatography (dichloromethane / methanol = 97 / 3) to obtain the title compound (23.2 mg, 70%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 10.6 (1H, s), 8.11 (1H, s), 7.90 (1H, dd, J = 7.6, 1.2 Hz), 7.74 (1H, s), 7.56 (1H, t, J = 7.6 Hz), 7.52-7.48 (1H, m), 7.31-7.24 (2H, m), 6.91 (1H, s), 6.88 (1H, br s), 4.87 (1H, t, J = 7.6 Hz), 4.75-4.72 (1H, m), 4.15-4.07 (1H, m), 3.97-3.93 (1H, m), 3.74-3.71 (1H, m), 3.60 (3H, br s), 3.21-3.07 (3H, m), 2.47 (3H, s), 1.82-1.74 (1H, m), 1.59-1.51 (1H, m), 1.15-1.14 (3H, m).
[0732] Reference example 178 Preparation of methyl 3-(5-acetyl-4-methylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoate
[0733] [ka]
[0734] To a solution of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methyl-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate (31.2 mg, 0.05 mmol) in THF (0.5 mL) was added 1 M hydrochloric acid (0.1 mL, 0.1 mmol) and stirred at room temperature for 1 hour. The reaction solution was diluted with ethyl acetate, washed with water and saturated brine, dried over sodium sulfate, and evaporated under reduced pressure to give the title compound (26.7 mg, 92%) as a brown, clear oil. 1H NMR (400 MHz, CDCl3) δ 7.89 (1H, d, J = 7.6 Hz), 7.53 (1H, t, J= 7.6 Hz), 7.26 (1H, t, J = 7.6 Hz), 7.22 (1H, d, J = 8.0 Hz), 7.17-7.07 (3H, m), 6.77-6.32 (1H, m), 4.60-4.53 (1H, m), 4.30-4.25 (1H, m), 4.06-3.98 (1H, m), 3.89-3.79 (1H, m), 3.75-3.68 (1H, mz), 3.62-3.46 (3H, m), 3.24-3.14 (1H, m), 2.99-2.92 (1H, m), 2.47-2.42 (6H, m), 2.34-2.31 (3H, m), 1.73-1.62 (1H, m), 1.49-1.33 (1H, m), 1.11-1.04 (6H, m).
[0735] Reference example 179 Preparation of methyl 3-(5-acetylthiazol-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-propanoate
[0736] [ka]
[0737] To a solution of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiazol-2-yl]propanoate (23.7 mg, 0.040 mmol) in THF (0.5 mL) was added 1 M hydrochloric acid (0.1 mL) and stirred for 2 hours. 6 M hydrochloric acid (0.1 mL) was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was diluted with ethyl acetate, washed with water, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (19.0 mg, 89%) as a white oil. 1 H NMR (400MHz, CDCl3) δ 8.17 (1H, br s), 7.89 (1H, dd, J = 7.6, 1.6 Hz), 7.52 (1H, td, J = 7.6, 1.6 Hz), 7.28-7.24 (1H, m), 7.22-7.14 (4H, m), 4.79 (1H, t, J = 7.6 Hz), 4.57-4.55 (1H, m), 4.07-3.97 (1H, m), 3.84-3.81 (1H, m), 3.76-3.66 (1H, m), 3.63 (3H, s), 3.43-3.42 (1H, m), 3.02-2.96 (2H, m), 2.52 (3H, s), 2.35 (3H, br s), 1.75-1.64 (1H, m), 1.51-1.39 (1H, m), 1.09-1.07 (3H, m).
[0738] Reference example 180 Preparation of methyl 3-(5-acetyl-4-methylthiazol-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-propanoate
[0739] [ka]
[0740] To a solution of methyl 3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[4-methyl-5-(2-methyl-1,3-dioxolan-2-yl)thiazol-2-yl]propanoate (32.8 mg, 0.06 mmol) in THF (0.5 mL) was added 3M hydrochloric acid (0.1 mL, 0.3 mmol) and stirred at room temperature for 5 hours. Ethyl acetate was added to the reaction solution, which was washed with water and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate = 1 / 1 → dichloromethane / methanol = 98 / 2) to give the title compound (24.8 mg, 82%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.89 (1H, d, J = 7.6 Hz), 7.52 (1H, t, J= 7.6 Hz), 7.28-7.24 (1H, m), 7.22-7.15 (4H, m), 4.73 (1H, t, J = 7.6 Hz), 4.58-4.56 (1H, m), 4.07-3.98 (1H, m), 3.85-3.82 (1H, m), 3.76-3.70 (1H, m), 3.62 (3H, s), 3.43-3.42 (1H, m), 3.01-2.94 (2H, m,), 2.68 (3H, s), 2.44 (3H, s), 2.36 (3H, br s), 1.77-1.62 (1H, m), 1.52-1.38 (1H, m), 1.11-1.05 (3H, m).
[0741] Reference example 181 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0742] [ka]
[0743] A solution of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]-2,2-dimethylpropanoate (87.4 mg, 0.231 mmol), (R)-4-ethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepine 1,1-dioxide (52.7 mg, 0.231 mmol), potassium carbonate (96.0 mg, 0.693 mmol), and tetrabutylammonium iodide (17.1 mg, 0.046 mmol) in DMF (6.9 mL) was stirred at room temperature for 3.5 hours. The reaction solution was cooled to room temperature, ethyl acetate was added, and the mixture was washed with water and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The obtained crude product was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 67 / 33 → 46 / 54) to obtain the title compound (181.0 mg, quant.) as a pale yellow oily substance. 1 H NMR (400 Mz, CDCl3) δ 9.03 (1H, s), 8.66 (1H, dd, J = 5.6, 1.6 Hz), 7.51 (1H, dd, J = 4.0, 1.6 Hz), 7.24-7.20 (2H, m), 7.16-7.14 (1H, m), 7.12-7.08 (1H, m), 6.98-6.96 (1H, m), 4.70 / 4.69 (1H, s), 4.46-4.37 (2H, m), 4.22-4.16 (1H, m), 3.60 (3H, br s), 3.53-3.44 (1H, m), 3.18-3.12 (1H, m), 2.50 (3H, br s), 2.32 (3H, br s), 1.72-1.63 (1H, m), 1.54-1.47 (1H, m), 1.30 (3H, br s), 1.24-1.22 (3H, m), 1.07-1.02 (3H, m).
[0744] Reference example 182 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)propanoate
[0745] [ka]
[0746] To a solution of methyl 3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-3-[5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]propanoate (297.6 mg, 0.60 mmol) in tetrahydrofuran (1.8 mL) was added 2N hydrochloric acid (0.9 mL) and stirred at room temperature for 2 hours. The mixture was diluted with water and extracted with dichloromethane. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (230.4 mg, 85%) as a pale yellow oil. 1 H NMR(400 MHz, CDCl3)δ 7.49 (1H, d, J = 4.0 Hz), 7.28-7.24 (3H, m), 7.11 (2H, br s), 6.90-6.86 (3H, m), 4.74 (1H, t, J = 8.0 Hz), 4.48 (2H, s), 4.47 (2H, s), 3.82 (3H, s), 3.62 (3H, s), 3.15-3.00 (2H, m), 2.48 (3H, s), 2.27 (3H, s).
[0747] Reference example 183 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]propanoate
[0748] [ka]
[0749] To a solution of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)propanoate (230.4 mg, 0.509 mmol) in dichloromethane / water (10 / 1) (5.28 mL) was added DDQ (231.1 mg, 1.02 mmol) at 0 °C. The mixture was stirred at room temperature for 2 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, which was then extracted with dichloromethane. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 57 / 43 → 36 / 64) to give the title compound (149.6 mg, 85%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.49 (1H, d, J = 4.0 Hz), 7.29 (1H, br s), 7.10 (2H, br s), 6.87 (1H, br d, J = 4.0 Hz), 4.74 (1H, t, J = 8.0 Hz), 4.64 (2H, s), 3.60 (3H, s), 3.15-3.01 (2H, m), 2.46 (3H, s), 2.28 (3H, s).
[0750] Reference example 184 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]propanoate
[0751] [ka]
[0752] A suspension of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]propanoate (150.0 mg, 0.45 mmol) and lithium chloride (38.4 mg, 0.91 mmol) in dichloromethane (3.5 mL) was added with DIPEA (115.7 μL, 0.68 mmol) and methanesulfonyl chloride (41.8 μL, 0.54 mmol) and stirred at room temperature for 19 hours. Dichloromethane was added to the reaction solution, which was washed with saturated aqueous sodium bicarbonate and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 67 / 33 → 46 / 54) to afford the title compound (105.0 mg, 67%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 7.51 (1H, d, J = 4.0 Hz), 7.21 (1H, br s), 7.15 (2H, br s), 6.87 (1H, br d, J = 4.0 Hz), 4.74 (1H, t, J = 8.0 Hz), 4.56 (2H, s), 3.62 (3H, s), 3.15-3.00 (2H, m), 2.48 (3H, s), 2.38 (3H, s).
[0753] Reference example 185 Preparation of methyl 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)propanoate
[0754] [ka]
[0755] A solution of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]propanoate (35.0 mg, 0.10 mmol), (R)-4-ethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepine 1,1-dioxide (23.0 mg, 0.10 mmol), potassium carbonate (41.5 mg, 0.30 mmol), and tetrabutylammonium iodide (7.4 mg, 0.02 mmol) in DMF (3.0 mL) was stirred at room temperature for 4 hours. Ethyl acetate was added to the reaction solution, which was then washed with water and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The obtained crude product was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 55 / 45 → 36 / 64) to give the title compound (48.2 mg, 89%) as a colorless oil. 1 H NMR (400 Mz, CDCl3) δ 9.02 (1H, s), 8.65 (1H, d, J = 5.6 Hz), 7.50 (1H, br d, J = 4.0 Hz), 7.17 (2H, br s), 7.11-7.08 (2H, m), 6.88 (1H, br d, J= 4.0 Hz), 4.73 (1H, t, J = 7.6 Hz), 4.45-4.37 (2H, m), 4.16-4.09 (1H, m), 3.62 (3H, s), 3.51-3.43 (1H, m), 3.17-3.09 (2H, m), 3.05-3.00 (1H, m), 2.49 (3H, s), 2.33 (3H, s), 1.74-1.65 (1H, m), 1.56-1.50 (1H, m), 1.04 (3H, br t, J = 7.6 Hz).
[0756] Reference example 186 Preparation of methyl 3-[4-fluoro-5-(1-hydroxyethyl)thiophen-2-yl]-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0757] [ka]
[0758] To a solution of methyl 3-(5-{1-[(tert-butyldimethylsilyl)oxy]ethyl}-4-fluorothiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate (131.8 mg, 0.21 mmol) in THF (2.0 mL), 1N tetrabutylammonium fluoride in THF (550 μL, 0.55 mmol) was added and stirred at room temperature for 1.5 hours. The solvent was removed by evaporation under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 76 / 24 → 55 / 45) to afford the title compound (95.5 mg, 94%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.29-7.27 (3H, m), 7.16 (1H, d, J = 8.0 Hz), 7.10 (1H, d, J = 8.0 Hz), 6.89 (2H, d, J = 8.4 Hz), 6.64, 6.63 (each 0.5H, s), 5.18-5.12 (1H, m), 4.51-4.48 (5H, m), 3.82 (3H, s), 3.61 (3H, s), 2.28 (3H, s), 1.87 (1H, br s), 1.51, 1.50 (each 1.5H, d, J = 6.4 Hz, thiophene β-CH3regioisomers), 1.30 (3H, s), 1.20 (3H, s).
[0759] Reference example 187 Preparation of methyl 3-[5-acetyl-4-fluorothiophen-2-yl]-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0760] [ka]
[0761] Manganese dioxide (822.2 mg, 9.45 mmol) was added to a solution of methyl 3-[4-fluoro-5-(1-hydroxyethyl)thiophen-2-yl]-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate (95.5 mg, 0.19 mmol) in dichloromethane (2.0 mL). The reaction mixture was stirred at room temperature for 2.5 hours. Manganese dioxide (317.7 mg, 3.65 mmol) was then added, and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The crude product was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 86 / 14 → 65 / 35) to give the title compound (92.1 mg, 97%) as a colorless oil. 1 H NMR(400 MHz, CDCl3)δ 7.29-7.27 (3H, m), 7.15 (1H, dd, J = 7.6, 1.2 Hz), 7.11 (1H, d, J = 7.6 Hz), 6.90 (2H, d, J = 8.4 Hz), 6.75 (1H, s), 4.55 (1H, s), 4.49 (2H, s), 4.48 (2H, s), 3.82 (3H, s), 3.62 (3H, s), 2.51, 2.50 (each 1.5H, s), 2.28 (3H, s), 1.32 (3H, s), 1.21 (3H, s).
[0762] Reference example 188 Preparation of methyl 3-(5-acetyl-4-fluorothiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2,2-dimethylpropanoate
[0763] [ka]
[0764] Methyl 3-[5-acetyl-4-fluorothiophen-2-yl]-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate (92.1 mg, 0.18 mmol), dichloromethane (2.5 mL), water (250 μL), and DDQ (63.9 mg, 0.28 mmol) were used as raw materials, and the procedure was performed in the same manner as in Reference Example 25 to obtain the title compound (65.7 mg, 94%) as a colorless oily substance. 1 H NMR(400 MHz, CDCl3)δ 7.31 (1H, d, J = 1.6 Hz), 7.15 (1H, dd, J= 8.0, 1.6 Hz), 7.11 (1H, d, J = 8.0 Hz), 6.75 (1H, s), 4.67 (2H, s), 4.55 (1H, s), 3.63 (3H, s), 2.50, 2.49 (each 1.5H, s, acetyl regioisomers), 2.29 (3H, s), 1.32 (3H, s), 1.20 (3H, s).
[0765] Reference example 189 Preparation of methyl 3-(5-acetyl-4-fluorothiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]-2,2-dimethylpropanoate
[0766] [ka]
[0767] To a suspension of methyl 3-(5-acetylthiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]propanoate (65.7 mg, 0.17 mmol) and lithium chloride (40.1 mg, 0.95 mmol) in dichloromethane (1.5 mL) was added DIPEA (90 μL, 0.52 mmol) and methanesulfonyl chloride (27 μL, 0.35 mmol), and the mixture was stirred at room temperature for 20 hours. Ethyl acetate was added to the reaction solution, which was then washed with 10% aqueous citric acid, saturated aqueous sodium bicarbonate, and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (71.8 mg, quant.) as a light brown, transparent oil. 1 H NMR (400 MHz, CDCl3) δ 7.23 (1H, d, J = 1.6 Hz), 7.21 (1H, dd, J = 8.0, 1.6 Hz), 7.15 (1H, d, J = 8.0 Hz), 6.76 (1H, s), 4.57 (2H, s), 4.44 (1H, s), 3.64 (3H, s), 2.514, 2.507 (each 1.5H, s), 2.39 (3H, s), 1.32 (3H, s), 1.22 (3H, s).
[0768] Reference example 190 Preparation of methyl 3-(5-acetyl-4-fluorothiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0769] [ka]
[0770] A solution of methyl 3-(5-acetyl-4-fluorothiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]-2,2-dimethylpropanoate (0.17 mmol), (R)-4-ethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepine 1,1-dioxide (41.0 mg, 0.18 mmol), potassium carbonate (72.3 mg, 0.52 mmol), and tetrabutylammonium iodide (13.1 mg, 0.035 mmol) in DMF (1.0 mL) was stirred at room temperature for 2 hours. The reaction solution was cooled to room temperature, ethyl acetate was added, and the mixture was washed with water and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure. The resulting crude product was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 57 / 43 → 36 / 64) to give the title compound (93.7 mg, 92%) as a colorless oil. 1 H NMR (400 Mz, CDCl3) δ 9.02 (1H, s), 8.65 (1H, dd, J = 5.6, 0.4 Hz), 7.21 (1H, dd, J = 7.6, 1.6 Hz), 7.17-7.14 (2H, m), 7.09 (1H, d, J = 5.6, 2.0 Hz), 6.76, 6.75 (each 0.5H, s), 4.55, 4.54 (each 0.5H, s), 4.47-4.36 (2H, m), 4.16, 4.14 (each 0.5H, d, J = 14.4 Hz), 3.640, 3.639 (each 1.5H, s), 3.51-3.43 (1H, m), 3.17 (1H, dt, J= 15.2, 2.8 Hz), 2.51, 2.50 (each 1.5H, s), 2.33, 2.32 (each 1.5H, s), 1.74-1.63 (1H, m), 1.60-1.49 (1H, m), 1.30, 1.29 (each 1.5H, s), 1.20 (3H, s), 1.05 (3H, t, J= 7.2 Hz).
[0771] Reference example 191 Preparation of 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid
[0772] [ka]
[0773] Methyl 3-[5-acetyl-4-fluorothiophen-2-yl]-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate (609.6 mg, 1.2 mmol), methanol / 1,4-dioxane (1 / 1) (10.0 mL), and 4N aqueous sodium hydroxide solution (5.0 mL, 20 mmol) were used as raw materials, and the procedure was performed in the same manner as in Example 43 to obtain the title compound (497.2 mg, 82%) as an orange solid. 1 H NMR(400 MHz, CDCl3)δ 7.32 (1H, d, J = 2.0 Hz), 7.27 (2H, d, J= 8.8 Hz), 7.21 (1H, dd, J = 8.0, 2.0 Hz), 7.10 (1H, d, J = 8.0 Hz), 6.89 (2H, d, J = 8.8 Hz), 6,73 (1H, s), 4.63 (1H, s), 4.48 (4H, s), 3.87 (3H, s), 3.81 (3H, s), 2.46 (3H, s), 2.27 (3H, s), 1.34 (3H, s), 1.25 (3H s).
[0774] Reference example 192 Preparation of 2-(trimethylsilyl)ethyl 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0775] [ka]
[0776] To a solution of 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (491.7 mg, 1.0 mmol) and HBTU (568.4 mg, 1.5 mmol) in dimethylformamide (5.0 mL) was added 2-(trimethylsilyl)ethanol (520 μL, 3.0 mmol), DIPEA (430 μL, 3.0 mmol), and 4-dimethylaminopyridine (63.5 mg, 0.52 mmol). After stirring for 22 hours at room temperature, additional DMAP (63.1 mg, 0.52 mmol) was added and the mixture was stirred for 3 hours at room temperature. 2-(Trimethylsilyl)ethanol (280 μL, 2.0 mmol) and DMAP (119.5 mg, 1.0 mmol) were added and the mixture was stirred for 19.5 hours at room temperature. The reaction mixture was then diluted with hexane / ethyl acetate (1 / 1) and washed with 1N hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 86 / 14 → 65 / 35) to give the title compound (409.4 mg, 69%) as a clear yellow oil. 1 H NMR(400 MHz, CDCl3)δ 7.31-7.26 (3H, m), 7.18 (1H, dd, J = 7.6, 1.6 H), 7.10 (1H, d, J = 7.6 Hz), 6.89 (2H, d, J = 8.8 Hz), 6.71 (1H, s), 4.61 (1H, s), 4.48 (4H, s), 4.10-4.05 (2H, m), 3.89 (3H, s), 3.81 (3H, s), 2.46, (3H, s), 2.27 (3H, s), 1.32 (3H, s), 1.21 (3H, s), 0.89-0.86 (2H, m), 0.01 (9H, s).
[0777] Reference example 193 Preparation of 2-(trimethylsilyl)ethyl 3-(5-acetyl-4-methoxythiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2,2-dimethylpropanoate
[0778] [ka]
[0779] Using 2-(trimethylsilyl)ethyl 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-2,2-dimethylpropanoate (409.3 mg, 0.69 mmol), dichloromethane (6.0 mL), water (600 μL), and DDQ (188.4 mg, 0.83 mmol) as starting materials, the title compound (316.9 mg, 97%) was obtained as a colorless oily substance by the procedure described in Reference Example 25. 1 H NMR(400 MHz, CDCl3)δ 7.32 (1H, d, J = 2.0 Hz), 7.21 (1H, dd, J= 8.0, 2.0 Hz), 7.11 (1H, d, J = 8.0 Hz), 6.73 (1H, s), 4.67 (2H, d, J = 5.6 Hz), 4.62 (1H, s), 4.10-4.06 (2H, m), 3.91 (3H ,s), 2.46 (3H,s ), 2.31 (3H, s), 1.56 (1H, t, J = 5.6 Hz), 1.32 (3H, s), 1.22 (3H, s), 0.90-0.86 (2H, m), 0.02 (9H, s).
[0780] Reference example 194 Preparation of 2-(trimethylsilyl)ethyl 3-(5-acetyl-4-methoxythiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]-2,2-dimethylpropanoate
[0781] [ka]
[0782] To a suspension of 2-(trimethylsilyl)ethyl 3-(5-acetyl-4-methoxythiophen-2-yl)-3-[3-(hydroxymethyl)-4-methylphenyl]-2,2-dimethylpropanoate (101.8 mg, 0.22 mmol) and lithium chloride (49.6 mg, 1.2 mmol) in dichloromethane (2.0 mL) was added DIPEA (115 μL, 0.66 mmol) and methanesulfonyl chloride (34 μL, 0.44 mmol) and stirred at room temperature for 15.5 hours. Ethyl acetate was added to the reaction solution, which was washed with 10% aqueous citric acid, saturated aqueous sodium bicarbonate, and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by evaporation under reduced pressure to give the title compound (110.3 mg, quant.) as a light brown, transparent oil. 1 H NMR (400 MHz, CDCl3) δ 7.26-7.23 (2H, m), 7.12 (1H, d, J = 7.6 Hz), 6.72 (1H, s), 4.60 (1H, s), 4.56 (2H, s), 4.09-4.05 (2H, m), 3.91 (3H, s), 2.73 (3H, s), 2.46 (3H, s), 1.31 (3H, s), 1.22 (3H, s), 0.88-0.84 (2H, m), 0.10 (9H, s).
[0783] Reference example 195 Preparation of 2-(trimethylsilyl)ethyl 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoate
[0784] [ka]
[0785] A solution of 2-(trimethylsilyl)ethyl 3-(5-acetyl-4-methoxythiophen-2-yl)-3-[3-(chloromethyl)-4-methylphenyl]-2,2-dimethylpropanoate (the entire amount of the compound synthesized in Reference Example 194), (R)-4-ethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepine 1,1-dioxide (51.0 mg, 0.22 mmol), potassium carbonate (59.6 mg, 0.43 mmol), and tetrabutylammonium iodide (18.8 mg, 0.051 mmol) in DMF (1.0 mL) was stirred at 25 °C for 1 hour and then at 40 °C for an additional 1 hour. The reaction solution was cooled to room temperature, hexane / ethyl acetate (1 / 1) was added, and the mixture was washed with water and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The obtained crude product was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 63 / 37 → 42 / 58) to obtain the title compound (154.1 mg, quant.) as a colorless, transparent oily substance. 1H NMR (400 Mz, CDCl3) δ 9.01 (1H, s), 8.66, 8.65 (each 0.5H, d, J = 5.6 Hz), 7.24-7.22 (2H, m), 7.14 (1H, d, J = 8.0 Hz), 7.10, 7.09 (each 0.5H, d, J= 5.6 Hz), 6.76, 6.75 (each 0.5H, s), 4.60, 4.59 (each 0.5H, s), 4.45-4.36 (2H, m), 4.16-4.05 (3H, m), 3.933, 3.932 (each 1.5H, s), 3.53-3.44 (1H, m), 3.18-3.11 (1H, m), 2.46 (3H, s), 2.32 (3H, s), 1.73-1.61 (1H, m), 1.58-1.46 (1H, m), 1.30 (3H, s), 1.21, 1.20 (each 1.5H, s), 1.05, 1.03 (each 1.5H, t, J= 7.2 Hz), 0.90-0.86 (2H, m), 0.02, 0.01 (each 4.5H, s).
[0786] Reference example 196 Preparation of 2-(5-bromo-3-fluorothiophen-2-yl)-2-methyl-1,3-dioxolane
[0787] [ka]
[0788] 1-(5-Bromo-3-fluorothiophen-2-yl)ethan-1-one (350.0 mg, 1.57 mmol), ethylene glycol (0.957 mL, 17.3 mmol), p-TsOH·HO (15.0 mg, 0.08 mmol), and toluene (9.7 mL) were used as starting materials, and the procedure was performed in the same manner as in Reference Example 76 to obtain the title compound (386.9 mg, 92%) as a pale brown oil. 1H NMR (400 MHz, CDCl3)δ 6.78 (1H, br s), 4.07-4.03 (2H, m), 4.02-3.97 (2H, m), 1.77 (3H, s).
[0789] Reference example 197 Preparation of methyl (E)-3-[4-fluoro-5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate
[0790] [ka]
[0791] Using 2-(5-bromo-3-fluorothiophen-2-yl)-2-methyl-1,3-dioxolane (150 mg, 0.56 mmol), tetrabutylammonium chloride (7.8 mg, 0.028 mmol), PdCl(dppf) CHCl (45.9 mg, 0.056 mmol), DMA (0.74 mL), methyl acrylate (151 μL, 1.7 mmol), and N,N-dicyclohexylmethylamine (359 μL, 1.7 mmol) as starting materials, and operating as in Reference Example 88, the title compound (86.3 mg, 56%) was obtained as a pale yellow solid. 1 H NMR(400 MHz, CDCl3)δ 7.58 (1H, d, J = 16.0 Hz), 6.93 (1H, s), 6.20 (1H, d, J = 16.0 Hz), 4.10-4.03 (2H, m), 4.02-3.99 (2H, m), 3.79 (3H, s), 1.80 (3H, s).
[0792] Reference example 198 Preparation of methyl 3-[4-fluoro-5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]-3-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)propanoate
[0793] [ka]
[0794] A solution of 2-(3-{[(4-methoxybenzyl)oxy]methyl}-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (46.7 mg, 0.13 mmol), methyl (E)-3-[4-fluoro-5-(2-methyl-1,3-dioxolan-2-yl)thiophen-2-yl]acrylate (86.3 mg, 0.32 mmol), and [RhCl(cod)]2 (6.3 mg, 0.013 mmol) in toluene (0.48 mL) was added with 2N potassium hydroxide solution (32 μL, 0.063 mmol) under an argon atmosphere and heated at 100 °C for 1.5 hours. Water was added to this mixture, which was then extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate (v / v) = 87 / 13 → 66 / 34) to obtain the title compound (43.7 mg, 67%) as a pale yellow oil. 1 H NMR(400 MHz, CDCl3)δ 7.27 (2H, br d, J = 6.8 Hz), 7.21 (1H, br s), 7.13-7.07 (2H, m), 6.89 (2H, br d, J = 6.8 Hz), 6.52 (1H, br s), 4.55 (1H, t, J = 8.0 Hz), 4.48 (4H,...
Claims
1. General formula (I): 【Chemistry 1】 [In the formula: R 1a and R 1b R may be the same or different and represents a hydrogen atom, an alkyl group, or a halogen atom. 2 R represents a group derived from an optionally substituted heterocycle, and the heterocycle represents thiophene, furan, pyrrole, or thiazole, or a fused ring containing any of these heterocycles. 4 and R 5 are the same or different and each represents a hydrogen atom or an optionally substituted alkyl group, or R 4 and R 5 are bonded together to form -NH-CH=N-. R 6 represents an alkyl group which may be substituted. 1 , A 2 , A 3 and A 4 are the same or different and represent CH or N (however, the number of N is one or less). Z represents a hydrogen atom or a halogen atom. A compound represented by the formula:
2. R 2 The compound according to claim 1 , a salt thereof, or a solvate thereof, wherein
3. The compound, its salt, or a solvate thereof according to claim 2 , wherein the substituent that the thienyl group may have comprises an electron-withdrawing group.
4. The compound, its salt, or a solvate thereof according to claim 2 or 3, wherein the substituents which the thienyl group may have include an acetyl group, an aminosulfonyl group, a cyano group, or a cycloalkylcarbonyl group.
5. R 2 is of the general formula (R2A): 【Chemistry 2】 [In the formula: R 3 represents an acetyl group, an aminosulfonyl group, a cyano group, or a cycloalkylcarbonyl group; Y represents a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group. The compound according to any one of claims 1 to 4, a salt thereof, or a solvate thereof, wherein
6. R 2 is of the general formula (R2Aa) or (R2Ab): 【Chemistry 3】 [In the formula: R 3 represents an acetyl group, an aminosulfonyl group, a cyano group, or a cycloalkylcarbonyl group; Y represents a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group. The compound according to any one of claims 1 to 5, a salt thereof, or a solvate thereof, wherein
7. R 3 The compound, its salt, or a solvate thereof according to claim 5 or 6, wherein is an acetyl group.
8. R 4 and the above R 5 and are the same or different and each is a hydrogen atom or an alkyl group, or a salt thereof, or a solvate thereof according to any one of claims 5 to 7.
9. R 1a and the above R 1b and are the same or different and each is a hydrogen atom or an alkyl group, or a salt thereof, or a solvate thereof according to any one of claims 5 to 8.
10. R 1a and the above R 1b are the same or different and each is a hydrogen atom or an alkyl group, R 3 is an acetyl group, R 4 and the above R 5 are the same or different and each is a hydrogen atom or an alkyl group, R 6 is an optionally substituted ethyl group, The above A 1 , the above A 2 and the above A 4 are all CH, and the A 3 is CH or N, The Y is a hydrogen atom, an alkyl group, a halogen atom, or an alkoxy group, and The Z is a hydrogen atom. The compound according to any one of claims 5 to 9, a salt thereof, or a solvate thereof.
11. R 1a and R 1b One of R is an alkyl group and the other is a hydrogen atom, or R 1a and R 1b are both alkyl groups, R 2 Is of the general formula (R2Aa): 【Chemistry 4】 [In the formula: R 3 represents an acetyl group; Y represents a hydrogen atom, an alkyl group, a halogen atom or an alkoxy group. and R 4 is a hydrogen atom, R 5 is an alkyl group, R 6 is an optionally substituted ethyl group, The above A 1 , the above A 2 , and the A 4 are all CH, and the A 3 is CH or N, and The Z is a hydrogen atom. The compound according to any one of claims 5 to 10, a salt thereof, or a solvate thereof.
12. A compound, a salt thereof, or a solvate thereof, comprising any one of the following: 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 1), 3-(5-acetyl-4-methylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 2), 3-(4-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 3), 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 4) 3-(5-acetylthiophen-2-yl)-3-[3-({4-[2-(benzyloxy)ethyl]-1,1-dioxide-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl}methyl)-4-methylphenyl]-2-methylpropanoic acid (compound 13), 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 16), 3-(5-acetylthiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 48), 3-(5-acetyl-4-fluorothiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 49), 3-(5-acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2,2-dimethylpropanoic acid (compound 50), 3-(5-Acetyl-4-methoxythiophen-2-yl)-3-(3-{[(R)-4-ethyl-1,1-dioxide-3,4-dihydro-2H-pyrido[4,3-b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-2-methylpropanoic acid (compound 51).
13. A medicine comprising at least one selected from the group consisting of the compound according to any one of claims 1 to 12, a salt thereof, and a solvate thereof.
14. The pharmaceutical according to claim 13, which is an Nrf2 (NF-E2-related factor 2) activator.
15. The pharmaceutical composition according to claim 13 or 14, which is a topical administration formulation.
16. The pharmaceutical composition according to any one of claims 13 to 15, which is an ophthalmic formulation.
17. The pharmaceutical composition according to claim 13 or 14, which is a parenteral administration formulation.
18. The pharmaceutical composition according to claim 13, 14, or 17, which is an intravenous formulation.
19. The pharmaceutical composition according to any one of claims 13 to 18, which is a pharmaceutical composition for preventing or treating a brain disease, a lung disease, a skin disease, an otorhinolaryngological disease, a kidney disease, or an ophthalmological disease.
Citation Information
Patent Citations
Nrf2 regulator
JP2017503786A
Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
WO1999041246A1
Nrf2 regulators
WO2015092713A1
Bisaryl heterocycles as NRF2 acti
WO2018109643A1
Ether linked triazoles as NRF2 regulators
WO2018109649A1
